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SUMMARY
Introduction
Despite advances in insulin therapy, the side effects associated with diabetes mellitus still 
remain. Pancreas transplantation has benefited diabetics with end-stage renal failure by 
reversing the diabetic state and preventing or reversing the progression of diabetes associated 
diseases. Currently the side effects associated with lifelong immunosuppression preclude 
pancreas transplantation as a viable treatment option for both type I and II diabetics.
In the laboratory, transplanted rat foetal pancreata have been shown to be able to reverse the 
clinical signs of streptozotocin-induced diabetes in an isogeneic model. Reversal of diabetes 
by allogeneic foetal rat pancreas transplantation, although possible has proved to be more 
difficult due to fierce rejection of the grafts and the diabetogenic effects of conventional 
immunosuppressants.
Aims
One of the goals, focus and intentions of this laboratory study in rodents, is to contribute new 
information to the scientific literature. The potential to “reverse” the diabetic state by 
allogeneic foetal pancreatic transplantation, was the main stimulus for this study.
Methods
Foetal pancreata of 16-18 days gestation were transplanted into a surgically prepared renal 
subcapsular space. Immunosuppressive protocols used to prevent rejection of the allogeneic 
foetal rat pancreata included donor specific transfusion (DST), cyclosporine [a calcineurin 
inhibitor (CsA)], mycophenolate mofetil [a purine syntase inhibitor (MMF)], and a mouse 
anti-rat CD4 monoclonal antibody (W3/25). Immunosuppressants were used as 
monotherapies and in combination.
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Results
Isogeneic foetal rat pancreas transplantation resulted in the growth and development of 
mature insulin producing islets of Langerhans at the site of engraftment. Allogeneic foetal 
pancreatic transplantation without immunosuppression resulted in complete rejection of the 
grafts at 14 days post-transplantation.
Histological assessment of allografts at 14 and 30 days post-transplantation showed that CsA 
was able to prevent acute rejection in our rat models although graft scores and survival were 
improved if CsA was combined with MMF. Intraperitoneal anti-CD4 monoclonal injections 
were well tolerated, and if given daily effectively prolonged graft survival up to 30 days. 
Combining DST with anti-CD4 and CsA induction therapy provided long-term graft survival 
without daily immunosuppression. This combination, together with allogeneic foetal rat 
pancreas transplantation, was effective in reversing the clinical signs of experimentally 
induced diabetes. To my knowledge these are the first published results in which reversal of 
streptozotocin induced diabetes was achieved by fully MHC mismatched foetal rat pancreatic 
transplantation.
Conclusion
Foetal rat pancreatic transplantation is a potential source of endocrine replacement, which, 
with effective immunosuppression allows for the development of functional islets able to 
reverse the clinical signs of experimentally induced diabetes in an allogeneic rat model. An 
unique immunosuppressive protocol, with potential clinical relevance in the human, 
combines anti-CD4 mAb, CsA and DST induction therapy, which alleviates the burden of 
daily immunosuppression and associated side effects.
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OPSOMMING
Inleiding
Ten spyte van die vordering met modeme insulienterapie bly die newe-effekte, waarmee 
diabetes mellitus geassosieer is, steeds ‘n probleem vir diabete. Diabetiese pasiente met 
eindstadium nierversaking trek geweldig voordeel uit nier-pankreasoorplantings wat die 
diabetes omkeer en die progressie van diabetesverwantesiektes voorkom of selfs omkeer. 
Die newe-effekte van lewenslange immuunonderdrukking skakel pankreasoorplanting uit as 
‘n lewensvatbare behandelingsopsie vir tipe I of II diabete.
In ‘n streptozotosien-gei'nduseerde diabetiese rotmodel kan isogenei'ese fetale 
pankreasoorplanting die kliniese tekens van diabetes omkeer. Die omkering van 
streptozotosien-gei'nduseerde diabetes deur allogeneiese fetale pankreasoorplanting behoort 
moontlik te wees indien verwerping en die diabetogeniese newe-effekte van konvensionele 
immuunonderdrukkers oorkom word.
Doelstellings
Een van die mikpunte, fokusse en oogmerke van hierdie laboratorium studie in knaagdiere, is 
om ‘n betekenisvolle bydrae tot nuwe kennis in die wetenskaplike literatuur, te maak. Die 
potensiaal om die diabetiese toestand deur allogeneiese fetale pankeasoorplanting om te keer, 
was die hoof stimulus vir die studie.
Metodes
Fetale rotpankreata van 16-18 dae gestasie was in ‘n chirurgies voorbereide spasie onder die 
nierkapsel oorgeplant. Immuunonderdrukkende protokolle, vir die voorkomming van 
verwerping van die allogeneiese fetale pankreasoorplantings, het donorspesifiekeoortappings 
(DST), siklosporien [‘n kalsineurien inhibitor (CsA)], mikofenolaat mofetiel [‘n purien
v
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sintase inhibitor (MMF)] en ‘n anti-rot CD4 monoklonale antiliggaam (W3/25) ingesluit. Die 
immuunonderdrukkers is as mono- of as kombinasieterapie gebruik.
Resultate
IsogeneTese fetale rotpankreasoorplanting het tot die ontwikkeling van volwasse 
insulienproduseerende eilande van Langerhans gelei, wat die kliniese tekens van 
streptozotosien-gei'nduseerde diabetes kon omkeer.
Allogenei'ese fetale rotpankreasoorplanting sonder immuunonderdrukking het tot algehele 
verwerping van die oorplanting binnel4 dae na oorplanting gelei.
Histologiese beoordeling van die oorplantings 14 en 30 dae na oorplanting het getoon dat 
CsA akute verwerping van fetale pankreasoorplantings in die rotmodelle voorkom. Indien 
CsA met MMF gekombineer word, word die oorplantings-telling en oorlewing verbeter. 
Intraperitoneale anti-CD4 monoklonale inspuitings was goed verdra, en indien daagliks 
toegedien, het dit die oorlewing van die pankreasoorplantings effektief tot 30 dae verleng. 
Die kombinasie van DST, anti-CD4 en CsA induksieterapie het tot langtermyn oorlewing van 
die pankreasoorplantings gelei sonder verdere daaglikse immuunonderdrukking. Die 
induksieterapie in kombinasie met allogenei'ese fetale pankreasoorplanting was effektief in 
die omkering van die kliniese tekens van streptozotosien-gei'nduseerde diabetes in die rot. 
Hierdie is, sover ek weet, die eerste keer dat omkering van streptozotosien-gei'nduseerde 
diabetes suksesvol met ‘n volledige MHC onverenigbare allogenei'ese fetale 
pankreasoorplanting behaal is.
Gevolgtrekkings
Fetale rotpankreasoorplanting is ‘n potensiele bron vir endokrien vervangingsterapie, wat met 
effektiewe immuunonderdrukking tot die ontwikkeling van funksionele eilande van 
Langerhans lei, wat die vermoe het om die kliniese tekens van experimenteel-ge'induseerde
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diabetes in ‘n allogeneiese rotmodel om te keer. ‘n Unieke immuunonderdrukkingsprotokol, 
met kliniese relevansie, kombineer DST met anti-CD4 mAb en CsA induksieterapie wat die 
las van daaglikse immuunonderdrukking en die geassosieerde newe-effekte van 
konvensionele immuunonderdrukking verlig.
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GLOSSARY
ALG anti-leucocyte globulin
ALS anti-leucocyte serum
ATG anti-thymocyte globulin
AO Albino inbred rat strain subline of WAG rat
APC antigen presenting cells
ATG Rabbit-anti-human T-Lymphocyte immune serum
CD2+ Pan T-lymphocyte surface molecule
CD25+ CD25 specific surface molecule
CD4+ CD4 specific surface molecule
CD8+ CD8 specific surface molecule
CsA cyclosporine
DA Dark Agouti inbred rat strain
DC dendritic cells
DEAE diethylaminoethyl-dextran
DPX histological mounting medium containing distrene,
dibutyl
DST donor specific transfusion
FACS flow Cytometry
Fc crystallizable fragment
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FK506 tacrolimus
FRP foetal rat pancreas
FRPT foetal rat pancreas transplantation
FSC forward scatter
GM-CSF granulocyte monocyte colony stimulating factor
H&E haematoxylin and eosin stain
i.m.i intramuscular injection
i.p.i. intraperitoneal injection
i.v.i. intravascular injection
ICAM intercellular adhesion molecules
ICC immunocytochemistry
IDDM insulin dependent diabetes mellitus
IFNy interferon gamma
Ig immunoglobulin
IGF-1 insulin growth factor 1
IL interleukine
IL-2 interleukin 2
IMPDH inosine monophosphate dehydrogenase
IVGTT intravenous glucose tolerance test
kV kilovolt
L3T4 anti-mouse CD4 monoclonal antibody
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LAT linker for activation of T-cells
Ick a SRC-family tyrosine kinase
LFA lymphocyte function associated molecule
mAb monoclonal antibody
MHC major histocompatibility complexes
MLR mixed lymphocyte reaction
MMF mycophenolate mofetil
MNC mononuclear cells
NIDDM non-insulin dependent diabetes mellitus
0X34 anti-rat CD2 monoclonal antibody
0X35 anti-rat CD4 monoclonal antibody
0X38 anti-rat CD4 monoclonal antibody
0X39 anti-rat CD25 (IL-2R) monoclonal antibody
0X8 anti-rat CD8 monoclonal antibody
PBL Peripheral blood lymphocytes
PBS phosphate buffered saline
PP Pancreatic polypeptide
PVG Black hooded (piebald) inbred rat strain
RIB5/2 anti-rat CD4 monoclonal antibody
RPMI synthetic tissue culture medium
RPT rat pancreatic transplantation
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RT1 antigen encoded by the MHC of the rat
SD Sprague-Dawley rat strain
ssc Side scatter
STZ Streptozotocin
TBS tris buffered saline
TGF-P transforming growth factor P
Thl T-helper 1 CD4 T-cells
Th2 T-helper 2 CD4 T-cells
TNF-a Tumor necrosis factor alpha
T-reg cells T- regulatory cells
W/F Wistar-Furth inbred rat strain
w/v weight per volume
W3/25 mouse anti-rat CD4 monoclonal antibody
WAT white adipose tissue
YTS 191.1 a depleting anti-mouse CD4 monoclonal antibody
ZAP-70 tyrosine kinase zeta-associated protein of 70 KDa
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Chapter  1
DIABETES MELLITUS - THE PROBLEM
Stellenbosch University http://scholar.sun.ac.za/
Introduction and History
Diabetes, a complex group of diseases with hyperglycaemia a characteristic feature, has been 
known and researched since antiquity, but still remains a worldwide health problem. Originally 
it was thought that diabetes was a disease of the kidneys, a concept which was further entrenched 
with the discovery of the sugar in, or sweetness of the urine by Thomas Willis 1621 -  79 '. The 
discovery that a pancreatectomy causes diabetes by Von Mering and Minkowsky in Strasbourg 
in 1889, lead to our present understanding of the cause of diabetes1.
The discovery of insulin by Frederick Banting, Charles Best, Macleod and James Collip in 1921, 
has not only saved the lives of millions of diabetics but has also greatly improved the prognosis 
and quality of life of diabetics worldwide1. However, despite this lifesaving contribution of 
insulin in preventing acute metabolic death by ketoacidosis, it soon become clear that diabetes is 
not simply a “sugar problem” but that the chronic complications of the disease persist even with
good insulin and diet control2. Subcutaneous injection of insulin presents its own problems with
• • 2 hyperinsulinaemia a further complication linked to the development of macroangiopathies .
Diabetes is not a single disease but includes a group of diseases caused by a wide range of known 
and unknown factors including various virusses, chemical toxicity and pollutants, genetic 
predisposition, geographic locality and diet. Clinically there are two types of “Diabetes” i.e. 
Type I insulin dependent diabetes mellitus (IDDM) and Type II non-insulin dependent diabetes 
mellitus (NIDDM), being characterized by the absence or presence o f plasma insulin 
respectively.
2
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Insulin and insulin receptors
The availability of insulin and target organ/cell insulin receptors are the major role players in the 
maintenance of euglycaemia. Insulin, a hormone coded by a gene on chromosome 11 is 
produced as preproinsulin, converted to insulin by removal of the connecting peptide (C-peptide) 
in the Golgi apparatus by enzymes with trypsin and carboxypeptidase activity. Insulin then 
complexes with Zn to form micro-crystals in the typical secretion granules seen in active P cells. 
Insulin release from the p-cells is stimulated by glucose, requiring glucose metabolism and ATP 
resulting in the closure of the K+ channels and increased inflow of Ca++ into the cell3. Following 
release, insulin binds to the insulin receptor of the target cell. The insulin receptor is coded by 
genes on chromosome 19 and consists of two a  subunits covalently bound to two P subunits 
situated on the surface of the target cell. Binding of insulin to its receptor on the target cell 
results in phosphorylation and autophosphorylation of tyrosine residues inhibiting 
glycogenolysis. The insulin-insulin receptor complex is then internalized, the insulin degraded 
and the insulin receptor is then recycled to the cell surface3. Thus any defect in insulin, insulin 
secretion or the availability of insulin receptors cause an increase in blood glucose levels and 
diabetes.
Diabetes mellitus onset and progression 
IDDM
IDDM is a multi factorial disease leading to selective destruction of the insulin secreting P-cells 
by an autoimmune process induced by environmental factors in early life, even as early as intra-
3
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uterine life4. In Western industrialized countries IDDM is the second most common chronic 
childhood disease after asthma3.
IDDM has a sudden onset, normally seen in younger patients, peaking in the mid-teens, caused 
by the destruction of the insulin producing endocrine p-cells either by direct cytotoxicity or by 
autoimmune destruction of these P-cells. The disease manifests itself at the stage when 
approximately 80% of the P-cells are destroyed which could take as long as 5 -15 years4. 
Typically symptoms at this late stage of the disease include hyperglycaemia and/or ketoacidosis. 
The progression of the disease is rapid requiring medical intervention. Causes of IDDM are 
more obscure with a genetic predisposition along with environmental factors, being the most 
obvious. Genetically, individuals with HLA class II DR3,4; DQ2,8 and class I A24 alleles are at
• S f t  7  8increased risk ’ ’ ’ . Of interest is the geographic distribution of childhood IDDM, showing a 
general increase in incidence from the equator towards the two poles. Northern Europe, Finland, 
Sweden and Scotland in particular, show a rapid increase in the incidence of IDDM as compared 
to Southern European countries. Finland has the highest incidence of childhood diabetes at 
30/100 000 per year compared to the 1/100 000 per year seen in Japan. Genetic factors are 
certainly thought to be a major contributing factor, with various environmental factors 
contributing to the rapid increase of incidence of childhood IDDM in Northern Europe. A 
study comparing identical twins of diabetic parents to non-identical twins of diabetic parents 
found that 58% of identical twins, compared to 17%, were concordant for diabetes. Insulin 
dependent diabetes mellitus is often found in family clusters but this is not conclusive proof of 
genetic predisposition as families share a similar environment and only approximately 5% of 
diabetics have a familial history of IDDM4.
4
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Epidemiologists have been able to show a seasonal variation in the onset of acute IDDM which 
was confirmed in both the Northern and Southern hemispheres with a higher onset in the autumn 
and winter months 9. Viral infection, alone or in combination with other environmental factors, 
is certainly one of the most likely candidates responsible for these seasonal variations1. Viral 
infections have however rarely been shown to be solely pathogenic for IDDM although 
congenital rubella is associated with an increased risk of IDDM with a similar onset age and 
immunogenic predisposition to idiopathic IDDM4.
NIDDM
NIDDM normally has a more chronic onset manifesting itself in later life and it is estimated that 
10% of Europeans above the age of 75 years may be diabetic with 45% of men in the age group 
75 -79 years in east Finland suffering from NIDDM3. Except for a genetic predisposition for 
developing NIDDM such as the Pima Indians of Arizona with an incidence of 30 -35%, 
evidence clearly shows that urbanization and industrialization along with a Westernized diet and 
lifestyle are the main factors contributing to NIDDM reaching endemic proportions.
NIDDM is caused by either an insufficient P-cell mass, especially prevalent in obese patients or 
insensitivity to insulin . Strong evidence exists that NIDDM in later life could be due to the loss 
of P-cells by an aborted IDDM autoimmune process1. Malnutrition during foetal development 
and early life has been show to increase the risk of developing NIDDM in later life especially 
when associated with obesity in later life. This phenomenon has been termed the “thrifty 
phenotype” and is probably associated with a lower P-cell mass caused by the early
malnutrition9. A change o f diet especially from a rural to a more Westernized diet containing
5
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highly refined carbohydrates, fat and alcohol, is associated with a higher incidence of diabetes, as 
seen in the Nauruans, Pimas and Aboriginal populations in New South Wales9. The estimated 
heritability of NIDDM is around 82% in a particular environment and changing the environment 
dramatically influences the genetic index even between twins3.
Complications associated with diabetes.
Diabetes is a major and increasing world health problem affecting approximately 130 million 
people10. Industrialization has seen non-communicable diseases increase dramatically with 
cancer, arterial disease and diabetes the leading causes of early death. Diabetes is the leading 
cause of blindness during working life and the second most common cause of kidney failure. 
Macro- and microvascular disease are common complications, often resulting in amputations, 
stroke and heart attacks in diabetics. The life expectancy of diabetics, on average, is reduced by
o #
a decade . The true cost of diabetes to the patient both in financial terms and in life expectancy 
is astronomic with costs rising as medical and life insurance premiums are loaded to counter the 
long-term complications. People suffering from IDDM are excluded from many employment 
opportunities e.g. becoming airline pilots1. Although insulin treatment has been refined and tight 
control o f blood glucose levels is possible though a controlled carbohydrate diet combined with a 
balanced insulin treatment regimen, complications do occur and are varied resulting in the high 
treatment costs of arterial sclerosis, retinopathy leading to blindness, renal failure and dialysis 
and debilitating amputations. These secondary complications still are particularly common in 
underprivileged third-world nations and races. Diabetics remain uninsurable by insurance 
companies or pay enormous premiums. The cost of insulin is staggering and most medical-aids
refuse cover for diabetics, even when excellently controlled. Although there is a good correlation
6
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between tight diabetic treatment control as measured by the glycaemic index, complications such 
as retinopathy, nephropathy and neuropathy still progress albeit at a slower rate. Sudden changes 
in diabetic control even for the better may accelerate the progression of the disease.
7
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Chapter  2
PANCREAS TRANSPLANTATION
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History of pancreas transplantation
Pancreas transplantation as an endocrine replacement therapy has a long history with the first 
record of a pancreas transplant being performed in 1893, 29 years prior to the discovery of 
insulin, by Drs P.W.Williams and Harsant of the Bristol Royal Infirmary. They transplanted 
three pieces of freshly slaughtered sheep pancreas sub-cutaneously into a 15 year old diabetic. 
The boy died three days after the transplantation. Histology of the grafts showed only fibrous
12  3stroma ’ ’ . Ssobolew and Allan recommended pancreas transplantation as a treatment for 
diabetes in 1902. Notes published by Pybus in the Lancet in 1924 described subcutaneous 
transplants of slices of human pancreas into two diabetic patients2. Both of the patients rejected 
their grafts but one showed a temporary reduction of glycosuria, a remarkable result considering 
that no immunosuppression was available and the strong rejecting potential of the skin. Luisada 
(1927), as described by Downing in a historical review of pancreatic islet transplantation, 
transplanted duct-ligated baboon pancreas under the tunica vaginalis of two young diabetics, but 
without any beneficial effect.
These early attempts at pancreas transplantation although imaginative and ambitious were
doomed to failure by rejection. Autogeneic transplantations, on various laboratory animals, were
however successful and contributed to the understanding of diabetes. Minkowski, (1892 and
1893 as quoted by Downing 1984), performed auto-transplants o f vascularized uncinate
processes o f canine pancreas under the skin. He then performed a pancreatectomy of the
remaining intra-abdominal pancreas. The dogs did not develop fatal diabetes. Downing further
describes that skeptics like Pfluger proposed that the transplanted segments were functional
because they were in fact still connected to and innervated by the duodenum. Subsequent studies
11
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by Hedon and Lombroso in 1910 (as quoted by Dowling 1984) showed that denervated 
segmental pancreas autografts were able to prevent diabetes in pancreatectomized animals thus 
establishing a relationship between the pancreas, diabetes and transplantation of pancreatic 
tissue2.
It must be appreciated that prior to the insulin era, transplantation was regarded as the only viable 
treatment. Intrasplenic transplantation of pancreatic tissue gained favour due to the hypothesis of 
pancreatic internal secretion. Early attempts by Allesandri (1913 as quoted by Dowling 1984), 
Ottolenghi (1901 as quoted by Dowling 1984) and Kyrle (1908 as quoted by Dowling 1984) to 
transplant fragments of dog pancreata into the splenic pulp were unsuccessful. Kyrle was able to 
transplant vascularised pancreatic segments into the spleen of dogs and guinea pigs and could 
show survival of the grafts after he ligated the pedicles. Unfortunately he did not do any 
functional studies2. Pratt and Murphy were however more successful with intra-splenic 
autografts of the vascularized uncinate process, which they then ligated after 22 days and 
removed the rest of the pancreas. The graft survived for 209 days with the dog remaining insulin
free for that period. The urine glucose levels were monitored and remained between 0% and 7%
2
The search for an ideal site for pancreas transplantation was actively pursued around the turn of 
the century with direct intrahepatic transplants of pieces of pancreas done by Alessandri (1896 as 
quoted by Dowling 1984) and Ottolenghi (1901 as quoted by Dowling 1984) allotransplanting 
pieces of guinea-pig pancreata into the liver, spleen, peritoneal cavity and subcutaneous tissues. 
All these grafts showed necrosis of the grafts, within 2 days. Dowling further describes how 
Badile did a comparative study on various transplantation sites using both allograft and
12
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autografts. He transplanted pieces of cat pancreas into the liver, spleen, greater omentum, 
retroperitoneal connective tissues and gastric mucosa. This study confirmed, what had been the 
pattern with pancreatic transplantation throughout, namely that allografts were rejected rapidly, 
but autografts were able to survive. In his study autogeneic grafts into the gastric submucosa 
survived for 105 days2.
By the late 1920’s it was established that autografts could survive in various sites provided the 
grafts were vascularised. It was also established that the exocrine portion of the grafts negatively 
affected graft survival. Various attempts were made to reduce exocrine secretion from the graft. 
Thiroloix in 1892, injected the pancreatic ducts with oil and lamp-black to suppress exocrine 
secretion and showed that splenic autografts although fibrosed, were able to maintain 
normoglycaemia. In 1929 Brancati employed duct-ligation of canine pancreas autografts into the 
greater omentum. These autografts survived for 28 and 34 days. Histology showed normal islets 
with atrophied exocrine acini2.
Pancreas transplantation
The demand for clinical pancreatic transplantation has grown rapidly following the first reported 
clinical segmental duct-ligated graft that was transplanted simultaneously with a kidney by Kelly 
et al. o f the University of Minnesota in 1966 4 5. Lillehei et al. followed with 14 pancreas 
transplantations between 1966 and 1973 and were the first to transplant whole 
pancreaticoduodenal grafts. Groth et al. in Stockholm did a large series o f enteric-drained grafts 
in 1973. The concept of urinary drainage was introduced by Gliedman et al. in 1971 and 
modified by Sollinger et al. at the university of Wisconsin in 1982 by a direct anastomosis of the 
pancreatic duct to the bladder. Nhiegm et al. at the University of Iowa further refined the
13
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technique by leaving a segment of duodenum attached to the pancreatic-duct to make 
anastomosis to the bladder easier.
The Report of the International Pancreas Transplant Registry 1991 shows that almost all the 
pancreas transplants performed in the USA between 1986 and 1991 were by the bladder drainage 
technique (94% of the total, n = 1224) while in Europe less than half the transplants were by the 
bladder drainage technique (42% of the total, n = 313). The bladder drainage technique has a 
smaller technical failure rate of 13% and 17%, in the USA and Europe respectively. The registry 
shows first year graft survival by this technique to be at 68% and 54% respectively. The 
intestinal drainage technique was the only other duct-management technique employed by 
American researchers (63 patients) in the period. The technical failure rates using this technique 
are higher with 28% and 25% in USA and Europe respectively. Duct injection was only done in 
Europe with a functional graft first year survival rate of 56% 6.
The aims of pancreas transplantation are firstly to establish normoglycaemia and insulin 
independence in the diabetic patient and secondly to prevent, halt or reverse the progression of 
secondary complications of diabetes. The object of pancreas transplantation is to improve the 
quality of life and this must be the only criterion in the selection o f transplant patients. Pancreas 
transplantation, as with other transplants, commits the patient to life-long immunosuppression at 
this time. The side effects of current immunosuppressive drugs could outweigh the advantage of 
the pancreas transplant even if the patient is euglycemic. Diabetic patients that would most 
certainly benefit from pancreas transplantation are patients with end stage renal failure due to 
diabetic nephropathy, requiring renal transplantation4. These patients are obligated to take 
immunosuppressives to maintain the renal graft. More than 75% of pancreas transplants reported
14
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during 1986 -  90 were simultaneous kidney/pancreas transplants with a 68% first year survival 
and patients were dialysis free and insulin independent2.
There are patients whose problems with diabetes severely impacts on their quality of life. 
Diabetic patients with autonomic or somatic neuropathy have a high mortality. Pancreas 
transplantation has been shown to improve the condition of these patients as measured by their 
increase in nerve conduction velocities and autonomic index7. Reversal of severe secondary 
complications in diabetic patients by pancreas transplantation has been somewhat disappointing, 
as shown by the Minnesota series with the continued progression of retinopathy in 30% of 
patients with functioning grafts a figure similar to that of the patients with failed grafts. After 3 
years however, no further progession occurred in the recipients with funtioning grafts. However, 
70% with failed transplants advanced to a higher grade within 5 years5.
The recurrence of diabetic nephropathy occurrs in nearly half of the kidneys transplanted without 
pancreas in uraemic diabetic patients8. A successful pancreas transplant influences the 
progression and even reverses the course of diabetic nephropathy. Ten year follow up biopsies 
showed that glomerular and tubular membrane thickness and mesangial fraction volume of the 
glomerulus had decreased and returned to normal following pancreas transplantation5.
The Munich group (1992) demonstrated a beneficial effect on the microcirculation following a 
successful pancreas transplant and concluded that if the pancreas transplants were performed 
earlier in the course of the disease secondary complications might be prevented4.
Studies have shown that the quality of life is better in uraemic recipients who received both 
kidney and pancreas compared to those patients who received kidney transplants alone. Patients
15
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who received single pancreas transplants were also overwhelmingly positive regarding their 
improved quality of life, despite the side effects of immunosuppression. Both groups indicated 
that they would have a retransplant if the transplanted pancreas failed4.
The complex surgery required to perform vascularized whole pancreas transplants, which 
includes unnecessary exocrine acinar tissue, has boosted research into the transplantation of islet- 
rich tissues.
Islet transplantation
Two approaches are adopted namely, transplantation of isolated islets and foetal or neonatal 
transplantation.
The development o f islet isolation and transplantation has been hampered by the technical 
difficulties of isolating viable mammalian islets in sufficient numbers to have any effect on blood 
glucose levels. Younoszai et al. were the first to successfully isolate rat islets and were able to 
ameliorate chemically induced diabetes by intraperitoneal transplantation of isolated islets9.
Two methods of islet separation from pancreatic tissue have been employed. Microdissection 
techniques, as pioneered by Norberg in 1964 (as quoted by Dowling 1984) was found to be too 
traumatic, yielding only small numbers of viable islets. Moskalewski (as quoted by Dowling 
1984) was the first to employ collagenase to digest chopped guinea-pig pancreas and although 
the collagenase destroyed some islets, separation of the islets from the acinar exocrine tissue was 
possible. The technique was further refined by Lacy and Kostianovsky in 1967 (as quoted by 
Dowling 1984) by intraductal distention prior to digestion with collagenase. Islets were then
16
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separated from the digested pancreatic tissue by sucrose gradient centifugation. This 
modification secured approximately 300 intact islets from a single rat pancreas. Further 
refinements using ficoll gradients by Sorenson in 1968 improved the islet yield and paved the 
way for human islet separation in 1971 2.
In 1972, Ballinger and Lacy succeeded in the long-term amelioration of streptozotocin induced 
diabetes in rats by intraperitoneal and intramuscular isotransplantation of between 400 and 600 
separated islets. Islet transplantation was boosted when Kemp showed that intraportal 
embolisation of between 400 -  600 rodent islets could completely normalize blood and urine 
glucose levels within two days of implantation due to the increased viability of islets with an 
immediate blood supply together with a normal physiological route of insulin secretion l0.
Human clinical results, using this technique have, despite early optimism, been disappointing. 
Three hundred and five adult islet allografts had been performed in 38 institutions by December 
1995, and of these patients only 39 were functionally insulin independent at one month post­
transplantation and of these 39, only 24 were still insulin independent at 12 months. Only one 
patient was still insulin independent at four years 11.
Analysis of c-peptide negative patients receiving islet transplants, in the period 1990 -  94,
showed that of 96 patients known to be c-peptide negative prior to transplantation, 27% had basal
c-peptide levels in excess of 1 ng/ml at one year and of these only seven percent were insulin
independent u . If the only measure of success is insulin independence then these results are
dismal indeed; patients with persisting c-peptide levels, although not sufficient to be insulin
independent, benefitted by requiring lower doses of insulin and improved glycaemic control
leading to a decrease in complications12. Guidelines put forward by the International Islet
17
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Transplant registry for attaining insulin independence by islet transplantation are the following: 
harvesting of islets from pancreata within eight hours with adequate preservation; 
transplantation of > 6000 islets, with a mean diameter of at least 150 (am, per kilogram (kg) body 
weight; high level of immunosuppression using T-cell antibodies anti-leucocyte globulin (ALG) 
or anti-thymocyte globulin (ATG).
The above requirements demonstrate the problems encountered in islet transplantation especially 
regarding the obtaining of sufficient islet mass to ameliorate diabetes.
The introduction of the Edmonton Protocol, a steroid-free immunosuppressive regimen, together 
with optimal islet mass transplantation of 11000 islets/kg has dramatically altered the outcome of 
islet transplantation. Typically this would require a minimum of three donor pancreata. 
Currently the Edmonton series includes 35 patients of whom all achieved insulin independence 
post-transplantation, with the longest insulin-free follow-up being more than three years. 
Currently their one year insulin independence rate is 87% .
Foetal pancreas transplantation
A viable alternative to adult islet transplantation is foetal pancreas transplantation13,14. The 
possiblity of using foetal pancreatic tissue was first raised by Lazarow et al. in 197315. The early 
development of the endocrine tissue compared to the exocrine pancreas tissue provides an 
opportunity for the preferential exploitation of foetal pancreas as a source of endocrine rich tissue 
with a high growth potential16,17. Although many clinical foetal pancreas transplants have been 
done in Russia, China, Europe and the USA12, the subsequent ban on the clinical use of foetal
• • • •  1 2 1 8 1 9tissue, which still remains in force, has prevented further studies in the USA and Europe ’ ’ .
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Lafferty et al. transplanted human foetal tissue under the kidney capsule of donor kidneys that
were transplanted into diabetic patients scheduled for kidney transplantation because of their
•  20uremia . Although none of the patients became insulin independent all required less insulin 
following the transplant. Tissue taken from the grafts showed the development of islet tissue, 
which could be stained for the presence of insulin12.
Preclinical experimentation using the rodent and other animal models has paved the way for 
rapid and effective transplantation once the practical, political and ethical concerns have been 
overcome. The reversal of streptozotocin-induced diabetes in rats by renal subcapsular 
transplantation of foetal pancreata has been demonstrated by Brown et al. in 1976 and 1981, 
Mullen 1976 and Spence et al. in 198117*21’22’23_
Brown and Mullen showed that one syngeneic rat foetal pancreas of between 17 and 17V4 days 
gestation, engrafted under the kidney capsule of a Lewis rat, rendered previously diabetic by 
intravenous injection of 72.5 mg/kg streptozotocin, could reverse insulin dependence and 
ameliorate the diabetes. Brown confirmed the enormous growth potential of foetal pancreatic 
tissue and calculated that a single foetal pancreas engrafted under the kidney capsule could 
develop to 22% of the adult beta cell component. Normoglycaemic values were maintained by 
the single graft for about 4 months. Removal of the grafts returned the animal to the 
pretransplant levels of hyperglycaemia, polyuria and glycosuria. Brown has emphasised the 
following points: There is a 4000-fold increase in the insulin content of the grafts within the four 
month period from 0.2 mU to 818 mU which is 22% of the insulin content of normal rats and 
since the removal of approximately 90% of the pancreas is required to induce diabetes, it may be 
concluded that one foetal pancreas could reverse the diabetes and maintain euglycaemia.
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Another interesting point regarding beta cell proliferation is the stimulating effect of 
superphysiological glucose levels on beta cell mass. McEvoy et al. found the beta cell mass of 
transplanted foetal pancreata to be the same in normal and untreated diabetic rats but found a 
three fold increase if transplanted diabetic rats received insulin post-transplantation24,21. 
Transplantation of foetal pancreata into normal non-diabetic rat for two weeks, followed by 
removal of the kidney and the undisturbed grafts and transplanting them into diabetic rats 
resulted in improved graft function when compared to direct engraftment into a diabetic rat. 
Grafts that were maintained in the normal rat for 5 weeks showed an impaired release of insulin 
on glucose stimulation. It would thus appear that maintenance of normoglycaemic conditions is 
important for growth, development and function of transplanted foetal pancreata25.
Brown found that the basal and glucose stimulated blood insulin levels of the transplanted rats 
were moderately higher than normal. This, he proposes, is due to the altered venous drainage of 
the kidney subcapsular engraftment site. Dye injection studies have shown that the main venous 
drainage of foetal pancreas transplants from the kidney subcapsular site is into the renal vein and 
then into the inferior vena cava thus bypassing the liver 25. The liver usually extracts 
approximately 50% of the insulin present in the portal vein with each pass. Madison et al. 
showed that if  131I-labelled insulin is injected into the portal vein, 51% of the insulin is 
recovered in the liver while only 27% of insulin is recovered in the liver if the labeled insulin is 
injected into a peripheral vein21. The effect of the higher insulin levels, in the longer term, is not 
known. Rerouting the blood flow by shunting the renal vein end to side with the portal vein 
resulted in an immediate return of the insulin levels to normal, blood glucose clearance was
• • • 25improved and a normal insulin response was seen following intravenous injection . Brown et
al. showed that pancreata of between MVi and 18 days were most suitable with six foetal
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pancreata able to reverse diabetes in 93% of cases while four pancreata reversed diabetes in 73% 
of the cases25.
Histological evaluation of the grafts at one week showed groups of cells with beta cell staining 
characteristics and exocrine tissue, which progressively degenerated. At one to two months 
endocrine tissue was well formed, the exocrine portion was limited to ducts and connective tissue 
and adipose tissue surrounded the structures. Electron microscopy revealled both a - and [3-cells, 
and that the (3-cells were often partly degranulated indicating active insulin secretion25,26.
Metabolic studies done on successful transplanted diabetic rats showed, apart from a slightly 
elevated plasma insulin level, that other metabolic parameters (enzymes of the glycolytic 
pathway, glucokinase and pyruvate kinase which are severely depressed in the diabetic liver) had 
returned to normal values. Glucose-6-phosphate dehydrogenase and citric lyase, which are 
involved in lipid metabolism and fructose 1,6-diphosphatase and glucose-6-phosphatase which 
are involved in gluconeogenesis all returned to normal values 25,27.
Allogeneic foetal pancreas transplantation has not had the same success. Originally foetal 
pancreata were thought to be less immunogenic due to the immunologically immature nature of 
the grafts but in fact were found to be very antigenic and were fiercely rejected without effective 
immunosuppression 12.
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Chapter  3
TRANSPLANT IMMUNOLOGY
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Rejection
Rejection, an unknown phenomenen in early attempts at pancreas transplantation, severely 
affected pancreas allograft survival and thwarted the efforts o f early researchers. The 
introduction o f modem immunosuppressants especially cyclosporine, discovered by Borrel in 
1976, offered hope o f arresting the rejection process and in more consistent survival of 
allografts1,2.
Our knowledge and understanding o f the immune system and the mechanism o f allograft 
rejection has greatly increased and continues to expand rapidly on molecular and genetic levels3. 
The discovery o f monoclonal antibodies targeted against various cell-surface molecules has 
enabled us to identify the various cellular role players and cytokines involved in the rejection 
process.
The usual immunological rejection process against foreign antigens, eg. allograft is mediated by 
T-cells which, on encountering the foreign tissue, destroy these cells either by direct cytotoxicity 
or by the release o f cytokines. The target molecules recognised by these T-cells are mainly the 
major histocompatibility complexes (MHC) antigens, but can, in addition be targeted at the 
minor histocompatibility antigens3. These minor compatibility antigens are peptides, thought to 
be derived from polymorphic molecules other than the MHC complex3.
Major Histocompatibility Complex (MHC)
The major histocompatibility complex (MHC) molecules act as cellular identification markers 
which bind peptide antigens both intracellularly (presented on MHC class one) and
27
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extracellularly (presented on MHC class two), allowing cells o f the immune system (CD8 and 
CD4 T-lymphocytes respectively) to monitor normal cells3. There are distinct pathways in 
which peptides become associated with either the MHC class one or class two molecules.
In class one molecules, endogenous peptides are produced by proteosomes from intracellular 
proteins and transported by peptide transporters to the endoplasmic reticulum. In the 
endoplasmic reticulum the class one molecule is formed and peptide fragments o f between 8 - 1 0  
amino acids are incorporated into the peptide-binding groove. The peptides are bound in an 
extended P-structure with the amino and carboxy ends tightly bound to the opposite ends o f the 
groove.
Extracellular proteins, ingested into the cell by endocytosis, are degraded by lysosomes in an 
acidic endosomal compartment where the class two molecule is bound to it. Class two binding 
peptides are longer, between 12 and 28 amino acids and more variable in size. The binding 
groove o f the class two molecule is open at both ends and the peptides are not as tightly bound. 
The bound peptides often bulge out o f the open ends and rest on top o f the binding groove3.
The cells o f the immune systems are carefully selected and are constantly reminded o f what is 
self, as identified by these MHC antigens. Major histocompatibility complex antigens are 
encoded on at least three separate loci on chromosome 6 in humans (termed HLA A, -B, -C for 
class 1 and HLA DP, -DQ, -DR for class 2). In the mouse the MHC is encoded on chromosome
17 (termed H2D, -L, -R for class 1 and H2A, -E, -J for class 2). Each MHC has between 6 - 4 0  
or more alleles resulting in the extreme polymorphism found in each individual. This creates the 
high likelihood o f histoincompatibilities between unrelated individuals 4.
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MHC class one molecules consisting o f a polymorphic a-chain associated with a 
nonpolymorphic P2 microglobulin chain are present on all nucleated cells but are particularly 
abundant on lymphoid cells and vascular endothelium. Major histocompatibility complexes 
class two molecules consist o f covalently linked dimers o f a -  and p-chains. Major 
histocompatibility complexes class two molecules are expressed on antigen presenting cells 
(dendritic and Langerhans cells along with B cells, macrophages and vascular endothelium) and 
activated T-cells. Various immunological mediators called cytokines modulate MHC 
expression. Cytokines like interferon a , -P and -y along with TNF a  and -P are potent inducers 
o f MHC class 1 antigen expression. Induction o f increased MHC class 2 expression is more 
restricted, with interferon-y being a potent inducer o f class 2 expression.
Increased MHC expression increases the immunogenic potential o f  an allograft explaining the 
link between virus infection and graft rejection while the inhibition o f cytokines by cyclosporin, 
an IL-2 inhibitor, generally lowers the antigenicity o f the graft.
Recognition o f alloantigens
T-cells are selected in the thymus to weakly bind the MHC with their T-cell receptors. The T- 
cell subtypes CD4 and CD8 react with MHC class 2 and MHC class 1 antigens respectively5. T- 
cells are extremely sensitive to any structural differences associated with the MHC and have 
been shown to be able to detect and reject a skin allograft differing with only 1 -  3 amino acids 
in either the class 1 or 2 MHC antigens4. The introduction o f MHC mismatched allogeneic 
antigens, mismatched by either their major- and/or minor histocompatibilty antigens, results in a 
rapid and potent immune response.
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The minor histocompatibilty antigens are antigens derived from proteins particular to an 
individual (eg mitochondrial proteins) resulting in peptides/antigens derived o f different 
polymorphic molecules to the MHC but show similar donor to recipient differences3,6. The 
response is enhanced by the different ways in which these antigens are presented to the effector 
cells o f the host.
Direct recognition of alloantigens
Direct recognition o f the allogeneic MHC molecules as self-plus-X, by the great diversity o f host 
T-cell receptors is highly likely and leads to a rapid activation o f cytotoxic T-cells. This early 
acute response may involve as many as 5 to 10% o f the total peripheral T-cell pool caused by the 
high density o f MHC alloantigens on the graft. Some T-cells are peptide specific while others 
are MHC specific but able to bind the various peptides associated with that MHC molecule and 
some T-cells bind directly to the empty MHC molecules o f the donor cells3,5 ,7.
Indirect recognition of alloantigens
If the host does not react directly against the MHC antigens o f the graft two other mechanisms 
could induce destruction o f the graft. Firstly, the antigen presenting cells within the graft could 
present its own peptides in association with its MHC inducing a cytotoxic T-cells response or the 
hosts antigen presenting cells could present the foreign graft peptides in association with its 
MHC thus initiating a response against the foreign peptide5,8,9,10. The destruction o f the grafts 
presented to the effector cells in this manner would be mediated by lymphokines3.
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T-Cell activation molecules
The antigen specificity o f the T-cell receptor is provided by clonal restriction and consists of two 
chains, an a -  and a P-chain linked by disulfide bridges. The CD3 molecule is noncovalently 
bound to the T-cell receptor (TCR), the cytoplasmic domains o f the CD3 molecules are much 
longer than the TCR’s a -  and P-chains and thus provides a link between the TCR and the 
intracellular signaling pathway. The invariant chains o f the CD3 molecule contain a common 
domain that couples these proteins to the intracellular protein kinases3. Two protein kinases 
known to react with the antigen recognition activation motifs are Ick and fyn, both members of 
the Src family.
The CD4 and CD8 molecules are bound to the cytoplasmic protein tyrosine kinase Ick though a 
cysteine-containing motif shared by their cytoplasmic domains. CD4 and CD8 coreceptors 
therefore bring Ick into the proximity o f the TCR complex, where it acts on phosphorylated 
tyrosines within the antigen recognition activation motifs o f the CD3 and (^-chains 
(intracytoplasmic proteins associated with the TCR) early in the signal transduction pathway. 
Later the SH2 domain o f the CD4-associated Ick is bound to the stimulated TCR complex by 
tyrosine phosphorylated residues in the TCR complex. The binding o f CDA/lck to the TCR 
complex increases the avidity and effectivity o f signaling o f the TCR/MHC interaction 3.
Binding o f the TCR induces the tyrosine phosphorylation o f a host o f cytoplasmic and membrane
proteins. Phosphorylation o f phospholipase C-yl increases its activity and causes the cleavage of
phophatidyl inositol biphosphate, which results in the generation o f the second messengers,
inositol 1,4,5-triphosphate and diacylglycerol. Inositol 1,4,5-triphosphate induces a sustained
rise in intracellular calcium while diacylglycerol activates protein kinase C. These two signals
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synergise to induce and activate DNA-binding factors needed for IL-2 gene transcription. The 
rise in intracellular calcium activates calcineurin, a calcium-dependant serine/threonine 
phosphatase that modifies the cytoplasmic component o f nuclear factor o f the activated T-cells 
resulting in it translating to the nucleus. There it combines with newly formed Fra-1 and JunB 
proteins, induced by the diacylglycerol activated protein kinase C pathway, to form a functional 
nuclear factor o f activated T-cell complex, a positively acting transcription factor on the IL 2 
enhancer gene3. Tyrosine phosphorylation o f vav leads to the activation o f the ras signal 
transduction pathway. The oncogene, ras is a guanine triphosphate-binding protein that interacts 
directly with the serine-threonine kinase, RAF-1, which regulates the activity o f the kinase 
cascade including Mek and mitogen-activated protein (Map) kinase, leading to cell proliferation 
and differentiation by inducing c-fos and c-jun transcription factors. Expression o f an activated 
form of ras potentiates IL-2 promoter activity whereas the negative form of ras inhibits IL-2 
promotor activity. T-cell stimulation also causes the nuclear factor o f kB transcription factor to 
translocate to the nucleus which also regulates the stability o f cytokine mRNA by the induction 
o f RNA-binding factors 3.
T-cell costimulation pathway
Effective stimulation o f naive T-cells by antigen presenting cells (APC’s) requires a secondary 
non-antigen specific signal, provided by costimulation molecules. This is a safety mechanism in 
addition to positive and negative selection in the thymus and prevents naive T-cells from reacting 
against self-antigens. Failure to provide the costimulatory signal during antigen presentation by 
an antigen-presenting cell to a receptive naive T-cell results in anergy. Many costimulatory 
molecules have been identified including the various intercellular adhesion molecules ICAM-1,
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ICAM-2 and ICAM-3 and lymphocyte function associated molecule 3 (LFA-3) on the surface of 
APC’s binding to LFA-1 and LFA-2 on the T-cells does enhance T-cells proliferation but 
blockage o f these molecules does not induce anergy.
The major costimulatory signal appears to be the CD28 molecule binding to the B7 family 
present on the APC’s. Engagement o f the TCR in the absence o f CD28/B7 costimulation results 
in failure to induce an immune response resulting in anergy and preventing transplant rejection 3 
11 12. In humans CD28 is expressed on 95% of resting CD4 cells and on 50% of resting CD8 
cells in the peripheral blood.
CD28 is structurally homologous to cytolytic T-lymphocyte antigen 4 (CTLA-4) which is 
expressed on activated T-cells which delivers an negative secondary signal, further modulating 
T-cells response. CTLA-4 knock-out mice die after 4 weeks due to an uncontrolled 
accumulation o f activated T-lymphocytes3. Both these costimulatory molecules are deemed 
important in preventing transplant rejection" 13,14.
CD4 T-cells
Mature T-cells express either CD4 or CD8 molecules that bind the MHC class 2 and MHC class 
1 respectively. CD4 binds to the p2 segment o f the MHC class 2 molecule whereas CD8 binds 
to the a3 segment o f the class 1. CD4 lymphocytes are sub classified further by their 
lymphokine production. T-helper 1 (Th-1) cells are CD4 lymphocytes responsible for the 
delayed hypersensitivity type reactions and secrete interferon-y and TNF-a. T-helper 2 (Th-2) 
lymphocytes provide B cell help and secrete IL-4, IL-5, IL-6 and IL-104.
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Differentiation o f effector T-cells following antigen stimulation results from a regulated cascade 
of gene activation including the proto-oncogenes c-myc and c-fos, which are transcribed minutes 
after T-cell activation. These early activation gene products along with ongoing signal 
transduction give rise to the next wave o f gene activation including the transcription o f the IL-2 
and IL-2 receptor gene. T-cell proliferation is driven by IL-2 secretion, acting on T-cells 
expressing the IL-2 receptor thereafter the other cytokines like IL-3, IL-4, IL-5, IL-6 and IFN-y 
are also produced. After the initial burst o f cytokine secretion T-cells divide and differentiate 
under the influence o f IL-2 and IL-414,15.
Th-1 and Th-2
Activated CD4 cells are further subclassified according to the lymphokines they produce. Th-1 
cells mainly secrete IL-2, TN F-a and IFNy and Th-2 cells mainly secrete IL-4, IL-5, IL-6 and 
IL-10. These Th-1 and Th-2 cells originate from the same precursor, Th-0 cells, and cross 
regulate each other, e.g. IFNy inhibits Th-2 and IL-4 and IL-10 suppresses Th-116. TGF-p 
seems to be a cytokine that initiates the transformation o f Th-0 to Th-1 and suppresses both IL-4 
and IL-10 but not IL-2 thus encouraging Th-1 clonal expansion. Whether the transformation 
from Th-0 to either Th-1 or Th-2 is permanent and whether these clones can be reverted back to a 
Th-0 or switched between Th-1 and Th-2 is a contentious issue, but studies have shown that IFN- 
y secretion could be transiently induced in human allergen specific Th-2 clones by IL-12. The 
suppressive effect o f continuous IFN-y secretion in Th-1 or IL-4, and to a lesser extent IL-10, in 
Th-2 clones are the most likely mechanisms by which the cytokines secretory pattern o f either 
Th-1 or Th-2 clones is maintained 15.
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CD4 T-cells and rejection
Rejected grafts typically contain CD4 cells in which the Th-1 phenotype predominates, IFNy 
being the key cytokine in the rejection process as it activates macrophages, endothelial cells and 
increases MHC expression along with transporter proteins associated with antigen presentation3. 
The role o f IL-10 is still controversial having both an immunesuppressing and 
immunestimulating effect. IL-10 is seen in grafts during the induction and maintenance phases 
o f tolerated grafts but is absent in rejecting grafts. Inhibition o f IL-10 with specific antibodies 
leads to rejection o f the graft3.
CD8 T-cells and rejection
CD8 cytotoxic T-cells are able to kill allograft cells by two different mechanisms. Firstly CD8 
cells secrete cytolytic granules that contain a variety o f cytolytic proteins including perforin, a 
complement like molecule, and granzymes, a type o f serine protease. Perforin polymerizes the 
cell membrane o f target cells resulting in osmotic lysis o f the cells. Granzyme induces apoptosis 
by deregulating the normal cell cycle process. Granzyme B and perforin are expressed highly in 
grafts undergoing acute rejection3. Although CD8 cells can induce apoptosis in the target cells 
via the FAS/FAS ligand pathway it is probably more important in the controlling o f lymphocyte 
proliferation than graft destruction3. Inhibition o f either CD4 or CD8 cells in mixed MHC class 
1 and 2 incompatibility allografts prolongs graft survival, suggesting some synergy between the 
subsets in the graft rejection process4.
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Chapter  4
IMMUNESUPPRESSION AND TOLERANCE
Stellenbosch University http://scholar.sun.ac.za/
Tolerance
In 1953 Medawar and his colleagues found that by exposure o f the immune system to alloantigen 
during foetal development or the neonatal period induced tolerance to this antigen provided the 
presence o f the antigen was maintained1. It is clear that various mechanisms are involved in the 
induction and maintenance o f tolerance. Tolerance can be divided into central and peripheral 
tolerance.
Central (intra-thymic) tolerance
It is generally accepted that the thymus is the site o f central tolerance induction. The thymus 
provides the unique microenvironment for the proliferation o f T-cell precursors. Immature
thymocytes proliferate in the cortex at an astonishing rate o f 5 x l0 7 cells/day o f which only about
6 • 2 1x10 mature cells emigrate from the thymus into the periphery each day . This means that
approximately 98% o f thymocytes generated in the thymus each day die by either positive or
negative selection. Early double positive CD4+CD8+ thymocytes that express TCRs that cannot
recognise and bind to self MHC complexes, expressed on the thymic epithelial cells, fail positive
selection and are eliminated. Self-reactive thymocytes that bind with high avidity to the MHC
complexes o f thymic epithelial cells and dendritic cells are selectively (negative selection)
removed by apoptosis2,3,4. These cells are eliminated from the pool even if costimulated by
B7/CD28. Doubly positive thymocytes that pass both the positive and negative selection process
lose either CD4 or CD8 and increase their expression o f TCR2. These nearly mature thymocytes
then encounter bone marrow derived dendritic cells in the cortico-medullary and medullary
regions o f the thymus . Dendritic cells are thought to be the most potent cells in eliminating
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self-reactive T-cells during intrathymic development5. The presence o f donor derived dendritic 
cells following the establishment o f donor microchimerisms and subsequent graft acceptance 
could be due to this interaction6. The role o f the thymus in the induction o f self-tolerance has 
been undisputed for years and is clearly demonstrated in thymectomised newly bom mice which 
develop a wide-spread autoimmune syndrome affecting various organs7. Similarly ablation of 
the thymic medullary epithelial cells by cyclosporine resulted in organ-specific autoreactivity7. 
However, thymic selection only occurs against intra-thymic antigens. Originally described by 
Waksman more that 30 years ago, injection o f self- or allo-antigen into the thymus leads to a 
therapeutic induction o f specific tolerance7,8,9. Transplanting allografts into early neonates 
results in the expression o f alloantigen on the surface o f thymic epithelial cells. This induces in 
vivo tolerance to the allograft3. Besides some proof that activated peripheral T-cells might re­
enter the thymus medulla, it is accepted that extra-thymic tissue antigens are ignored by the 
thymus3,8.
T-cells develop in the thymus, and as a result o f random rearrangements o f their antigen receptor
genes, they mature into thymocytes expressing both CD4 and CD8 on their surface (DP
thymocytes). In order to proceed to the single CD4 or CD8 positive (SP) mature thymocyte, the
T-cell receptor must interact with self-peptides (Ag) bound in the clefts o f the major
histocompatibility complex (MHC) molecules on the surface o f antigen-presenting cells (APC).
A high-avidity (and therefore potentially autoimmune) interaction with self-Ag/MHC will lead to
central thymic removal, mainly by clonal deletion, whereas a low-avidity interaction leads to
positive selection and export into the periphery as a naive T-cell. Immune responses in the
periphery (spleen, lymph nodes, Peyers patches, etc) are also subject to control mechanisms that
include clonal deletion and anergy as well as regulation and suppression. These mechanisms are
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important both to maintain tolerance to self-antigens that were not expressed in the thymus 
during negative selection and might be recognized by the emerging naive T-cells, as well as to 
limit responses to foreign antigens by primed T-cells once the invading pathogen has been 
eliminated by the immune response. The aim in using therapeutic agents such as monoclonal 
antibodies that block CD4 and CD8 molecules in vivo is to harness and amplify these natural 
tolerance and regulatory mechanisms to control responses to foreign tissues following 
transplantation o f self-tissues in autoimmune disease (from Waldmann et al. 199810).
Peripheral (post-thymic) tolerance
Despite extensive negative selection (elimination) in the thymus, self-reactive T-cells are 
inadvertently transported to the periphery8. Peripheral tolerance is the mechanism that ensures a 
second line o f control against immune reaction to self-antigens in the periphery. The peripheral 
component eliminates, inactivates, downregulates (suppresses) or polarises (Th-1 - Th-2) 
autoreactive clones o f T-cells to extrathymic expressed self-antigens8. Several non-exclusive 
mechanisms are thought to regulate peripheral tolerance3.
In older animals with a competent peripheral immune system, central tolerance alone is not 
sufficient to induce tolerance and the emphasis shifts to the induction o f peripheral T-cell 
tolerance. The induction o f peripheral tolerance has become the most readily exploited modality 
in the context o f organ transplantation6.
Deletion o f the peripheral immunologically competent cells can be achieved in various ways.
Whole body irradiation and the use o f antilymphocyte antibodies (ALS) cause indiscriminate
destruction o f all lymphocytes leading to severe immune deficiency rather than tolerance to the
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allogeneic cells. Clonal deletion o f reactive cells to allogeneic antigens can be effected by Fas- 
mediated induction o f apoptosis4. The Sertoli cell o f the testis has been implicated in the 
maintenance o f the immune privilege found in the testis. These cells secrete CD95L (Fas-ligand) 
and it is postulated that when T-cells become activated they express CD95 (Fas) on their cell 
surface. Binding o f the surface CD95 by the ligand leads to programmed cell death (apoptosis) 
of the activated cell, thus resulting in clonal deletion o f those cells11. Selawry and Cameron 
attempted co-transplantation o f testis tissue and allogeneic pancreas islets in 1993, but they found 
that prolonged survival o f the graft was only seen in animals that received a course o f CsA post­
transplantation. This could have been due to the cell purification and separation techniques 
employed resulting in a low yield o f viable Sertoli cells which were unable to provide sufficient 
Fas ligand immediately post-transplantation12,13. Korrbutt improved the harvesting technique by 
culturing testicular cells for 48 hours, which resulted in the formation o f cell aggregates found to 
consist o f Sertoli cells. These aggregates were then be transplanted together with the pancreas 
islets under the kidney capsule. Results showed that provided sufficient testicular cells were co­
transplanted long-term survival up to 105 days was possible13. The growth factors that are 
secreted by Sertoli cells e.g. IGF-1, TGF-(3 and laminin are further benefits to pancreas graft 
survival and developm ent13.
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Immunesuppressive agents
Many immunesuppressive agents and therapies have been employed in transplantation and the 
list o f immunesuppressive agents is growing rapidly. Currently autoimmune diseases, allergies 
and transplant rejection therapy, treated with anti-inflammatory and immunesuppressive drugs 
are the third biggest demand, behind cancer and cardiovascular disease, on health services in the 
western world10. Immunesuppressive agents/therapies are not specific to the antigen and have a 
general suppressive effect on the whole immune response thus reducing the immune potency of 
the patient. Clinically a balance has to be found between sufficient immunesupression to prevent 
graft rejection and the complications (infection and malignancy) caused by too much 
immunesuppression14.
Intense immunesuppression leading to a high degree o f immunodeficiency can be achieved by 
indiscriminate depletion o f lymphocytes. This strategy is often employed during rejection 
episodes and induction therapy during the initial days o f transplantation. Polyclonal antibodies 
like anti lymphocyte serum (ALS) and ATG - a rabbit anti-human T-lymphocyte immune 
globulin and monoclonal antibodies aimed at the CD3 molecule e.g. OKT3 are very effective. 
Both these antibodies induce a rapid depletion o f the T-cells which is dose dependent leaving the 
individual either partially or completely immunologically incompetent or highly vulnerable to 
opportunistic infections and tumours. A similar result can be achieved by irradiation o f the 
lymphoid organs1 .
A less drastic approach to immunesuppression is to modulate or suspend the immune response 
following allogeneic transplantation. The immune response offers several opportunities for
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intervention. Antigen recognition by the T-cell induces a cascade o f events, which is required to 
induce an effective immune response to the antigen.
Regulatory cells
A large body of evidence is emerging that clearly shows that tolerance does not equal the 
absence o f alloreactivity. CTL assays o f tolerised animals have shown the presence of 
alloreactive cytotoxic T-cells. This demonstrates the complexity o f the underlying tolerogenic 
mechanisms3.
Two models for the origin o f regulatory T-cells have been proposed. In the so-called “choices” 
model it is postulated that naive T-cells stimulated by antigen under conditions o f inadequate 
help or costimulation become tolerant regulatory T-cells. These cells are in an alternate state o f 
activation and consequently would require a continued source o f antigen to maintain the 
appropriate state o f activation. Akdis, Yssel and Weiner who have presented evidence that T- 
regulatory cells are differentiated and formed from naive T-cells in the periphery on 
encountering antigens present in high concentrations support this hypothesis15. The second 
model is referred to as the “lineage” model proposes that regulatory T-cells are produced in the 
thymus which are committed only to a suppressive function on encountering the appropriate 
antigenic stimulation16. A group o f prominent immunologists including Stevens and Masson 
support this theory suggesting that T-regulatory cells leave the thymus as a distinct subset o f 
mature T-cells15.
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In both cases, the generation o f T regulatory cells is an active process, which requires the 
continued presence o f the antigen, and it would appear that these suggested mechanisms are 
connected15. Maintenance o f T-regulatory cells is known to be highly dependent on a continuous 
supply o f antigen. Withdrawal o f antigen results in a rapid decline in the suppressive capabilities 
of T-regulatory cells16.
T-regulatory cells have been implicated in the induction o f active peripheral tolerance and the 
sequential induction o f "infectious" tolerance in subsequent non-tolerised recipients17,18,19. The 
first notion that CD4 T-cells could be mediating suppression in transplantation was made by Hall 
et al. in 1985 following findings that a short period o f CsA treatment prolonged allograft survival 
in rats. This was at a time when it was accepted that T- suppressor cells were within the CD8 
subset16. The existence o f CD4 T-cells that could suppress graft rejection in mice following a 
short course o f non-depleting anti-mouse CD4 and CD8, was shown in 1993 by Qin and co­
workers20,16. Since then the demonstration o f CD4 suppressor cell involvement in graft tolerance 
has been shown in a wide range o f rodent transplantation models16.
The generation o f regulatory cells to relevant self-antigens is emerging as one o f the most 
important tolerogenic mechanisms in the periphery.
Certainly the thymus is critical for the establishment o f regulatory cells and tolerance by anti- 
CD4/donor specific antigen therapies15. Countinho and co-workers proposed a thymus selection 
model, which proposes that thymocytes binding a ligand with high avidity would enter a T-reg 
cell pool8,21.
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Introduction o f intraocular antigens into the eye, an immuneprivileged site, induces rapid antigen 
specific CD4+CD25+ T regulatory thymocytes inducted by eye-derived APCs8. Beschomer et al. 
showed the presence o f donor-origin DCs in the corticomedulla o f CsA treated rats injected 
intravenously with lymphopoietic cells22. CD4+CD25+ regulatory thymocyte release to the 
periphery only occurred once the CsA therapy was stopped. This suggests that there is an 
association between the entrance o f circulating DCs into the thymus and the establishment of 
acquired thymic tolerance by CD4+CD25+ regulatory thymocytes8.
Evidence is also presented which shows that the introduction o f antigen intravenously and orally 
induces antigen-specific CD4+CD25+ T-reg cells from nai've CD4 precursors in the periphery. It 
appears that cytokines/ APCs interaction plays an essential role in the establishment o f peripheral 
T-regulatory cells. Stimulation o f T-cells with immature dendritic cells (DC) leads to the 
development o f T-regulatory cells. IL-10 has been shown to inhibit DC maturation and could be 
central to the establishment and maintenance o f peripheral T-reg cells23,24,25’26.
Regulatory T-cells (Tr-1 cells) have been shown to express CD4, CD25, CD45RBlow, and 
constitute 5 -  10% o f the peripheral CD4+ cells in normal mice26,27,28,29. Elimination o f these 
cells induces various autoimmune diseases 1. Studies have shown these CD4 cells do not 
proliferate on antigen stimulation but suppress proliferation o f other antigen reactive T-cells. 
These cells are able to suppress rejection by both naive and primed CD4 and CD8 T-cells16.
Activation and expansion o f self-reactive T-cells, that have escaped thymic clonal deletion is
actively suppressed in the periphery by naturally occurring CD4+ regulatory T-cells, the majority
of which constitutively express CD25 (IL-2 receptor enchain). Foxp3 a common gene, which
encodes a forkhead-winged-helix transcription factor designated Scurfin expression, is
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predominantly expressed by and restricted to the CD25+CD4+ population in both the thymus and 
periphery30. Foxp3 may be a master regulatory gene for cell-lineage commitment or 
developmental differentiation o f regulatory T-cells in the thymus and the periphery. Therefore 
Foxp3 might be a more specific marker than currently used cell-surface molecules (such as 
CD25, CD45RB, CTLA-4, and GITR), which are unable to completely discriminate between 
regulatory T-cells and activated, effector, or memory T-cells30.
The cytokine profile o f these cells is still contentious with some authors reporting that these cells 
do not secrete cytokines while some evidence has been shown that these cells transcribe for IL-4, 
IL-10 and TGF-p15’26’29.
Discrepancies are also noted in the mechanism of action in these CD4+CD25+ cells. In vitro 
studies generally show that the suppressive effect o f these CD4+CD25+ cells are caused by cell­
cell interactions mainly with the APCs resulting in suppression o f IL-2 production. The in vivo 
scenario is very different to that o f the in vitro here IL-10 and TGF-P production by these 
regulatory cells have been shown to be the most likely suppressive mechanism ’ . Anti- 
TGF-pi mAb has been shown to reverse CD4+CD25+ suppression in a dose specific manner28. 
CD4+CD25+ cells express surface membrane bound TGF-P both in its latent and active 
configuration on their cell surfaces. Enhanced levels o f TGF-P receptor type II are present on the 
surface o f these cells28. An unexpected finding that triggering o f the TCR o f responder cells 
induces upregulation o f TGF-P receptor type II has provided a possible explanation o f how T-reg 
cells interact with responder/effector cells28. Direct TGF-P receptor/ TGF-p/ TGF-P receptor 
binding between the T-reg cell and a T-effector cell mediates a suppressive biochemical
pathway. Binding o f the TGF-P receptor II by TGF-P phosphorylates TGF-P receptor I which
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propagates a signal by phosphorylation o f cytosolic proteins including Smad proteins (Smad2/3) 
which then translocates to the nucleus where they modulate specific genes including genes that 
promote IL-2 production28.
CD4+CD25+ cells also express the T-lymphocyte-associated antigen-4 (CTLA-4), a negative 
costimulatory signal following T-cell activation. Acute rejection is associated with an 
upregulation o f CD28/CTLA-4/B7 molecules on peripheral blood T- and B-cells, clearly 
indicating the importance o f this co-stimulatory pathway in the rejection process29,34. The 
precise mechanism whereby CTLA-4 signaling contributes to suppression o f effector cells is still 
unknown Binding o f CTLA-4 is thought to induce TGF-P production26,28. The preferential 
binding o f CTLA-4 to CD80 and CD86 thus preventing CD28 costimualtory signaling is another 
possibility26. Blockage o f the CD28/B7 pathway by CTLA-4 has been shown to lead to 
indefinite survival o f islet, cardiac and renal allografts35,36.
The role o f B-cells as APCs in liver transplantation is o f particular interest as high levels of 
serum IL-10 post-transplantation hinders the ability o f macrophages and dendritic cells to 
stimulated Th-1 effector cells but not Th-2. B7 molecules on monocytes remain at basal levels 
during acute rejection episodes in liver transplants while B-cells express high levels o f B7. In 
non-rejecting liver transplants B-cells are mostly B7 negative (resting B-cells) indicating that at 
least in liver rejection B-cells are the APCs that modulate rejection through CD28/CTLA-4/B7 
costimulation34.
There is enough evidence to show that TCR and CD28 transduce early stimulatory signals in the 
T-cell immune response and that CTLA-4, which is expressed later, inhibits the response
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possible by reducing IL-2 secretion or apoptosis34. CTLA-4 has a higher affinity for B7 than 
CD28 but produces a weaker signal. Therefore, alloantigens presented to T-cells by APCs that 
have low levels o f B7 will result in prefertial binding o f CTLA-4 resulting in a tolerogenic 
response. Antigen presentation by APCs with high levels o f B7 results in stronger CD28 
signaling which overrides the weaker CTLA-4 signal thereby inducing T-cell activation and 
rejection34. The CD28/CTLA-4/B7 costimulation scenario is further complicated by the different 
stimulatory signals elicited by the different B7 molecules. Blockade o f B7-1 and CTLA-4 
promotes and accelerates rejection, while blockage o f B7-2 prolonged graft survival37’38.
CD4+/CD25+ cells have been shown to be particularly responsive to inflammatory cytokines 
especially those engaging the CCR4 and CCR8 receptors. This could indicate that these cells 
actively home in on sites o f inflammation39.
T-cell anergy
Effective ligation o f the TCR by antigen/MHC complex molecules along with an appropriate co­
stimulatory signal (B7/CD28) induces activation o f the reactive cell resulting in cytokine 
secretion and clonal expansion o f the reactive cells. Ineffective binding o f the TCR- 
antigen/MHC complex and/or failure to activate a costimulatory signal, such as B7/CD28, results 
in an attenuated activation signal, which is insufficient for an effective immune response, leads to 
specific T-cell anergy3’4’10. In vivo antigen-specific naive T-cells require the collaborative 
interaction between specialised APCs and the correct environment i.e. cytokines and appropriate 
co-stimulatory signals. If  the number o f antigen-specific naive cells is too low or has insufficient 
avidity to form a stable cluster around the APC, the correct environment is not created and these 
cells revert to a tolerance/anergic state. These anergic cells compete for antigen and if enough
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are present, a state o f general tolerance against a specific antigen is induced. This process is 
analogous to the process whereby therapeutic antibodies like anti-CD4, both depleting and non­
depleting, induce tolerance. The antibody either depletes the antigen-reactive cells to such an 
extent that the remaining cells cannot produce a stable cluster/environment for an effective 
response or with an non-depleting antibody, blockade o f activation molecules like CD4 reduces 
the avidity o f these anti-reactive cells which then default to an anergic state. Waldmann refers to 
this as the civil service state because the minimum requirement o f the tolerant T-cells (analogous 
to government officials) is the ability to passively interfere with the attempts o f naive T-cells 
(analogous with public interest groups) to get a response started10.
Anergic cells classically produce little IL-2, IL-4 and IFN-y. The downregulation o f IL-2 
secretion seems to be one o f the major pathways o f inducting anergy. Anergic cells produce 
significant amounts o f IL-10 and TGF-p, both regulatory cytokines6. IL-10 has been shown to 
induce an antigen-specific anergy in CD4 cells. These cells fail to proliferate or produce 
cytokines in response to antigen stimulation32. Another characteristic o f anergy is that effector 
T-cell function can be restored by treatment with IL-240. Targeting the ERK-1/2 signalling 
pathway has been shown to induce alloantigen specific anergy in human T-cells. Following 
engagement o f the TCR, various kinases are activated, including extra cellular-related kinase 
(ERK), these intum transactivate various gene products necessary for T-cell function. Krieger et 
al. has demonstrated that blocking ERK downregulates CD25 thus suppressing IL-2 dependent 
proliferation o f T-cells41. An interesting finding by Krieger et al. was that addition o f CsA to 
ERK-pathway blockade promoted this ERK-induced alloantibody T-cell anergy41.
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Negative selection of T-cells in the periphery
Elimination o f antigen specific T-cells occurs in the periphery. A similar system to the thymus 
selection o f high avidity to antigens is present in the periphery. T-cells bearing high affinity 
TCRs to specific antigens are eliminated by apoptosis while T-cells with a weaker affinity to the 
specific antigen clonally proliferate. This prevents excessive T-cell clonal expansion and is a 
self-protection mechanism3. Candidate sites for peripheral clonal deletion include the gut, bone 
marrow and the liver. Van Pel et al. showed that thymecomised mice are still able to develop 
donor-specific tolerance after sublethal conditioning consisting o f a single dose o f anti T-cell 
monoclonal antibody and low dose total body irradiation. The authors were able to demonstrate 
the presence o f donor T-cells and donor APCs in the GALT o f the small intestine thereby 
concluding that the gut was the primary organ supplying the microenvironment for clonal 
deletion o f alloreactive cells, in euthymic and thymecomised mice42.
Microchimerism and tolerance
Billingham, Brent, and Medawar in 1953 were the first to show that it was possible to induce 
chimerism-associated neonatal tolerance deliberately1. This discovery escalated over the next 15 
years to the first successful bone marrow transplantations in humans in 196843.
Donor cells and genetic material can usually be detected within a recipient following organ 
transplantation. This phenomenon is referred to as peripheral (micro)chimersim, which in some 
cases can be long lasting. Donor material has been detected in the periphery o f recipients up to 
29 years after renal transplantation44,45. Starzl et al. in 1992 were the first to show that that long- 
surviving organ transplant recipients had persistent microchimerisms. They then put forward the 
hypothesis that organ transplantation induced peripheral microchimerisms which are associated
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with long-term acceptance o f allografts and that this process plays an active role in the induction 
and maintenance o f unresponsiveness43’45’46. Passenger leukocytes i.e. leukocytes present within 
the transplanted organ, especially immature dendritic cells migrate to recipient's lymphoid 
tissues, especially the spleen, where these cells interact with recipient CD4+ cells thereby 
eliciting an immunological response45. This process contributes greatly to the immunogenicity 
of the grafts45,47. Chimerisms can be introduced to establish tolerance. In practice this can be 
achieved by either donor transfusion or donor bone marrow transplantation. The establishment 
o f a mixed lymphohaematopoietic chimerisms resulting in a low but persistant levels o f donor- 
derived dendritic cells which are capable o f providing a persistent source o f antigen in the 
thymus and thereby effecting negative selection and establishing donor specific tolerance45,46’48.
CsA and FK506
Immunosuppressants like cyclosporine (CsA), tacrolimus (FK506) bind to cyclophilin and FK- 
binding protein respectively to form an intra-cytoplasmic active complex, which in turn binds to 
and inhibits calcineurin. Inhibition o f calcineurin prevents activation o f cytokine promotor genes 
(e.g. IL-2, IFN-y, GM-CSF, TNF-a, IL-4 and CD40L) and therefore prevents cytokine-induced 
proliferation49. Both cyclosporine and tacrolimus are highly effective in graft maintenance with 
tacrolimus being more potent. Clinical trails comparing FK506 to CsA found that liver and renal 
patients on FK506 had fewer acute rejection episodes and less refractory and chronic rejection. 
More patients became hyperglycaemic requiring insulin following FK506 but fewer patients had 
elevated cholesterol49. Nephrotoxicity is a potential side effect o f both FK506 and CsA, which is 
probably due to vasospasm in the kidney, induced by calcineurin inhibition. Infectious
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complications were higher in the FK506 groups but could be due to the higher level of 
immunosuppression49.
Sirlolimus
Sirolimus (Rapamycin) is a antibiotic similar to FK506 binding to the same intracellular binding 
protein (FKBP). Unlike FK506, the sirolimus -  FKBP complex does not inhibit calcineurin but 
it binds to and inhibits the autophosphorylation o f the target o f rapamycin, a protein with a kinase 
domain49. Inhibition o f the target o f rapamycin interrupts the signaling pathway between the 
cytokine receptors and the cell cycling arresting cells at the G l - to S-phase transition during their 
cell cycle. Studies combining sirolimus with CsA have show a reduction o f acute rejection but 
an outbreak o f Pneumocystis carinii during the trial suggests excessive immunodeficiency 
induced by the combination49.
Mycophenolate mofetil (MMF)
Mycophenolate mofetil (MMF) and its active agent mycophenolic acid (MPA) which inhibits 
inosine monophophate dehydrogenase (IMPDH) the rate limiting enzyme in de novo purine 
biosynthesis, therefore interrupting the de novo purine synthesis pathway, which is required by 
activated lymphocytes for cell division. Most other cells are able to use the salvage pathway and 
proliferate normally. MMF combined with CsA has shown similar efficacy compared to CsA 
and azathioprine but MMF does not have the same marrow toxicity49. MMF does have 
gastrointestinal toxicity, caused by the high levels o f glucuronide in the bile. The efficacy of 
MMF is further enhanced if combined with FK506 which appears to alters the MPA metabolism
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increasing its half-life. MMF has also been shown to suppress glycosylation and adhesion 
molecules in human monocytes49.
Immunosuppression and tolerance
In contrast to original beliefs that cyclosporine does not induce tolerance, and in fact counteracts 
tolerance induction, evidence is slowly emerging that under certain circumstances cyclosporine 
could help induce tolerance. Hall et al. showed in 1985 that they could achieve prolonged 
cardiac allograft survival in rats after a brief period o f treatment with CsA 16'50 [combination o f a 
short course o f CsA (7x daily doses) with DST ( lx  weekly) four weeks before transplantation of 
cardiac grafts into MHC class I disparate rats]. In this research, Yang et al. made a strong case 
that the major role players in the induction o f tolerance in these rat models were, not as expected 
the CD4 T-cells but appeared to be mediated in an allospecific manner by B-cells51. Studies on 
rat cardiac allografts have shown that combining DST with a short course o f CsA significantly 
suppressed alloantibody formation51. Tolerance was broken by co-infusion o f normal B-cells 
and CD4 T-cells which resulted in high levels o f allospecific cytotoxic antibodies51. The graft 
unresponsiveness was not always permanent and often grafts were lost in time51. CsA alone has 
been shown to have little effect on B-cell proliferation but has been shown by several groups to 
prevent apoptosis o f immature T- and B-cells while CsA has been shown to directly mediate 
apoptosis in mature lymphocytes51.
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Antibodies used for immunosuppression
Polyclonal antibodies like anti-leukocyte serum (ALS), anti-thymocyte globulin (ATG) deplete 
the peripheral immune system o f T-cells, by activating the complement system following binding 
of the relevant antibody to the cell. Depletion o f the T-cells is dose dependant leaving the 
individual partially or completely immune deficient. This form o f treatment is used as induction 
therapy and is also used for rescue therapy during a rejection episode. The indiscriminate action 
o f polyclonal therapy is due to the nature o f polyclonal antibodies i.e. a cocktail o f antibodies 
against various individual antigens introduced and occurring naturally in the animals in which 
the antibodies are being raised.
Monoclonal antibodies on the other hand can be raised to a single antigen and are extremely 
specific. Monoclonal antibodies can also be either depleting i.e. inducing cytolysis by 
complement activation or non-depleting where the antibodies bind the surface antigens without 
activation o f complement. OKT3 an anti-CD3 monoclonal antibody was the first monoclonal 
antibody approved for transplant immunosuppression. OKT3 clears T-cells (CD3 positive cells) 
from the circulation within minutes, leaving the patient severely immune compromised. Some 
T-cells do however eventually return to the blood but initially these cells do not express surface 
CD3 molecules, and since CD3 interacts with the T-cell receptor these cells have greatly reduced 
function52.
CD4+ T-cells are known to play a central role in most immune responses. CD4 cells recognize 
exogenously derived antigen, presented by antigen presenting cells (APC) and they are the cells 
that drive the activation o f the effector cells against these antigens. Targeting the CD4 molecule 
with various monoclonal antibodies in order to manipulate the response has shown promising
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results in various experimental animal models. Depleting CD4 monoclonal antibodies has been 
shown to induce permanent acceptance o f grafts. In 1986 the Waldmann and Wofsy groups 
showed that a short course o f depleting CD4 mAb induced long-term tolerance to foreign 
immunoglobulins in rats and mice respectively. This finding was further supported by the 
findings o f Fathman that the depleting anti CD4 mAb L3T4 suppressed the response to sperm 
whale myoglobulin in mice10. One o f the first rat anti-mouse CD4 mAb GK1.5 (isotype IgG2b) 
antibodies used in vivo, shown to be highly cytolytic in the presence o f complement, blocked all 
MHC class II antigen specific functions including cytolysis, proliferation and release of 
cytokines 53. Depletion o f the CD4 cells is dose dependent but even high doses can only remove 
approximately 90-95% o f the CD4 cells from the peripheral blood, lymph nodes and spleen. The 
remaining 5-10% o f antibody resistant cells are cells expressing low levels o f CD4 and are 
thought to be memory cells53. The thymus protects the CD4 thymocytes from cytolysis and even 
high doses o f GK1.5 mAb have little effect on the thymocyte populations. Following a maximal 
dose o f 5 mg/kg GK1.5 the CD4 cells returned to pretreatment levels at around 100 days.
In rats, similar results were achieved using a mouse anti-rat CD4 mAb OX-38. A high dose o f 9- 
13mg/kg induces long-term depletion o f CD4 cells, with only 50 -  60% o f the original CD4 cells 
being present at 80 days post-treatment. These rats were however still immunocompetent with 
the ability to reject third party grafts and to mount mixed lymphocyte and cytotoxic T-cell 
responses53.
The recovery o f the peripheral CD4 cells, following treatment with depleting mAb, due to 
replenishment from precursors re-establishes immunocompetence but in an altered form . 
Burkhardt (1989) compared the efficacy o f the depleting CD4 mAb GK1.5 to a nondepleting
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CD4 mAb H I29.19, a rat anti-mouse CD4 mAb isotype IgG2a (shown to be a poor inducer of 
complement-mediated lysis), in preventing foetal pancreas allograft rejection in fully MHC 
mismatched mice54. Examination o f the splenic T-cell populations, following anti CD4 
treatment, showed that GK1.5 (anti-L3T4a)55 had removed almost all the CD4+ (<1%) cells from 
the spleen while >95% o f the CD4+ cells that were present, demonstrated the presence o f rat IgG 
on their surfaces54. They found that both the depleting and non-depleting mAb prevented graft 
rejection at 14 days but rejection occurred at 28 days.
The cells infiltrating the graft were almost exclusively CD8 positive cells. They concluded that 
the CD8 cells were able to reject both MHC I and MHC II mismatched allografts but at a slower 
rate but that the addition o f CsA to both the mAb had a synergistic effect, improving graft 
survival and suppressing graft infiltration by CD8 cells54. Although Burkhardt was disappointed 
in the results he made a valid comment that long-term acceptance o f isolated adult islets had been 
achieved in other strain combinations54.
Waldmann showed that it was possible to induce tolerance in an allogeneic marrow transplants, 
under the cover o f nondepleting CD4 and CD8 mAbs, in animals with multiple minor MHC 
mismatches16. These mice then became chimeric and accepted skin grafts o f the donor. The 
induction o f tolerance in fully MHC mismatched animals could not be achieved by CD4 and 
CD8 mAb alone but by further immunosuppression by irradiation (600 rads) or other 
myeloablation using the alkylating agent dimethylmyeleran (DM M )10.
The differences in efficacy o f CD4 mAb in different animal models was shown by llano (1989)
in a study using anti CD4 mAbs 0X 35 and 0X 38 for transplantation o f PVG vascularized
neonatal heart allografts in low responding DA (RTIa) and high responding Wistar Furth (W/F)
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rats56. The low responder DA rats had indefinite survival o f all their grafts while the high 
responding W/F rats showed prolonged graft survival compared to the controls, they had all 
rejected their grafts at 42 days. Comparison o f the MLC proliferation o f the T-cell subsets using 
irradiated PVG spleen cells as stimulators on CD4’ and CD8+ enriched cell populations showed a 
marked difference in the alloreactivity in these strains56.
In the high responding W/F model CD8+ cells proliferated following stimulation while the CD8+ 
cells in the low responding DA rats showed no increase in cell numbers. CD4 proliferation, 
following stimulation, was high in both the high and Low responding models. It would therefore 
appear that in high responding animals CD8+ cells proliferated upon antigen stimulation without 
the presence o f CD4 cells, by producing exogenous cytokines thus overcoming the need for CD4 
help56.
The lack o f responsiveness seen in the low responders (DA) is not due to a defect in their 
immune response. Rejection can be restored by infusion o f as little as lx l0 6 naive CD4+ cells 
while the infusion o f CD8+ cells could not reverse the unresponsiveness. Proliferation of the 
CD8+ cell could be induced in culture by cytokine manipulation. Addition o f anti-CD8 (0X8) 
mAb to the anti-CD4 therapy prevented the induction o f unresponsiveness56.
Manipulation o f the early CD4 positive T-cells by anti-CD4 mAbs, following antigen exposure, 
to induce a more tolerant Th-2 response has become a popular method o f prolonging graft 
survival in various animal models. W3/25, a mouse anti rat anti-CD4 mAb, isotype IgGi binding 
to domain 1 o f the CD4 molcule57, was shown to inhibit the mixed lymphocyte response (MLR) 
of PVG/c (RT1C) lymphnode as responding cells stimulated with H 0.B2(RT1U) spleen cells as
well as other strain combinations including AO vs DA and PVG/c vs DA. A concentration o f 25
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ng/ml gave maximal inhibition o f the MLR for allogeneic stimulation but could not inhibit the 
MLR response following T-cell mitogenic stimulation with concanavalin A (con A) or 
phytohaemagglutinin (PHA) even if  the concentration o f the W3/25 was increased to 2.5 ug/ml, a 
100 times that required to maximally inhibit alloantigen stimulated M LR’s58,59. Inhibition of 
these W3/25 positive cells (CD4+ lymphocytes) was specific without killing them. A control 
mAb W3/13 (CD43), did not affect the MLR of these cells58.
W3/25 was shown to be effective in the treatment o f experimentally induced allergic 
encephalomyelitis (EAE) in Lewis rats. A single 1.5 mg i.p. injection o f W3/25 was 
administered at the first sign o f encephalomyelitis i.e. limp tail, hind leg weakness or hind leg 
paralysis, occurring normally at day 12 -  13 after immunization with guinea pig MBP. 
Following W3/25 administration affected rats recovered in a day or two compared to 5 -  6 days 
in the control animals60. A further study on EAE, Mannie looked at the possible mechanisms and 
effect o f W3/25 therapy in this EAE model. Using reverse transcription polymerase chain 
reaction (RT-PCR) he could show that the W3/25 profoundly reduced the IL-2/IL-4 cDNA ratio 
and although the IL-4 mRNA was reduced the IL-2 mRNA was totally inhibited following 
allogen stimulation but not mitogen stimulation59.
In vitro studies did however show that although IL-2 production might be slightly reduced, an
increase o f IL-2 was detectable after 48 hours in a 1° MLC before proliferation was detected and
continued to increase as proliferation increased in a similar manner to that seen in uninhibited
controls57. Cells activated in the presence o f W3/25 also displayed normal levels o f IL-2
receptor. What was very apparent was that IFN-y production was completely inhibited in the
W3/25 treated 1° MLC. This inhibition o f IFN-y synthesis by W3/25 had a dramatic effect on
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the synthesis o f IL-4. Quantitative RT-PCR of 1° MLCs showed similar message levels between 
the W3/25 treated and control groups for IL-4, IL-10 and IL13. IL-4 levels showed an dramatic 
300 times increase in IL-4 synthesis compared to the untreated control groups in a 2° MLC57. 
Supplementation o f the W3/25 treated MLC with IFNy and IL-2 induced a 50% increase in 
proliferation while addition o f these cytokines to the untreated control cultures had no effect. IL
13 showed a similar effect with IL 13 levels increased 100-fold that o f the control cultures in the 
2° MLC. In contrast the IL-10 synthesis was not increased with similar levels between the 
W3/25 and non-treated control cultures57.
Experimentation to confirm the increased production o f IL-4 in the 2° MLC of the cells treated 
with W3/25 in the 1° MLC, the ability o f IL-4 or IL13, present in high levels in the supernatant 
o f the W3/25 treated 2° MLC, to upregulate MHC class II expression on B-cells was assessed. 
Both 24-hour and 48-hour supernatant significantly upregulated MHC class II expression on the 
B-cells, which could be blocked by the addition o f 0X 81, which is a neutralizing mAb to rat IL- 
457. Enhanced IL-4 production in the 2 0 MLC is most likely caused by the inhibition o f IFN-y 
since the addition o f IFN-y to the 1° MLC of W3/25 treated cultures blocked the subsequent 
increase o f IL-4 production in the 2° MLC. An interesting finding was that IFN-y synthesis was 
not inhibited in the 2° MLC showing that the inhibition o f IFN-y seen in the 1° MLR could be 
reversed57.
IFN-y has been shown to promote Th-1 clones over Th-2 clones in mice57’61. Proliferation o f 
Th-1 cells also requires that the peptide to which a response is generated is present in abundance 
and binds with great affinity to the MHC class II molecules o f the APC. Therefore compared to
the Th-2 cells, Th-1 cells would require a greater number o f high affinity peptide-MHC
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interactions to be activated. Anti-CD4 mAb binding o f CD4 interferes with MHC-CD4 
costimulation57’62, providing an attenuated signal. Due to the attenuated signal it is quite 
conceivable that only Th-2 cells proliferate if antigen is introduced under the cover o f an anti- 
CD4 mAb and more specifically W3/2557. Proliferation without CD4 costimulation, inhibited by 
the antibody, and the high levels o f IL-4 and IL-13 secreted by these CD4 positive cells in a 2° 
MLC, under cover o f W3/25 in the 1° MLC would support such a theory57.
This would suggest that W3/25 and very likely other anti-CD4 mAbs interfere with CD4 
costimulation o f T-cells following antigen recognition, differentially promoting Th-2 
proliferation and cytokine secretion o f especially IL-4 and the inhibition o f Th-1 cytokines 
especially IFN-y and TGF-P production57’59,63’64.
Induction of tolerance
Ondera using the nondepleting mAb RIB5/2 in his rat cardiac allograft model and Waldmann’s 
group, using anti-CD4 and anti-CD8 mAb in MHC minor mismatched skin allografts in 
thymectomized mice showed that the tolerance achieved, was infectious and that naive recipients 
could be tolerised by splenocytes o f tolerant animals10,65. Ondera showed that the infectious 
tolerance could be abrogated by depletion o f CD4+ cells with a depleting anti-CD4 mAb (0X36) 
while depletion o f CD8+ cells with anti-CD8 mAb (0X 8) had no effect, proving that CD4+ cells 
were required to maintain tolerance10,65. These CD4+ regulatory T-cells, generated in response to 
alloantigen in the presence o f anti-CD4 mAb, may well represent putative immunoregulatory Th- 
2-like cells which migrate to the spleen and may be sequestered at the graft site in tolerant 
animals65.
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These cells, on alloantigen stimulation, are associated with increased expression o f IL-4 and IL-
10 mRNA in the grafts o f both primary and secondary recipients65. The ability o f anti-CD4 mAb 
to preferentially promote Th-2 cells could be explained by the fact that the ligation o f the surface 
CD4 molecule by the CD4 mAb activates protein tyrosine kinase p56lck, which is associated with 
the cytoplasmic portion o f the CD4 molecule. Since Th-2 cells use protein tyrosine kinase for 
signal transduction, activation o f p56lck by cross linking o f the CD4 molecule with anti-CD4 
mAb, increases levels o f cAMP in these Th-2 lymphocytes, which in turn could provide a 
negative signal to inhibit Th-1 activation66.
Alloantigen and CD4 antibody induction of tolerance
Functional tolerance by introducing donor specific antigen (peripheral blood or splenocytes) 
under the cover o f anti-CD4 mAbs has been demonstrated in various rat and mouse 
models29’67,68,69,70. The most likely mechanism of tolerance induction by anti-CD4/Donor 
specific antigen is by regulatory cells, both during the induction phase and the maintenance of 
tolerance19,29,65. This anti-CD4 induced immune regulation effective suppresses naive and 
activated CD4 and CD8 cells in an antigen specific manner19. Furthermore the acquired anti- 
CD4 tolerance can be transferred from the recipient into a secondary recipient, which clearly 
indicates the role o f regulatory cells19. Woods and the Oxford transplant immunology group 
have demonstrated in a rodent model that if DST is given in combination with anti-CD4 mAb 
therapy 28 days prior to transplantation these rats will accept the grafts without any further 
immunosuppression. This crucial period is thought to be required for the clonal development o f 
specific regulatory cells29,70.
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Alloantibodies
Anti-CD4 mAb therapy with RIB5/2 in the cardiac model prevented the class switch of 
alloantibodies from IgM to IgG and was able to suppress IgG alloantibody production 
indefinitely in that model65. The prevention o f this class switch may be critical for long-term 
acceptance o f allografts as the deposition o f intragraft IgG is a classical feature o f chronic 
rejection65. Immunoglobulin class switching is induced by complex T- and B-cell interactions in 
which the cytokines they produce especially IFN-y plays a major role65. Furthermore, the 
production o f antiidiotypic antibodies in response to the injected monoclonal antibodies is 
severely suppressed by anti-CD4 monoclonal antibodies showing little or no humoral reactivity 
to the injected antibody, provided sufficient antibody is given65,71.
Th-1 and Th-2 and graft tolerance.
It has been hypothesised that deflection o f the allogeneic immune response from a Th-1 like 
response, which is associated with acute graft rejection, to a Th-2-like response may help to 
establish and maintain graft acceptance or even tolerance. The activity o f so-called suppressor 
cells which represent anergic cells which tolerise or actively suppress other non-tolerant cells 
may be explained by the Th-1/Th-2 paradigm64. Pawelec et al. showed differentiation o f human 
Th-0 T-cell phenotyes, to either Th-1 or Th-2, following alloantigen stimulation via the direct 
pathway could be manipulated in vitro by the neutralization or addition o f certain cytokines. 
Brief exposures o f IL-4 or IL-10 diverted the response to that o f a Th-2 while TGF-(3 favored the 
development o f a Th-1 phenotype64.
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The generally accepted principle that Th-1 cytokines promote graft rejection while Th-2 cytokine 
favors acceptance or functional tolerance o f allografts has been questioned by some researchers. 
Using a depleting mouse anti-CD8 mAb, in a mouse model, Chan et al. showed cytokines (IL-2, 
IFN-y, IL-4, IL-5 and IL-10) expressed in their rejecting cardiac allografts to be o f a mixed Th- 
l/Th-2 type. In comparison the cytokine profiles o f the unmodified rejection groups consisted of 
only Th-1 cytokines with IL-2 and IFN-y being present and no IL-4 and IL-5 present. In the anti- 
CD8 treated group, the intragraft infiltrate consisted o f macrophages, lymphocytes and a 
significant amount o f eosinophils, which were not present in the unmodified rejection groups. 
Eosinophils, know to be responsive to Th-2 cytokines and IL-5 in particular which they have
79been shown to be the effector cells in the rejection process o f these grafts .
A similar scenario exists in transgenic CD95L expressing islets allografts, which instead of 
being immune priviliged and causing apoptosis o f graft infiltrating effector cells, (the grafts) 
were rapidly rejected by neutrophils73,74’75. Despite these and other experiments Th-2 cytokines,
76and especially IL-4 has been shown to be essential for the establishment o f neonatal tolerance . 
In vivo introduction o f anti-IL-4 in neonates prevents the induction o f tolerance by IL-4 secreting 
tolerogenic T-cells77.
Donor specific antigens and transfusions.
Similarly, the introduction o f foreign alloantigens into the developing immune system of 
neonatal mice induces specific tolerance in the mouse. These tolerised mice will accept 
allografts from the specific donors indefinitely but reject third party grafts1.
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In adults donor-specific transfusions have been shown to have a modulating effect on graft 
rejection and has been show to prolong cardiac and renal allograft survival which is associated 
with an decrease in mRNA for IL-2 and IFN-y and an persistent production o f IL-4 and IL-10
78 • •mRNA . While this is very effective in selective strain combinations, unresponsiveness is not 
always maintained and most grafts are eventually rejected68. The Nuffield group o f Sir Peter 
Morris and Kathryn Wood has actively researched combination o f donor-specific antigen and 
anti-CD4 mAb to induce donor unresponsiveness. Fully H-2 and minor mismatched adult mice 
combinations received two injections o f YTS 191.1 (50 ug) on days -28  and -27  prior to 
transplantation. On day -27  they also injected 0.25 ml donor specific whole blood. No further 
treatment was given and the animals transplanted. Following this protocol most cardiac grafts 
survived more than 100 days but the authors acknowledge that they could not induce the same 
graft acceptance in other fully mismatched allogeneic strain combinations68. Using a similar 
depleting anti-CD4 mAb YTA 3.1.2 Bushell o f the same group irradiated the donor blood prior 
to transfusion to see whether the graft acceptance was due to microchimerisms from stem cells 
within the donor blood. Interestingly, if the DST was treated with a single high dose o f 
irradiation (2000 rads) rejection followed but if  he gave three doses o f the irradiated blood DST 
the tolerogenic effect was restored. From this he concluded that the graft acceptance, following 
this protocol, was most likely due to the persistence o f alloantigen during the 3 days in which the 
anti-CD4 mAb had its effect and not due to the establishment o f a microchimerism79. Woods et 
al. describes the effect o f anti-CD4 and alloantigen therapy as a perturbment o f the proximal 
signalling events following TCR/CD3 ligation, resulting in reduced tyrosine phosphorylation of 
Zap-70 and LAT and reduced association o f tyrosine-phosphorylated LAT with Ick. This 
ultimately results in severely reduced proliferation o f the responding CD4+ T-cells. The
65
Stellenbosch University http://scholar.sun.ac.za/
signalling profile o f the anti-CD4-treated cells resembled that o f anergic T-cells. This could be a 
result o f a common mechanism involving perturbation in the formation o f the central 
supramolecular activation cluster o f the immunological synapse by impaired recruitment o f CD4 
and CD28, thereby resulting in severely reduced lck activation80.
DST in the clinical setting
Medawar in 1946 first reported accelerated graft rejection o f skin transplants in rabbits that had 
received prior blood transfusions81. The immunomodulating effect o f allogeneic blood 
transfusions was first revealed by a positive association between kidney graft survival and the 
number o f allogeneic transfusions received by the recipient82. In a randomised clinical study 
Opelz et al. found that despite the use o f new potent immunosuppression the beneficial effect o f 
blood transfusions on kidney graft survival is still observed83.
Several immulogical mechanisms have been proposed that may be involved with the 
tolerogenic/immunomodulatory effect o f donor transfusion. These include clonal deletion, 
clonal anergy, introduction o f anti-idiotypic antibodies and regulatory cells. Transfusions are 
also thought to induce a Th-2 type response rather than a Th-1 response. The cytokines produced 
by Th-2 cells include IL-4, IL-10 and TGF-P which are able to downregulate cytotoxic T-
S'} 84. __ __cells ’ ’ . The shift to a Th-2 response will occur if the antigen presenting cells in the blood are 
unable to provide the proper co-stimulatory signals to T-cells82. Blood transfusions introduce 
allogeneic MHC II bearing APCs, which can directly activate CD4 recipient helper cells.
However the ex vivo storage o f blood affects the effectivity o f the APC and in particular their
• • • 86 ability to provide costimulatory signals essential for T-cell activation .
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The fate o f donor lymphocytes post transfusion is not well known. The establishment o f a donor 
cell microchimersim, demonstrating tolerance between donor and recipient has been 
demonstrated for more than a year in multiple transfused trauma patients86.
Evidence is emerging that soluble factors in the blood transfusion product may play an important 
role. Supernatant o f blood products contain several soluble molecules with immunomodulatory 
properties. These include soluble HLA class I and soluble FAS ligand molecules. These 
molecules are able to block the reactivity o f alloantigen specific T-cells by inducing apoptosis of 
the potentially reactive cells82.
One of the main reasons for not employing pretransplant transfusions in the clinical setting is the 
inadvertent introduction o f alloantibody, which renders the patients unsuitable for 
transplantation. However, the DST-induced sensitisation might in fact be less harmful than 
initially perceived. In fact, the presence o f alloantibody after DST infusion could identify 
recipients with elevated risk o f rejection requiring aggressive anti-rejection therapy. The non-
• • 87antibody producers will benefit from the DST modulating effect on T-cell-mediated rejection .
67
Stellenbosch University http://scholar.sun.ac.za/
BIBLIO G R A PH Y
1 Billingham RE, Brent L, Medawar PB. Actively aquired tolerance o f foreign cells. Nature 
1953; 172: 603.
2 Janeway CA, Travers P. Immunobiology: The immune system in health and disease. Oxford: 
Blackwell Scientific Publishers; 1994.
3 Arnold B. Levels o f peripheral T-cell tolerance. Transpl Immunol 2002; 10: 109 -  114.
4 Aradhye S, Turka LA. Will Tolerance Become a Clinical Reality? Am J Med Sci 1997; 313 
(5): 310-314.
5 Janeway CA, Goodnow CC, Medzhitov R. Immunological tolerance: danger -  antigen on the 
premises. Curr Biology 1996; 6 (5): 519 -  522.
6 Lechler R, Bluestone JA. Transplantation tolerance putting the pieces together. Curr Opin 
Immunol 1997; 9(5): 631-3.
7 Kyewski B, Derbinski J, Gotter J, Klein L. Promiscuous gene expression and central T-cell 
tolerance: more than meets the eye. Trends in Immunology 2002; 23 (7): 364 -  371.
8 Goldschneider I, Cone RE. A central role for peripheral dendritic cells in the induction o f 
acquired thymic tolerance. Trends in Immunology 2003; 24 (2): 7 7 -8 1 .
68
Stellenbosch University http://scholar.sun.ac.za/
9 Stadlbauer THW, Schaub M, Magee CC, Kupiec-Weglinski JW, Sayegh MH. Intrathymic 
immunomodulation in sensitized rat recipients o f cardiac allografts: requirements for 
allorecognition pathways. J Heart Lung Transplant 2000; 19 (6): 566 -  575.
10 Waldmann H, Cobbold S. How do monoclonal antibodies induce tolerance? A role for 
infectious tolerance? Annu Rev Immunol 1998; 16: 619-44.
11 Vaux DL. Immunology. Ways around rejection. Nature 1995; 377(6550): 576-7
12 Selawry HP, Cameron DF. Sertoli cell-enriched fractions in successful isleT-cell 
transplantation. Cell Transplant 1993; 2(2): 123-9.
i o .Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation o f allogeneic islets with allogeneic 
testicular cell aggregates allows long-term graft survival without systemic immunosuppression. 
Diabetes 1997; 46(2): 317-22
14 Halloran, P.F. Immunosuppresive agents in clinical trials in transplantation. Am J Med Sci 
1997;313:283-288.
l5GrouxH. An overview of regulatory T-cells. Microbes and Infection 2001; 3: 8 8 3 -8 8 9 .
16 Waldmann H. Regulating the immune response to transplants: a role for CD4+ regulatory 
cells? Immunity 2001; 14: 399 -  406.
17 Karim M, Bushell AR, Wood KJ. Regulatory T-cells in Transplantation. Curr opinion in 
Immunol 2002 14: 584-591
69
Stellenbosch University http://scholar.sun.ac.za/
18 Ondera K, Chandraker A, Volk HD, Lehmann M, Korom S, Stadlbauer THW, Kato K, Kasai 
S, Sayegh MH, Kupiec-Weglinski JW. Role o f regulatory T-cells in the “infectious” tolerance 
pathway in transplant recipients. Transplant Proc 1998; 30: 1 3 -1 5 .
19 Cobbold S, Waldmann H. Infectious tolerance. Current Biology 1998; 10: 518 -  524.
20 Qin S, Cobbold SP, Pope H, Elliott J, Kioussis D, Davies J, Waldmann H. "Infectious" 
transplantation tolerance. Science 1993; 259(5097): 974-7
91 . . .  . .Modigliani Y, Coutinho A, Pereira P, Le Douarin N, Thomas-Vaslin V, Burlen-Defranoux O, 
Salaun J, Bandeira A. Establishment o f tissue-specific tolerance is driven by regulatory T-cells 
selected by thymic epithelium. Eur J Immunol 1996; 26(8): 1807-15
22 Beschomer WE, Yao X, Divic J. Recruitment o f semiallogeneic dendritic cells to the thymus 
during post-cyclosporine thymic regeneration. Transplantation 1995; 60(11): 1326-30.
Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction o f interleukin 10-producing, 
nonproliferating CD4(+) T-cells with regulatory properties by repetitive stimulation with 
allogeneic immature human dendritic cells. J Exp Med 2000; 192(9): 1213-22
24 Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific 
inhibition o f effector T-cell function in humans after injection o f immature dendritic cells. J Exp 
Med 2001; 193(2): 233-8
25 Powrie F, Maloy KJ. Immunology. Regulating the regulators. Science 2003; 299(5609): 1030 
- 1.
70
Stellenbosch University http://scholar.sun.ac.za/
26 Read S, Powrie F. CD4+ regulatory T-cells. Curr opinion in Immunology 2001; 13: 644 -  
649.
27 Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance 
maintained by activated T-cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a 
single mechanism o f self-tolerance causes various autoimmune diseases. J Immunol 1995; 
155(3): 1151-64.
28 Chen W, Wahl SM. TGF-p: the missing link in CD4+CD25+ regulatory T-cell-mediated 
immunosuppression. Cytokine and Growth 2003; 14: 85 -  89.
29 Kingsley Cl, Karim M, Bushell AR, Wood KJ. CD25+CD4+ regulatory T-cells prevent graft 
rejection: CTLA-4- and IL -10-dependent immunoregulation o f alloresponses. J Immunol 2002; 
168(3): 1080-6.
30 •Hori S, Nomura T, Sakaguchi S. Control o f regulatory T-cell development by the transcription 
factor Foxp3. Science 2003; 299(5609): 1057-61
i Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen- 
specific anergic state in human CD4+ T-cells. Exp Med 1996; 184(1): 19 -29 .
32 Groux H. An overview o f regulatory T-cells. Microbes Infect 2001; 3(11): 883-9.
33 Zelenika D, Adams E, Humm S, Graca L, Thompson S, Cobbold SP, Waldmann H. 
Zregulatory T-cells overexpress a subset o f Th-2 gene transcripts. J Immunol 2002; 168: 1069 -  
1079.
71
Stellenbosch University http://scholar.sun.ac.za/
34 Minguela A, Martin L, Torio A, Muro M, Garcia-Alonso AM, Moya-Quiles MR, Sanchez- 
Bueno F, Parrilla P, Alvarez-Lopez MR. CD28/CTLA-4 and CD80/CD86 costimulatory 
molecules are mainly involved in acceptance or rejection o f human liver transplant. Human 
Immunology 2000; 61: 658 -  669.
35 Rastellini C, Salam A, Kuddus R, Aitouche A, Braun M, Leach r, Peach R, Fung JJ, Starzl TE, 
Rao AS. Mechanisms underlying the developemnt o f T-cell tolerance following interruption of 
signalling at the CD28/B7 and CD40/gp39 interface. Transplant Proc 1999; 31: 845.
36 •Perico N, Remuzzi G. Prevention o f transplant rejection -  curent treatment guidelines and 
future developments. Drugs 1997; 54 (4); 534 -  570.
37 Yamada A, Kishimoto K, Dong VM, Sho M, Salama AD, Anosova NG, Benichou G, 
Mandelbrot DA, Sharpe AH, Turka LA, Auchincloss H Jr, Sayegh MH. CD28-independent 
costimulation o f T-cells in alloimmune responses. J Immunol 2001; 167(1): 140-6
38 • •Guerder S, Carding SR, Flavell RA. B7 costimulation is necessary for the activation o f the 
lytic function in cytotoxic T lymphocyte precursors. J Immunol 1995; 155(11): 5167-74
39 Karim M, Bushell AR, Wood KJ. Regulatory T-cells in transplantation. Current opinion in 
Immunology 2002; 14: 5 8 4 -5 9 1 .
40 Ng WF, Baker RJ, Hernandez M, Chaudhry A, Lechlol RI. The role o f T-cell anergy in the 
maintenance o f donor-specific hyporesponsiveness in renal transplant recipients. Transplant Proc 
2001; 33: 154-155.
72
Stellenbosch University http://scholar.sun.ac.za/
41 Krieger P-M, Saermann GA, Bohmig GA, Miihlbacher F, Zlabinger GJ1. Targeting the ERK- 
1/2 signalling pathway results in alloantigen-specific anergy in human T-cells. Transplant Proc 
2002; 34: 1 4 0 3 - 1404.
42 van Pel M, Hilbrands L, Smits D, van Breugel DW, van Eck M, Boog CJ. Permanent 
acceptance o f both cardiac and skin allografts using a mild conditioning regimen for the 
induction o f stable mixed chimerism in mice. Transpl Immunol 2003; 11(1): 57-63.
43 Starzl TE. History o f clinical transplantation. World J Surg 2000; 24(7): 759-82.
44 Starzl TE, Demetris AJ, Trucco M, Zeevi A, Ramos H, Terasaki P, Rudert WA, Kocova M, 
Ricordi C, Ildstad S. Chimerism and donor-specific nonreactivity 27 to 29 years after kidney 
allotransplantation. Transplantation. 1993; 55(6): 1272-7.
45 Wood K, Sachs DH. Chimerism and Transplantation Tolerance. Immunology Today 1996;
17 (12): 584- 587.
46 Starzl TE, Demetris AJ, Trucco M, Ramos H, Zeevi A, Rudert WA, Kocova M, Ricordi C, 
Ildstad S, Murase N Systemic chimerism in human female recipients o f male livers. Lancet. 
1992; 340(8824): 876 - 7.
47 Lechler RI, Batchelor JR. Restoration o f immunogenicity to passenger cell-depleted kidney 
allografts by the addition o f donor strain dendritic cells. J Exp Med. 1982; 155(1): 31 - 41.
73
Stellenbosch University http://scholar.sun.ac.za/
48 • . . .Tomita Y, Khan A, Sykes M. Role o f intrathymic clonal deletion and peripheral anergy in 
transplantation tolerance induced by bone marrow transplantation in mice conditioned with a 
nonmyeloablative regimen. J Immunol. 1994; 153(3): 1087 -98.
49 Halloran, PF. Immunosuppresive agents in clinical trials in transplantation. Am J Med Sci 
1997;313:283-288.
50 Hall BM, Jelbart ME, Gurley KE, Dorsch SE. Specific unresponsiveness in rats with 
prolonged cardiac allograft survival after treatment with cyclosporine. Mediation o f specific 
suppression by T-helper/inducer cells. J Exp Med 1985; 162(5): 1683-94.
51 Yang C-P, Sittu E, Bell EB. Specific B-cell tolerance is induced by cyclosporine A plus 
donor-specific pretreatment: prolonged survival o f MHC class I disparate cardiac allogreafts. J 
Immunol 2000; 164: 242 7 -24 3 2 .
52 •Colvin R.B.. Cellular and molecular mechanisms o f allograft rejection. Annu Rev Med 1990; 
41:361-375.
Shizuru JA, Alters SE, Fathman CG. Anti-CD4 monoclonal antibodies in therapy: creation of 
nonclassical tolerance in the adult. Immunol Rev 1992; 129:105-30.
54 Burkhardt K, Charlton B, Mandel TE. An increase in the survival o f murine H-2-mismatched 
cultured fetal pancreas allografts using depleting or nondepleting anti-CD4 monoclonal 
antibodies, and a further increase with the addition o f cyclosporine. Transplantation 1989; 47(5): 
771-5.
74
Stellenbosch University http://scholar.sun.ac.za/
55 Dialynas DP, Wilde DB, Marraek P, Pierres A, Wall KA, Havran W, Otten G, Loken MR, 
Pierres M, Kappler J, et al.. Characterization o f the murine antigenic determinant, designated 
L3T4a, recognized by monoclonal antibody GK1.5: expression o f L3T4a by functional T-cell 
clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol Rev 1983; 
74: 29 - 56.
56 llano AL, Mcconnell MV, Gurley KE, Spinelli A, Pearce NW, Hall BM. Cellular basis of 
allograft rejection in vivo. V. Examination o f the mechanisms responsible for the differing 
efficacy o f monoclonal antibody to CD4+ T-cell subsets in low- and high-responder rat strains. J 
Immunol 1989; 143(9): 2828-36.
57 Stumbles P, Mason D. Activation o f CD 4+ T-cells in the presence o f a non-depleting 
monoclonal antibody to CD 4 induces a Th2- type response in vitro. J Exp Med 1995; 182: 5-13
58 Webb M., Mason DW, Williams A.F. Inhibition o f mixed lymphocyte response by 
monoclonal antibody specific for rat T-lymphocyte subset. Nature 1979; 282: 841.
59 Mannie MD, Morrison-Plummer J, Me Connel TJ. Differentiation o f Encephalitogenic T-cells 
Confers Resistance to an Inhibitory Anti-CD4 Monoclonal Antibody. J Immunol 1993; 151: 
7293.
60 Brostoff SW, Mason DW. Experimental allergic encephalomyelitis: successful treatment in 
vivo with a monoclonal antibody that recognizes T-helper cells. J Immunol 1984; 133(4): 1938- 
42.
75
Stellenbosch University http://scholar.sun.ac.za/
61 Gajewski TF, Joyce J, Fitch FW. Antiproliferative effect o f IFN-gamma in immune 
regulation. III. Differential selection o f TH-1 and TH-2 murine helper T-lymphocyte clones 
using recombinant IL-2 and recombinant IFN-gamma. J Immunol 1989; 143(1): 15-22.
62 Van Den Broek MF, Van De Langerijt LGM, Van Brugggen MCJ, Billingham MEJ, Van Den 
Berg WB. Treatment o f rats with monoclonal anti-CD 4 induces Longterm resistance to 
Streptococal cell wall-induced arthritis. Eur J Immunol 1992; (22): 57-61.
63 Pelegri C, Morante MP, Castellote C, Castell M., Franch A. Administration o f a non-depleting 
anti-CD 4 monoclonal antibody (W3/25) prevents adjuvant arthritis even upon re-challenge: 
parallel adminisration o f a depleting anti-CD 8 monoclonal antibody (0X 8) does not modify the 
effect o f W3/25. Cellular Immunology 1995; (165): 177-182.
64 Pawelec G, Rehbein A, Scholtz E, Friccius H, Pohla H. Cytokine modulation o f Th-1/ Th-2 
phenotype differentiation in directly alio responsive CD4+ human T-cells. Transplantation 1996; 
(62): 1095-1101.
65 Ondera K, Hancock W, Graser E, Lehmann M, Sayegh MH, Strom TB, Volk H-D, Kupiec- 
Weglinski JW. Type 2 helper T-cell type cytokines and the development o f ‘infectious” tolerance 
in rat cardiac allograft recipients. J Immunol 1997; 158: 1572-1581.
66 Munoz E, Zubiaga AM, Merrow M, Sauter NP, Huber BT. Cholera toxin discriminates 
between T-helper 1 and 2 cells in T-cell receptor-mediated activation: role o f cAMP in T-cell 
proliferation. J Exp Med 1990; 172(1):95-103
76
Stellenbosch University http://scholar.sun.ac.za/
67 Motoyama K, Lehmann M, Flye MW. Analysis o f donor-specific unresponsiveness to rat 
allografts by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) plus donor antigen. 
Transplant Proc 1999; 31(1-2): 1237-8.
/ :o Pearson TC, Madsen JC, Larsen CP, Morris PJ, Wood KJ. Introduction o f transplantation 
tolerance in adults using donor antigen and anti-CD4 monoclonal antibody. Transplantation 
1992; 54: 4 7 5 -4 8 3 .
69 Arima T, Lehman M, Flye MW. Induction o f donor specific transplantation tolerance to 
cardiac allografts following treatment with non-depleting (RIB 5/2) or depleting (OX-38) anti- 
CD4 mAb plus intrathymic or intravenous donor alloantigen. Transplantation 1997; 63: 284- 
292.
70 Saitovitch D, Bushell A, Mabbs DW, Morris PJ, Wood KJ. Kinetics o f Induction of 
Transplantation Tolerance with a Nondepleting Anti-CD4 Monoclonal Antibody and Donor- 
specific Transfusion Before Transplantation. Transplantation. 1996; 61: 1642.
71 Lehmann M, Stemkopf F, Metz F, Brock J, Docke W-D, Plantikow A, Kuttler B, Hahn H-J, 
Ringel B, Volk H-D. Induction o f Longterm survival o f rat skin allografts by novel highly 
efficient anti-CD 4 monoclonal antibody. Transplantation 1992; 54: 959-962.
72 Chan SY, Debruyne LA, Goodman RE, Eichwald EJ, Bishop DK. In vivo depletion o f CD8+ 
T-cells results in Th-2 cytokine production and alternate mechanisms o f allograft rejection. 
Transplantation 1995; 59(8): 1155-61.
77
Stellenbosch University http://scholar.sun.ac.za/
73 Kang SM, Schneider DM, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S. Fas 
ligand expression in islets o f Langerhans does not confer immune privilege and instead targets 
them for rapid destruction. Nat Med 1997; 3(7): 738-43.
74 Kabelitz D. Apoptosis, graft rejection, and transplantation tolerance. Transplantation 1998; 
65(7): 869-75.
75 Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression o f CD95 ligand on islet 
beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet 
allografts. Proc Natl Acad Sci U S A 1997; 94(8):3943-7.
76 • •Powell TJ JR, Streilein JW. Neonatal tolerance induction by class II alloantigens activates IL- 
4-secreting, tolerogen-responsive T-cells. J Immunol 1990; 144(3):854-9.
77 Schurmans S, Heusser CH, Qin HY, Merino J, Brighouse G, Lambert PH. In vivo effects of 
anti-IL-4 monoclonal antibody on neonatal induction o f tolerance and on an associated 
autoimmune syndrome. J Immunol 1990; 145(8):2465-73.
78 • •Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems. The differential 
activation o f Th-2-like effector cells in peripheral tolerance. Transplantation 1992; 53(6): 1281- 
94.
79 Bushell A, Pearson TC, Morris PJ, Wood KJ. Donor recepient icrochimerism is not required 
for tolerance induction following recipient pretreatment with donor-specific transfusion and anti- 
CD 4 antibody. Transplantation 1995; 59: 1367-1371.
78
Stellenbosch University http://scholar.sun.ac.za/
Pullar CE, Morris PJ, Wood KJ. Altered proximal T-cell receptor signalling events in mouse 
CD4+ T-cells in the presence o f anti-CD4 monoclonal antibodies: evidence for reduced 
phosphorylation o f Zap-70 and LAT. Scand J Immunol 2003; 57(4): 333-41.
81 Sablinski T, Sayegh MH, Hancock WW, Kut JP, Kwok CA, Milford EL, Tilney NL, Kupiec- 
Weglinski JW. Differential role o f CD4+ cells in the sensitization and effector phases of 
accelerated graft rejection. Transplantation 1991; 51: 226 - 231.
82 Claas FH, Roelen DL, van Rood JJ, Brand A. Modulation o f the alloimmune response by 
blood transfusions. Transfus Clin Biol 2001; 8: 315 -317.
Opelz G, Vanrenterghem Y, Kirste G, Gray DW, Horsburgh T, Lachance JG, Largiader F, 
Lange H, Vujaklija-Stipanovic K, Alvarez-Grande J, Schott W, Hoyer J, Schnuelle P, 
Descoeudres C, Ruder H, Wujciak T, Schwarz V. Prospective evaluation o f pretransplant blood 
transfusions in cadaver kidney recipients. Transplantation 1997; 63: 964 -947.
84 Josien R, Douillard P, Guillot C, Muschen M, Anegon I, Chetritt J, Menoret S, Vignes C, 
Soulillou JP, Cuturi MC. A critical role for transforming growth factor-p in donor transfusion 
induced allograft tolerance. J Clin Invest 1998; 11: 1920 -1926.
85 Koga S, Luke PP, Specht SM, Rominski B, Jaquins-Gerstl A, Hoffman RA, Thomson AW, 
Jordan ML. Inhibition o f the allograft response by donor specific blood transfusion: association 
with reduced local Th-1 cytokines and nitric oxide but enhanced prostaglandinE2 production. 
Transplantation 2000; 12: 1788-1796.
80
79
Stellenbosch University http://scholar.sun.ac.za/
Brand A. Immunological aspects o f blood transfusions. Transplant Immunology 2002; 10: 
1 8 3 - 190.
86
87 Yang C-P, Shittu E, Bell EB. Specific B-cell tolerance is induced by cyclosporin A plus 
donor-specific blood transfusion pretreatment: prolonged survival o f MHC class I disparate 
cardiac allografts. J Immunol 2000; 164: 2427 - 2432.
80
Stellenbosch University http://scholar.sun.ac.za/
Chapter  5
MOTIVATION FOR THE STUDY
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Motivation.
The prevalence o f diabetes mellitus is increasing rapidly worldwide and in South Africa afflicts 
many underprivileged population groups. Diabetes, apart from cardiovascular disorders, trauma 
and cancer remains one o f the leading causes o f premature death in man.
Stats SA numbers for the top 20 leading causes o f death are derived from what is written on 
death certificates. Most diabetics die o f the complications o f diabetes so their deaths are 
attributed to those diseases and not diabetes per se (these amount to about 11-15%). If you add 
these to deaths due to diabetes (and remove them from the other lists) diabetes comes to the top 
of deaths due to non-infectious diseases. In the Stats SA top 20 causes o f death, the order 
becomes: 1 and 2 due to trauma, 3 - 5  due to AIDS, TB and pneumonia and in 6th place are 
diabetes and one o f the cardio diseases.
End-stage renal failure and cardiovascular related disorders (i.e. arteriosclerosis, accelerated 
coronary artery disease) frequently complicate the course o f diabetes, despite conventional 
medical treatment; this has been documented globally over decades. Target-organ failure affects 
both caucasian and black populations and is not in dispute. This places huge demands on renal 
dialysis facilities and cardiac units. Many unfortunate individuals afflicted by diabetes with 
advanced complications, especially in Africa, are sent home to die from a terminal disorder and 
secondary complications. Many are in the age group o f 40 -  60 years. Surgical amelioration o f 
diabetes by pancreatic replacement in selected patients has theoretical and clinical advantages. 
Hyperglycaemia and need for insulin therapy can be abrogated whilst the graft functions; the 
daily fluctuations o f blood sugar levels are taken care o f by the graft. “Diabetics” are then able
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to resume a “normal diet” and do not have to fear the danger o f coma, hypo- and hyperglycaemia 
and death. This is beneficial to diabetics. On the other hand, the application o f pancreatic 
transplantation, outside the USA [7697 o f 10289 pancreas transplants reported to the 
International Pancreas Transplant Registry (1998) were done in the USA], has been viewed 
critically, due to poor clinical results1,2. However many persons with complicated diabetes have 
benefited substantially from pancreas whole organ transplantation2. Provided organ rejection can 
be controlled, the sustainment o f pancreatic replacement therapy (as a source o f insulin) is 
undisputed. Indeed many human diabetics have been rendered insulin independent and free from 
uraemia for periods longer than 10 years after transplantation3. A cure for diabetes is yet to be 
documented but results are encouraging. In the light o f this, all new information regarding the 
potential amelioration o f the diabetic state, by P-cell replacement, is a valuable adjunct in the 
treatment o f diabetes mellitus.
Restoration o f endocrine function, and the correction o f metabolic derangements remains the 
ultimate goal in the management and treatment o f type 1, insulin dependent diabetes mellitus. 
Pancreatic transplantation has met with increased success (because o f improved 
immunosuppression) and the need for such replacement, especially in diabetics with end-stage 
renal disease, has grown rapidly, outstripping the supply o f donor organs4,5,6. A successful 
pancreas graft, provided rejection is prevented, restores normoglycaemia and reduces many of
7 90the serious metabolic complications common to diabetes ' .
Islet transplantation in humans is problematic (because o f accelerated islet cell rejection) and has
")0 • •not met with the same success as whole pancreas transplantation . This also applies to 
laboratory models18. Isolation o f sufficient numbers o f viable islets, and other technical aspects,
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have been stumbling blocks hampering clinical application. Foetal pancreas transplantation, as a 
source o f endocrine replacement, offers several attractive benefits including ease and safety of 
transplantation and the potential o f the foetal pancreas endocrine component to grow and 
differentiate11. The preferential early development o f the endocrine component in the foetal 
pancreas, counteracts the need for isolation o f the islets from exocrine tissue shown to be 
necessary for successful non-vascularized islet engraftment11,13,14. Reversal o f chemically 
induced diabetes in mice and rats by foetal pancreas transplantation is possible and euglycemia 
can be maintained for long periods provided that adequate immunosuppression is maintained".
One o f the major stumbling blocks hindering the clinical application o f foetal islet transplantation 
is the fierce rejection o f the allogeneic grafts due to the high antigenicity of allogeneic foetal 
pancreata21,22. Mandel (1984) showed that organ cultured foetal pancreas was less immunogenic.
Culture resulted in exocrine degeneration resulting in selective survival o f islet cells. Islet
. ' ) ' lendocrine cells are less antigenic, possibly because they lack MHC II antigens .
New immunosuppressive drugs and treatment protocols have alleviated the diabetogenic side- 
effects seen with conventional macrolide and steriod based immunosuppression24,5. Pancreatic 
transplantation, for treating type 1 diabetics with complications, has benefited from new 
immunosuppression protocols24.
The use, in this study, o f established conventional immunosuppressants such as cyclosporine and
newer immunosuppressive drugs, like tacrolimus (FK506) and mycophenolate mofetil (MMF),
may further contribute to the application o f these drugs as immunosuppressants in the preclinical
and clinical setting. The use o f monoclonal antibodies raised against specific target activation
molecules like the CD4 molecules, as biological immunosuppressants, offers attractive potential
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alternatives to other immunosuppressants25. In this study, the use o f monoclonal antibodies 
against epitopes o f cell surface receptor molecules which are associated with alloantigen 
recognition, will hopefully improve our understanding o f the graft rejection process and 
immunosuppression.
The possibilities o f treating diabetes mellitus by implantation o f foetal islets, in conjunction with 
effective immunosuppression, is very exciting and the central theme o f this study.
Hypotheses tested and outcomes studied.
In order to test the null hypothesis, the following hypotheses were investigated:
1. Syngeneic foetal RPT is not capable o f reversing major clinical, endocrine and metabolic 
derangements in chemically-induced diabetes in laboratory rats.
2. Engraftment o f whole syngeneic and allogeneic foetal pancreas beneath the rodent renal 
capsule is not viable or durable.
3. Proliferation o f engrafted syngeneic foetal pancreas does not occur.
4. Short -  medium term engraftment (first 14 days after engraftment) and survival o f islet 
allografts does not occur after allogeneic FRPT in non-diabetic allogeneic rats.
5. Rejection or prolongation o f graft survival o f FRPT, compared to untreated allografts, does 
not occur following the administration o f the available clinical immunosuppressive agents, 
W3/25, CsA, FK506 and MMF either alone or in combination.
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Expected Research outcomes:
1. That syngeneic whole foetal pancreatic transplantation under the kidney capsule results in the 
proliferation and maturation o f viable endocrine tissue in a laboratory rat model (WAG => 
WAG and DA => DA).
2. Pancreatic allograft (WAG => SD and DA => SD) survival (short and intermediate term) in 
an established laboratory rat transplantation model using conventional immunosuppressants 
i.e. cyclosporine (CsA), tacrolimus (FK506), mycophenolate mofetil (MMF) and an 
experimental monoclonal antibody W3/25 (a specific immunosuppressant against the CD4 
molecule).
3. The immunosuppressive agents W3/25, CsA, FK506 and MMF (used alone or in 
combination) prevent allograft rejection and provide for short term endocrine development 
following FRPT.
Aims and Objectives of study.
One of the goals, [focus and intentions] o f this laboratory study in rodents, is to contribute new 
information to the scientific literature. The potential to “reverse” the diabetic state, was the main 
stimulus for this study.
The aim o f this research project was to study the effect o f isogeneic and allogeneic foetal rat 
pancreas transplantation, as a form o f surgical endocrine replacement therapy, in experimental 
laboratory diabetic and non-diabetic rat models.
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The chief objectives of the study were to:
• establish a reliable, chemically induced laboratory, diabetic rodent model,
• assess the efficacy of immunosuppressive agents, including CsA, FK506, MMF and an 
experimental mouse anti-rat CD4 antibody, to suppress rejection of allogeneic foetal rat 
pancreatic allografts,
• assess the pharmacokinetic effects of the various immunosuppressants on the immune 
system by flow cytometric analysis of peripheral blood lymphocytes,
• study and compare the survival and endocrine development following isogeneic and 
allogeneic foetal rat pancreatic transplantation in diabetic and non-diabetic recipients,
• research, in detail, the histological process after foetal pancreatic transplantation and 
focus on the degree of rejection following immunosuppression in the allograft model,
• perform morphometric analysis of graft survival and endocrine development following 
foetal rat pancreas engraftment into both isogeneic and allogeneic laboratory models,
• contribute to the fundamental experimental and theoretical knowledge (endocrine, 
histological and immunological) of diabetes mellitus and transplantation of foetal islet 
allografts.
Ethical issues.
A rigid ethical code of conduct has been adhered to according to the “Ethical Considerations in
Medical Research Revised Edition MRC” -  pages 34 -  39 pertaining to animal research since
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registration of Protocol 87/072. In particular the proper use of analgesics, and the administration 
of anaesthetics according to recognized veterinary practice, has enjoyed high priority. As far as 
anaesthesia in rats is concerned, this laboratory has found the use of ether, ketamine 
hydrochloride (Ketalar®), local anaesthesia and chloral hydrate (either singly or in combination) 
completely adequate for procedures needed in this project. Postoperative warmth is provided by 
short-term overhead lighting, which also reduces immediate postoperative pain. A register of 
experimentation reflecting animal number, procedure and outcome is kept and available for 
inspection.
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Chapter  6
LABORATORY MODEL 
METHODOLOGY
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Diabetic laboratory model (After Brown et al. 1976, Mandel 1984 and Kemp et al. 1978) 
Streptozotocin is a diabetogenic agent used to induce a diabetic state in various laboratory animal 
models. Streptozotocin-induced diabetes has been widely used in pancreas transplantation 
studies, especially in the rat1'5.
Induction: Intravenous injection of 50 mg/kg streptozotocin (Sigma Chemical Co, St Louis, 
USA) in 0.1 M citrate buffer pH 4.0 given into the tail vein of adult rats resulted in diabetes 
within 2 - 3  days of the injection.
Diabetic state: Streptozotocin induced diabetes shows all the clinical signs associated with an 
insulin dependent type diabetes with hyperglycaemia, glycosuria, ketonuria, polyuria, and 
polydipsia. Monitoring of whole blood glucose (Glucometer, Ames, Isando, South Africa) was 
performed daily and the diabetic animals were supported with insulin (Actraphane®, Novo, 
Johannesburg, South Africa) as prescribed in table 1.
Pre-transplantation: Pre-transplantation blood glucose levels were tightly controlled with soluble 
insulin (table 1) to prevent uncontrollable ketoacidosis. Only diabetic animals, with whole blood 
glucose (WBG) levels ranging between 5.5 and 7.0 mmol/1, were subjected to operation.
Post-transplantation: Whole blood glucose levels were monitored daily and the animals were 
supported with insulin as per schedule (table 1). Insulin support was only withdrawn once the 
animal was able to maintain a WBG level of below 8.0 mmol/1 for 3 consecutive days without 
insulin administration. Thereafter WBG levels were monitored weekly.
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Non-fasting WBG Insulin (Actraphane®)
<10 mmol/1 No insulin
1 0 -1 5  mmol/1 1 Unit
15 .1 -20  mmol/1 2 Units
> 20 mmol/1 3 Units
Table 1: Insulin treatment schedule pre-transplantation and post-transplantation
Histocompatibilty strains tested
WAG to WAG (syngeneic)
DA to DA (syngeneic)
DA to Sprague-Dawley (allogeneic; strong responder)
DA to PVG (allogeneic; inbred strain)
Donor (WAG - inbred strain)
WAG RT1U inbred rats (Origin: 1924; A.L. Bacharach, Glaxo Laboratories, United Kingdom, 
inbred from Wistar stock, Gill et al. 1995 in immunology of the rat, Festing 1979 in Inbred 
strains in biomedical research) were used as donors. Inbred WAG rats, descendants from the 
original stock, imported from Harlan, U.K. April 1994 were available as specific pathogen free 
(SPF) rats at our animal facility, Tygerberg Faculty of Health Sciences. Histocompatibilty 
testing of syngeneic isografts were histologically evaluated (Pilot study - Prof DF du Toit,
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Department of Anatomy and Histology) and no rejection of renal subcapsular foetal pancreas 
transplantation was demonstrated.
Dark Agouti (DA-inbred strain)
DA RTIavl. Inbred for more than 50 generations. Origin unknown, possibly related to COP, a 
black hooded rat bred by Curtis 1921 at the Columbia University for Cancer Research6. Harlan 
UK received their DA strain in 1979 from the Agricultural Research Centre Cambridge and we 
imported our stock from Harlan UK in 1998. Our DA rats are kept under specific pathogen free 
conditions in the animal facility, Faculty of Health Sciences, University of Stellenbosch. The 
DA is widely used in experimental transplant immunology. Histocompatibilty testing of 
syngeneic isografts were histologically evaluated (Pilot study, Department of Anatomy and 
Histology) and no rejection of renal subcapsular foetal pancreas transplantation isografts was 
demonstrated.
Recipient (SD -  outbred strain)
Sprague-Dawley rats (strain initiated by R. Dawley, Sprague-Dawley Company, Madison, 
Wisconsin, 1925). Species began by mating a hooded male (unknown origin) with 6 albino 
females (Douredoure strain, from Wistar). The original hooded male was then mated with the 
female offspring for seven consecutive generations. Thereafter the colony was outbred to 
develop a stable heterogenous stock. The colony was then closed shortly after its development 
and no new stock was introduced. The Sprague-Dawley colony at our animal facility was bred 
from stock bought from Witwatersrand University in 1994. These rats originated from Harlan, 
U.K. and were direct descendents of the original stock bought from the former Sprague-Dawley 
company in 1980. Sprague-Dawley rats are large robust albino rats known to be very docile and
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tolerate surgery well. The haplotype of outbred rats, like the Sprague-Dawley rats, is variable 
and are therefore not characterized by Harlan (personal communication with Dr A Deeny, 
Harlan, U.K.).
PVG (inbred strain)
PVG haplotype RT1C. Black hooded rat. Inbred for more than 70 generations. Originate from 
Kings College of Household Science then to Lister Institute and to Virol before transfer to Glaxo 
in 1946. Strain was inbred by Glaxo. Harlan UK received their inbred PVG strain from the 
Agricultural Research Centre, Cambridge in 1979. PVG rats, imported from Harlan in 1989, 
have since been kept under specific pathogen free conditions in the animal facility, Faculty of 
Health Sciences, University of Stellenbosch. PVG rats are very docile rats which tolerate 
surgical procedures well.
Isograft (syngeneic) controls
WAG foetal pancreata o f 16 -18 days gestation were transplanted under the kidney capsule of 
adult (5 months) male non-diabetic WAG rats. Recipient WAG rats were between 4 and 6 
months old and weighed between 350 and 470 g at the time of transplantation. Grafts were 
harvested at 14 and 30 days post-transplantation and evaluated histologically for signs of 
rejection. These grafts were used as histological controls and to evaluate graft development and 
growth.
Allogeneic transplantation (Allografts)
Allograft model: DA => SD (outbred strain). This model severely rejects foetal pancreas 
allograft in the renal subcapsular space7. Foetal pancreata (16 -  18 days gestation) from pregnant
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inbred DA rats were transplanted into adult non-diabetic male Sprague-Dawley (outbred strain) 
rats. All rats were obtained from the central research facility and were bred from specific 
pathogen free stock. Recipient Spraque-Dawley rats were between 4 and 6 months old and 
weighed between 430 and 520 g. Animals where then randomized into the experimental groups 
as shown in table 2.
Allograft model: DA => PVG (inbred strain). Haplotype R T la to RT1C. This model has a 
delayed response to the allograft antigens. Foetal pancreata (16 -  18 days gestation) from 
pregnant inbred DA rats were transplanted into adult non-diabetic and diabetic PVG (inbred 
strain) rats. All rats were obtained from the central research facility and were bred from specific 
pathogen free stock. Recipient PVG rats were between 4 and 6 months old and weighed between 
250 and 280 g. Animals where then randomized into the experimental groups as shown in table 
2.
Suitability of the allograft experimental model
High responder allograft model (DA => Sprague-Dawley): The suitability of the DA => Sprague- 
Dawley rat model has been established by this group in various publications7' 14. Our studies 
have indicated severe rejection (histocompatibilty barrier) in the WAG => SD combination when 
utilizing a “preferred site” of foetal pancreas transplantation8’9,10,12. We have demonstrated that, 
without immunosuppression, rejection ultimately destroys grafts within 4 days of transplantation 
in these strains.
Inbred strain allograft model: DA => PVG. Haplotype R T la to RT1C. This haplotype 
combination has been shown to have a low response to the donor antigen resulting in delayed
98
Stellenbosch University http://scholar.sun.ac.za/
allograft rejection and allowing for better graft survival15. In a pilot study, done in the 
Department of Anatomy, Faculty of Health Sciences, University of Stellenbosch, we 
demonstrated that renal subcapsular foetal pancreas allografts were rejected by 14 days post­
transplantation if no immunosuppression was used. Immunosuppression, using low dose CsA (2 
mg/kg/d) and combination CsA (2 mg/kg/d) and MMF (50 mg/kg/d) therapy, achieved good 
foetal pancreas allograft survival in the renal subcapsular space over a 30 day period. Stumbles 
and Mason (1995) have done in vitro work on this model and found that, when W3/25 was 
introduced with the DA antigens, IFN-y was completely inhibited while IL4 secretion was 
enhanced16.
Anaesthesia and alleviation of pain.
All procedures were performed under general anaesthetic, consisting of a combination of di- 
ethyl-ether inhalation and Ketamine hydrochloride (Brevinaze®, Pharmacare, Port Elizabeth, 
South Africa) (0.1 -  0.2 ml) intramuscular injection. Dose adjustments were made according to 
weight. This regimen has proven to be effective by this laboratory over many years. Lignocaine 
by local infiltration was used, in addition to the general anaesthetic, to overcome spasm of the 
veins during catheterization.
Intra- and postoperative management of animals.
Once anaesthetized the abdomen was shaven with an electrical hair clipper and the skin surface 
disinfected with Hibitane® (Zeneca, Woodmead, South Africa) in 70% ethyl alcohol. Animals 
were kept warm under a heating lamp during the whole operative procedure and dehydration was 
prevented by injecting 2 -  3 ml of warm sterile Ringer's lactate solution into the peritoneal
cavity, prior to closure of the operation wound. Once sutured, the wound was cleaned with
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saline, disinfected with Hibitane® and ethyl alcohol and dried with a sterile cotton swab, 
(g) . . .  .
Chloromex antibiotic ointment was applied topically to the wound to prevent infection. Ethyl 
ether was withdrawn after dressing the wound and the animal allowed to regain consciousness. 
Conscious animals were returned to a clean cage and kept warm under a heating lamp. Animals 
had immediate access to clean water but food was withdrawn for 24 hours post-transplantation to 
allow for the secondary ileus. Thereafter animals had free access to food [Standard maintenance 
rat pellets (Epol S.A.) contained protein, 200 g/kg; carbohydrate, 100 g/kg; moisture, 100 g/kg; 
fat, 25 g/kg; phosphorus, 8 g/kg; fibre, 50 g/kg; calcium/phosphorus ratio 1.1 - 1.5:1.0; vitamin 
C, 50 g/kg] and water. Parenteral prophylactic antibiotics [0.2ml Benzyl penicillin (Pharmacare, 
Johannesburg, South Africa) and 0.1 ml Amikin® (Bristol-Myers Squibb, Bedfordview, South 
Africa)] were given, by intramuscular injection, for a minimum of 3 days post-transplantation. 
This strategy was followed to prevent wound and deep intra-abdominal infection occurring after 
transplantation.
Harvesting of Foetal Rat Pancreata.
Time bred, foetal pancreata of 16-19 days gestation were obtained from pregnant WAG RT1V 
(Origin: Bacharach 1924 inbred from Wistar stock) females. Time breeding was done by placing 
a male WAG rat with 4 female WAG rats for a period of 3 days. Mating was timed from the first 
day the male and females were put together. The pregnant females were anaesthetized with di- 
ethyl-ether (AR grade, 99% assay, anaesthetic ether, B&M Scientific, Cape Town, South Africa) 
inhalation and intramuscular injection of 0.1 ml of ketamine hydrochloride 10 mg/ml 
(Brevinaze®, Pharmacare, Port Elizabeth, South Africa). The abdomen of the donor was 
disinfected with Hibitane® (Zeneca, Woodmead, South Africa) and ethyl alcohol and the foetuses
100
Stellenbosch University http://scholar.sun.ac.za/
were removed by laparotomy and hysterectomy (figures 4 and 5). Each foetus was removed from 
its amniotic sac and, using the liver as a landmark, the abdomen of the foetus was opened and the 
pancreas identified using an operating microscope (figures 6 and 7). The foetal pancreas was 
carefully dissected from the duodenal loop, stomach and spleen, using the operating microscope 
and fine jewellers forceps (figure 8). Care was taken to prevent inclusion of fat or parts of 
adjacent organs. Once removed, the foetal pancreas was placed in cold (4°C) RMPI culture 
medium (Gibco, Inchinnan, Scotland) and kept on ice until required for transplantation (figure 9). 
Cold ischaemic times were kept as short as possible, usually between 20 and 90 minutes.
Figure 1: Anatomical drawing showing the position of the pregnant uterus and foetuses in the 
abdomen of a pregnant rat. The uterus is Y-shaped and may contain as many as 7 -9  foetuses.
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Figure 2: Basic instrumentation required to perform the harvesting of foetal pancreas 
transplants. An operating microscope Carl Zeiss, Germany, is required for the fine dissection 
of the pancreas from the attached organs in the rat foetus and for transplanting the harvested 
pancreas under the kidney capsule.
»
n> —
Figure 3: Standard surgical instruments, including a fine jewellers forceps are used during the 
surgical procedure.
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Figure 4: The uterus of a 17-day gestation pregnant female rat containing several foetuses. 
The foetuses are surgically removed from the uterus while the female is under general 
anaesthesia.
Figure 5: A foetus, just removed from the uterus, still in the amniotic sac and with the 
attached placenta
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Figure 6: 17-day gestation rat foetus removed from its amniotic sac. The pancreas is 
dissected from foetus under a surgical microscope.
Figure 7: The liver (arrow) and stomach are apparent anatomical landmarks used to locate the 
pancreas. The pancreas is carefully dissected from the attached organs under the surgical 
microscope using fine jewellers forceps.
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Figure 8: A foetal pancreas (arrow) removed from the foetus is shown in the jaws of a fine 
jewellers forceps.
Figure 9: After removal the pancreas is kept on ice in RPMI culture medium, until 
transplantation is affected.
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Figure 10: Access to the recipients peritoneal cavity is by midline laparotomy.
Figure 11: Once exposed, the kidney is gently packed off from the surrounding intestine with 
gauze. Note the incision (arrow) on the kidney surface through which a subcapsular pocket is 
prepared for the foetal pancreas transplants.
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Figure 12: Anaesthetised adult transplant recipient after closure of the wound. In all cases 
topical antibiotic creams were applied and parenteral antibiotics (amikin and penicillin) 
given. Ketalar® is suitable for short term anaesthesia.
Figure 13: Once recovered from anaesthesia, graft recipients were housed in standard 
laboratory cages (40 x 280cm) containing sterilised woodshavings as bedding
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Technique of Transplantation.
A midline laporotomy incision was performed on adult Sprague-Dawley recipient rats under 
general anaesthesia and the right kidney gently exposed by manually transposing the kidney 
anteriorly (vertically) in the wound (fig 11). From a technical point of view, the right kidney is 
easier to utilize for engraftment than the left. In most cases this could be done without disturbing 
the small bowel or colon. Gauze, moistened with saline, is carefully packed around the kidney. 
This stabilizes the kidney and protects the surrounding organs (gut). Once the kidney is exposed, 
an incision of 5-7 mm, just deep enough to incise the capsule, is made on the ventral surface of 
the kidney. By carefully undermining the cut edge of the capsule with a jeweler's forceps, a 
subcapsular pocket is created by gently teasing the capsule from the underlying kidney 
parenchyma. Any bleeding is controlled by gentle external pressure with a cotton tipped ear bud. 
Once bleeding is controlled, the subcapsular pocket is irrigated with sterile saline and RPMI 
medium (Gibco, Inchinnan, Scotland). Using a small curved forceps, the harvested pancreas 
grafts are gently placed, individually, into the prepared pocket. The transplanted pancreata (2 - 4 
per recipient) are tightly packed together into the lateral aspect of the pocket and excess fluid 
evacuated by gentle external pressure, using a cotton bud. To prevent fluid collections, the 
overlying capsule was fenestrated in the vicinity of the grafts. This allowed evacuation of excess 
serous fluid that may cause seroma formation. Following engraftment, the subcapsular incision 
is left unsutured and the kidney is returned to the anatomical position. The abdominal incision is 
closed by approximating the abdominal muscles and overlying skin with Dexon® 4/0 (Davis &
•  • •  ® Geek, NJ, USA). The operation wound is then cleaned and disinfected with topical Neosporin 
antibiotic ointment (GlaxoWellcome, Midrand, South Africa) application. The ear of the 
transplant recipient is labelled according to a standardized identity system and parenteral
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antibiotic [0.2 ml Benzyl penicillin (Pharmacare, Port Elizabeth, South Africa) and 0.1 ml 
amikin® (Bristol-Myers Squibb, Bedfordview, South Africa)] is given, by intramuscular 
injection, to prevent intra-abdominal sepsis after transplantation. The recipient is allowed to 
recover from the anaesthesia and then returned to a warm cage.
Motivation of the experimental groups used (see table 2).
Syngeneic (DA to DA) foetal pancreas transplantation was used, as an isogeneic control, to study 
foetal pancreas development and growth in an anatomically displaced environment, under the 
kidney capsule.
Untreated allograft controls were included to assess the rejection potential of the allogeneic (DA 
to SD) model in terms of changes in peripheral blood lymphocyte subtypes and histological 
changes, within the graft, induced by the unmodified rejection process.
Cyclosporine is regarded as the gold standard in terms of short-term immunosuppression, and 
remains the basis of most immunosuppressive regimens18'22. Long-term usage is questionable, 
due to the inability to prevent chronic rejection in organ allografts22.
FK506 is structurally different to cyclosporine and binds to a different binding-protein but, like 
cyclosporine, both block the enzyme calcineurin, an essential enzyme in the activation 
pathway23,24,25. Despite their similarities, FK506 appears to be more potent26,27,28. Patients on 
cyclosporine therapy, with persistent rejection episodes, are often converted to FK506 as rescue 
therapy27,29,30. FK506, also known to interfere with insulin coding, is more diabetogenic than 
CsA 30 although this is disputed by some studies31. Comparing CsA and FK506 monotherapy
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groups, in terms of their effect on pancreatic endocrine tissue development, has clinical relevance 
that can be studied in this developing foetal pancreas model.
Combining CsA or FK506 monotherapy with other immunosuppressants, especially purine 
inhibitors like aziothiopine or mycophenolate mofetil (MMF), allows for a reduction in toxic 
dose shedules7, ’ 2,33. In this study, MMF, used in combination with CsA, was chosen as recent 
clinical trails have shown that MMF is more effective than azathiopine, if combined with CsA17.
Reduction of CD4 cells with depleting anti-CD4 monoclonal antibodies such as 0X35 and OX
38 in the rat, and L3T4 in the mouse, compromises the immune response in a non-specific way, 
leading to long-term elimination of CD4+ cells34. Provided that sufficient CD4+ cells are 
eliminated, these animals can theoretically accept allografts indefintely34,35.
The use of nondepleting anti-CD4 mAbs, like RIB 5/2, have shown that depletion of CD4 cells is 
not necessary and that these non-depleting anti-CD4 mAbs, induce unresponsiveness and 
acceptance of the graft, even after therapy has been withdrawn37"41. W3/25, a nondepleting anti­
rat CD4 mAb raised in mice, has been shown to prevent the induction of experimentally induced 
autoimmune diseases but it’s effectivity in preventing graft rejection in an allogeneic rat model 
has not been established 10,16,41’42’43,44’45. Work done in vitro by the Mason group in Oxford has 
shown that W3/25 therapy, at the time of antigen introduction, promotes a Th-2 like response 
thereby suppressing Th-1 associated cytokines like IFN-y16,46. Although controversial, Th-1 
cytokines, and especially IFN-y, are thought to promote allograft rejection36,40.
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Experimental groups.
The following experimental groups were studied:
GROUPS TREATMENT PERIOD
(DAYS)
N
TISSUE CONTROLS
Normal adult pancreata to access normal 
histology and staining techniques (LM, ICC, 
EM).
10
17-day gestation transplanted foetal pancreata at 
3, 5,10, 20, 30 days post-transplantation.
25
SHAM OPERATED CONTROLS
1 Adult SD rats 14 5
SYNGENEIC TRANSPLANT CONTROLS 
(DA=> DA)
2 Controls -  no immunosuppression 14 8
ALLOGRAFTS (DA => SD) 
(Histocompatibilty barrier -  Outbred strain)
3 Untreated controls (unmodified rejection) 14 10
4 CsA 5 mg/kg/d - i.m.i. daily for 14 days 14 10
5 MMF alone (50 mg/kg/d) -  oral gavage daily for 
14 days
14 7
6 CSA (5 mg/kg/d) and MMF 50 mg/kg/d -  i.m.i. 
and oral gavage daily for 14 days
14 5
7 CSA (5 mg/kg/d) and MMF 50 mg/kg/d -  i.m.i. 
and oral gavage daily for 30 days
30 7
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8 W3/25 200 (j.g/d (purified from ascites) - i.p.i. 
daily for 14 days
14 8
9 W3/25 500|ig/d (purified from ascites) - i.p.i. 
daily for 14 days
14 6
10 W3/25 500 )j.g/d (purified from ascites) - i.p.i. 
daily for 30 days
14 6
11 DST lx  3 ml i.v.i. for 14 days 14 5
12 DST lx  3 ml i.v.i. and CsA 5 mg/kg/d for 5 
days, withdrawn for 9 days
14 5
13 DST lx  3 ml i.v.i. and W3/25 500 |ug/d i.p.i. for 
5 days, withdrawn for 9 days
14 6
14 DST lx  3 ml i.v.i. combined with W3/25 500 
jj.g/d i.p.i. and CsA5mg/kg/d for 5 days, 
withdrawn for 9 days
14 7
15 DST lx  3 ml i.v.i. combined with W3/25 500 
jug/d i.p.i. and CsA5 mg/kg/d for 5 days, 
withdrawn for 25 days
ALLOGRAFTS (DA => PVG) 
(Histocompatibilty barrier -  Inbred strain)
30 12
16 Untreated controls 14 5
17 CsA (5 mg/kg/d) i.m.i. daily for 14 days 14 6
18 MMF alone (50 mg/kg/d) -  oral gavage daily for 
14 days
14 5
19 CSA (5 mg/kg/d) and MMF 50 mg/kg/d -  i.m.i. 
and oral gavage daily for 14 days
14 6
20 CSA (5 mg/kg/d) and MMF 50 mg/kg/d -  i.m.i. 
and oral gavage daily for 30 days
30 6
21 W3/25 200 (ag/d (purified from ascites) - i.p.i. 
daily for 14 days
14 6
22 W3/25 200 (j.g/d (purified from ascites) - i.p.i. 
daily for 30 days
30 6
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23 DST lx  3 ml i.v.i. for 14 days 14 5
24 DST lx  3 ml i.v.i. and CsA 5 mg/kg/d for 5 
days, withdrawn for 9 days
14 5
25 DST lx  3 ml i.v.i. and W3/25 500 jag/d i.p.i. for 
5 days, withdrawn for 9 days
14 5
26 DST lx  3 ml i.v.i. combined with W3/25 500 
)j.g/d i.p.i. and CsA5 mg/kg/d for 5 days, 
withdrawn for 9 days
14 5
27 DST lx  3 ml i.v.i. combined with W3/25 500 
(ig/d i.p.i. and CsA5 mg/kg/d for 5 days, 
withdrawn for 25 days
DIABETIC GROUPS
Control groups
30 8
28 WAG normal non-diabetic controls 5
29 SD normal non-diabetic controls 5
30 WAG diabetic controls, STZ 50 mg/kg induced 
diabetes
30 5
31 SD diabetic controls, STZ 50 mg/kg induced 
diabetes
Isogeneic group
30 5
32 WAG => WAG, FRPT, STZ 50 mg/kg induced 
diabetes
Allogeneic group
30 6
33 DA => SD, FRPT, STZ 50 mg/kg induced 
diabetes, DST lx  3 ml i.v.i. combined with 
W3/25 500 ^g/d i.p.i. and CsA5 mg/kg/d for 5 
days, withdrawn for 25 days
30 10
Table 2: Experimental Transplantation Groups
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Immunosuppressants. 
Choice and motivation for immunosuppressants
Cyclosporine has revolutionized organ transplantation48'51. Multi-organ transplantation has 
benefited from the introduction of cyclosporine17,18’51’52,53’54’55. Cyclosporine binds to the 
intracellular protein, cyclophillin, and the resulting complex, inhibits calcineurin, an enzyme 
required for early T-cell activation gene expression, particularly IL-222,23,56. The 
pharmacokinetics and pharmacodynamics of CsA has been thoroughly researched and has been 
greatly responsible for our present understanding of the rejection process22. Despite the advent 
of newer immunosuppressive drugs such as tacrolimus (FK506), sirolimus (rapamycin),
• • * 1 7 1 8 5 1  52mycophenolate mofetil, cyclosporine remains the gold standard for immunosuppression ’ ’ ’ ’
53,54, 55, 57
Tacrolimus (FK506) is a new immunosuppressive drug that binds to a different intracytoplasmic 
protein called FK-BP (FK binding protein)23,25,28. Like CsA, FK506 also binds to and inhibits 
calcineurin, a Ca++ dependent serine threonine phosphatase that plays a central role in IL2 
promotor encoding following T-cell activation23,24,25,57. The binding sites of the CsA and FK506 
complexes are not identical but overlap significantly thus causing a similar inhibition of early T- 
cell activation gene expression23,25,24,58. Despite their similarities FK506 is claimed to be 100 
times more potent than CsA59,60.
Mycophenolate mofetil (MMF) inhibits inosine monophosphate dehydrogenase, a rate-limiting 
enzyme in de novo purine synthesis23’25. Activated lymphocytes require this pathway for 
proliferation while most other cells can use the alternative salvage pathway of purine synthesis 
for normal cell division25’49,57,61’62’63’64’65. MMF acts synergistically with CsA allowing for dose
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lowering of CsA in sensitive patients32’49,53,54’57,66. Due to its selective purine inhibition of 
activated lymphocytes, MMF might enhance long-term graft acceptance or even induce 
tolerance67 68.
The graft rejection process is initiated by the CD4 T-helper cells which, on recognition of a 
foreign antigen, produce and secrete cytokines which further activate effector cells in an auto- 
and paracrine manner70'76 Blocking or preventing the CD4 activation signal, with an anti-CD4 
monoclonal antibody, alters the immune response to a more tolerant Th-2 like response leading 
to prolongation of the graft survival74"83. The anti-rat CD4 monoclonal antibody W3/25 has 
been shown to induce a Th-2 like response on alloantigen stimulation in an in vitro mixed 
lymphocyte reaction16’44,45’84. W3/25 treatment, as far as we know, does not inhibit/interfere with 
the activation cascade, as does CsA, FK506 and MMF, but may modify the response to the 
alloantigen which has a greater likelihood of inducing a state of acceptance or tolerance of the 
graft36’70’73
Introduction of donor derived antigens e.g. donor specific transfusions, under cover of anti-CD4 
monoclonal antibody treatment, has been shown to induce donor specific tolerance in various 
rodent laboratory transplantation models85'88. Saitovitch et al. showed that if DST is given under 
cover of anti-CD4, 28 days prior to transplantation, rats accept their grafts without further 
immunosuppressionError! Bookmark not defined.’84. In this study 3 ml of DA heparinised 
venous blood was transfused into the recipient via the lateral tail vein.
The use of a short course of CsA, in combination with DST, has also been shown to promote 
donor specific unresponsiveness in rats by tolerizing B-cells85.
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The combination of DST, W3/25 and CsA, to establish donor specific foetal rat pancreatic graft 
acceptance, is an unique immunosuppression protocol which combines the potent effect of anti- 
CD4 and DST with the more controversial tolerogenic effect of short course CsA.
Cyclosporine (CsA)
Sandimmune® 50 mg/ml (Novartis, Kempton Park, South Africa), was administered 
intramuscularly into the gluteus muscle. To ensure adequate immunosuppression, the parenteral 
route of administration was selected. The injection site was rotated daily and the dosage 
calculated according to the daily weigh. Doses used were 2 mg/kg/d, 5 mg/kg/d and 10 mg/kg/d. 
A dose of 2 mg/kg/d was found to be the minimum effective dose to prevent foetal pancreas 
allograft rejection by this laboratory7. CsA treatment was commenced on the day of 
transplantation.
Mycophenolate Mofetil (MMF)
MMF, supplied by Roche Pharmaceuticals, was made up in 1% carboxymethyl cellulose (Fluka 
Chemie, Buchs, Switzerland) to a concentration of 50 mg/ml. The MMF solution was given at a 
dose of 50 mg/kg/d, by oral gavage. The supplier does not recommend parenteral administration. 
A dose response curve (pilot study) showed that MMF caused severe haemorrhage of the 
intestine, especially the lower portion of the small intestine and the large intestine, if the daily 
dose exceeded 100 mg/kg/d. At a dose of 300 mg/kg/d, 100% of the recipients had died by day 
five. At 200 mg/kg/d most of the recipients had severe malaena (black stools) by day five and 
continued to lose weight rapidly. Doses varying between 40 mg/kg/d (rat) and 80 mg/kg/d 
(mouse) are needed to suppress allografts in experimental models (Hao et al. 1992). Knechtle et 
al. 1992 showed that 20 mg/kg/d was a sub-optimal dose in rats. In our studies we found that the
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dose could be safely increased to 100 mg/kg/d. MMF was used either alone or in combination 
with CsA (2 mg/kg/d). MMF treatment started on the day of transplantation.
Mouse anti-rat CD4 monoclonal antibody - clone W3/25. 
The choice of W3/25 as immunosuppressant:
The W3/25 hibridoma has proved itself as a specific mouse anti-rat CD4 monoclonal antibody 86
87 88 •. It is now commercially available for immunophenotyping of rat CD4 lymphocytes (Caltag 
cat. Nr. MR 5100). W3/25, a non-depleting mouse IgGl isotype antibody, binds to the domain 1 
of the rat CD4 molecule16,44. 0X38, a depleting anti-rat CD4, mouse IgG2b isotype, monoclonal 
antibody which binds to the same domain as W3/2589, has also been shown to effectively prolong 
graft survival34,37,38’70. W3/25 hibridoma is produced in the department o f Medical Biochemistry, 
University of Stellenbosch and is readily available.
Preparation of monoclonal antibody (method after Mason et al. 1980; Parham et al. 1982 and 
Johnstone et al. 199690’91’92):
W3/25 hybridoma cells were kept frozen in Eppendorf tubes under liquid nitrogen in a cryo- 
protectant containing dimethyl sulfoxide (Sigma, St Louis, USA). These cells were then rapidly 
defrosted in a 37 °C water bath, the cryoprotectant diluted out in 50 ml RPMI (Gibco, Paisley, 
Scotland) and foetal calf serum (Flow Laboratories, UK). The cells were then recovered by 
gentle centrifugation ±800 rpm and resuspended in 10ml culture medium (RPMI and 1% calf 
serum) in a 10 ml tissue culture flask. Cells were then cultured in a CO2 incubator overnight and 
checked for viability and growth. Provided there were enough viable cells they were diluted 1:5 
or 1:10 and allowed to grow in the incubator for a further 2-3 days whereafter they were further 
diluted 1:5 in 50 ml culture medium (RPMI and 1% FCS). Just before the cells reached
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confluency they were divided into 2x 50 ml culture flasks and cultured for a further day or two. 
The cells were then gently centrifuged at 800 rpm at 4 °C, the supernatant removed and stored. 
The cells were washed in 5 ml sterile PBS, counted in a haemocytometer and the cell suspension 
diluted to a final concentration of ±3.0 x l06/ml and kept on ice.
Preparation of Balb/c mice for hybridoma cell inoculation (method after Johnstone et al.
1996 92).
5 - 1 0  days prior to inoculation of mice with the W3/25 hybridoma, each mouse received 0.5 ml 
pristane (2,6,10,14-tetramethyl-pentadecane, Sigma, St Louis, USA) by intraperitoneal injection. 
This gave sufficient time for the recipient mice to develop a reactive ascites/exudate, which 
supplies essential nutrients to the hybridoma cells.
Inoculation of the pristane primed mice with hybridoma.
5 - 1 0  days after the mice have been pristane primed, each mouse received an intraperitoneal 
injection with 0.5 ml or 1.5xl06 of the cell suspension. If ascites formed, the abdomen became 
visibly distended within 7 to 10 days. With time the abdomen distended, the hair of the mouse 
straightened and tachypnoea occured (rapid breathing).
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Figure 14: A Balb/c mouse, inoculated with W3/25 hybridoma cells 10 days previously. The 
production o f Ig containing ascites by the inoculated W3/25 cells has induced abdominal 
distention.
Figure 15: The W3/25 immunoglobulin-secreting tumor, growing in the abdomen. The ascitic 
fluid was collected by laparotomy.
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Figure 16: An electron micrograph (x3500) o f the W3/25 immunoglobulin-secreting tumour 
cells show characteristics of active protein secretion including the presence o f euchromatin 
nuclei (-♦), multiple nucleoli (■=>) and rough endoplasmic reticulum. Scale bar = 2.9 pm.
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Figure 17: A higher magnification electron micrograph (xlOOOO) shows a W3/25 tumor cell 
containing rough endoplasmic reticulum with dilated cistemae (-►). Scale bar = 1.0 pm.
Once the mice had developed optimal ascites they were euthanased with CO2 and sterilized by 
immersion in 70% alcohol. The abdominal skin was carefully removed and the abdominal cavity
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entered by a small incision. Ascites, containing the W3/25 monoclonal antibody, was then 
collected in sterile 50 ml Falcon tubes (Becton Dickinson, Cedex, France) and kept on ice.
The ascites was gently centrifuged at 800 rpm, the supernatant decanted into another sterile tube 
and 1 mMol sodium azide (BDH Chemicals, Poole, UK) added to the supernatant as a 
preservative. The cells from the ascites were resuspended with sterile PBS, the concentration 
readjusted to 1 -  1.5x106 cells, and injected into the next generation of pristane primed mice.
In our experience with ascitic mice there is a low yield from the in vitro cell cultured W3/25 
hybridoma, but the yield improved dramatically once the cells were transferred from mouse to 
mouse. Other workers in the field have also seen this with a variety of hybridomas (Mrs H 
Veenstra of the Department of Medical Biochemistry, Faculty o f Health Sciences, University of 
Stellenbosch, Tygerberg: personal communication).
Precipitation of W3/25 IgG from ascites (After Parham et al. 1982 9I).
Once sufficient ascites was collected, the fluid was pooled and centrifuged at lOOOOxG for 30 
minutes in order to remove the smaller particulate matter. The volume was accurately measured, 
18% w/v Na2S04 (BDH Chemicals, Poole, UK) was added during constant stirring on a magnetic 
stirrer. The Na2S04 and the ascitic fluid were allowed to incubate for 30 minutes at 37°C and 
then centrifuged at x8000 rpm for 15 minutes to collect the precipitate. The precipitate was 
redissolved, in distilled water, to 33% of the initial volume. 18%w/v Na2S04 was again added 
under constant stirring and incubated at 37°C for a further 30 minutes. The suspension was 
centrifuged at x8000 for a further 15 minutes as described previously, but the supernatant was 
retained. The pellet was dissolved in distilled water to 20% of the initial volume. The
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preparation was then dialysed using Spectrapor® membrane tubing (Spectrum Medical 
Industries Inc, Los Angeles, USA) against TBS pH 7.4 (25 mM Tris HC1 and 0.05 M NaCl) at 4 
°C. The TBS was changed every day until the conductivity of the buffer was the same as the 
starting buffer.
An ion exchange column was prepared with DEAE cellulose microbeads (Whatman DE-32, 
Whatman International Ltd, Maidstone, UK) by stirring the cellulose into xl5  w/v 0.5 N HC1, 
and allowed to stand for 30 minutes, then washed with distilled water until the effluent reached 
an intermediate pH of 4.0. The cellulose microbeads were recovered and stirred into x l5  w/v 0.5 
NaOH, and left to react for a further 30 minutes. Thereafter the beads were rinsed with distilled 
water until the effluent reached an intermediate pH of 8.0. A final rinse was done in a beaker 
and the supernatant poured off to remove the fine particles. The cellulose was stirred into a 
beaker with TBS (25 mM Tris HC1 pH 7.4 and 0.05 M NaCl). The cellulose was recovered and 
the column loaded (20 ml DEAE cellulose is sufficient for 50 ml ascites). The column was 
equilibrated by running TBS (25 mM Tris HC1 pH 7.4 and 0.05 M NaCl) through the column 
overnight or longer until the pH and conductivity of the buffer passing through the column was 
the same as the starting buffer. The dialysed preparation was allowed to slowly pass through the 
column while collecting the fluid, in 4 -  5 ml fractions. The concentration of each of the fraction 
was calculated using a Beckman Spectrophotometer, set at 280 nm absorbance. The fractions 
containing Ig were pooled and dialysed using Spectrapor® membrane tubing (Spectrum Medical 
Industries Inc, Los Angeles, USA) against 5 mM Tris-HCl, pH 7.5. The precipitate (IgM) was 
then removed by centrifugation and the supernatant dialysed, once again, against PBS pH 7.4 at
4 °C overnight. The concentration of the purified Ig was determined spectrophotometrically at
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280 nm and then aliquoted and frozen in suitable volumes. The antibody was diluted with sterile 
PBS to give a final working dilution for injection as shown per the experimental groups.
Spectrophotometrical assay of Immunoglobulin fractions
lg Fractions from column
Figure 18: 4 -5  ml fractions assayed spectrophotometrically at 280 nm produced a major peak of 
IgG between fractions 3 and 9. Increasing the salt concentration of the buffer to 100 mM, in 
fractions 17 to 22, yielded a further small peak. In this case fractions 3 to 9 were pooled to give a 
combined optical density of 3.139 and an IgG concentration 2.2 mg/ml (OD/1.43 = mg / ml).
Proteins and enzymes such as albumin and proteases stick to the DEAE cellulose microbeads
and are removed from the ascitic fluid. A purified IgG from the major peak was injected into the
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rats. This ensures that no unnecessary xenoantigen (mouse proteins) were inoculated along with 
the W3/25 monoclonal IgG.
Flow Cytometric techniques (Methods prescribed by Becton Dickinson data sheet93): 
Peripheral Whole Blood.
T-Lymphocytes, both CD4 and CD8 are known to play an central role in allograft rejection 64. 
Immunosuppressants target these effector T-cells by preventing transcription of activating 
cytokines and DNA synthesis23’25’94. Monoclonal antibodies target specific activating molecules 
e.g. CD4 thereby interfering with normal activation following antigen recognition36’37’38,40’Error! 
Bookmark not defined.’95,96. Peripheral blood T-lymphocytes mirror the effect of the 
immunosuppressants used thereby allowing us an easy and accurate method of monitoring the 
effect of these immunosuppressants on T-lymphocytes94’97,98,99. These results can then be 
correlated with graft survival.
Monitoring of peripheral blood lymphocytes
Peripheral blood was collected via the tail vein in a heparinized Eppendorf tube and kept at room
temperature. 100 fo.1 of the whole blood was pipetted into a 3 ml Falcon tube and 30 ul tissue
culture supernatant containing the monoclonal antibody (approximately 10 fig Ig/ml) was added,
vortex mixed and incubated at 4 °C (on ice) for 30 minutes. The tissue culture supematants used
included 0X34 (CD2), W3/25 (CD4), 0X 8 (CD8) and 0X39 (CD25). 3G8, an anti-human
CD 16 mAb was included as a non-specific control. All supematants were cultured from the
hybridoma bank of the Department of Medical Biochemistry, University of Stellenbosch.
Specificity of the supematants was determined on rat thymocytes by flow cytometry. Following
incubation with the primary antibody, unbound antibody was removed by three washes in PBS,
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pH7.4, and centrifugation (5minutes at 1500 rpm). Excess PBS was discarded and 30ul of 
diluted (1:250) secondary FITC conjugated Goat anti-mouse IgG, affinity purified and absorbed 
against rat serum (Kirkegaard & Perry Laboratories Inc, cat no. 02-18-15, Gaitherburg, USA) 
antibody added, vortex mixed with the blood and incubated for 30 minutes at 4 °C in the dark at 
room temperature. Following the secondary incubation the red blood cells were removed by 
lysing with FACS® lysing solution (Becton Dickinson, San Jose, USA) 2 ml diluted 1:10 in 
distilled water, for 10 minutes at room temperature. The cells were then washed once more with 
PBS, centrifuged at xl500 rpm and resuspended in 250 ul PBS pH 7.4 containing 1% 
formaldehyde (BDH Chemicals Ltd, Poole, UK). The specimens were either read directly or 
stored overnight at 4 °C before analysis with the FACScan (Becton Dickinson, San Jose, USA).
Determination of bound W3/25 following in vivo injection of W3/25 (Groups 10 -  14).
To determine the amount of surface CD4 molecules that were bound in vivo, by W3/25, lOOjil 
whole blood from recipient rats was washed in PBS and 30 ul diluted secondary FITC 
conjugated Goat anti-mouse IgG (Kirkegaard & Perry Laboratories Inc, cat no. 02-18-15, 
Gaitherburg, USA) antibody added, vortex mixed and incubated in the dark. The red blood cells 
were lysed with FACS® lysing solution (Becton Dickinson, San Jose, USA) and the samples 
washed with PBS, centrifuged at xl500 rpm and resuspended in 250p.l PBS pH 7.4 containing 
1% formaldehyde (BDH Chemicals Ltd, Poole, UK). The percentage surface CD4 molecule 
bound by W3/25 could be determined by correlating the difference in positivity between these 
tubes and the tubes in which W3/25 was added.
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Flow Cytometry
Flow cytometrical techniques that were used were as prescribed and published in standard flow 
cytometry textbooks and manufacturers training manual105' 108. Specimens were analysed on a 
FACScan® using Lysys II® software (Becton Dickinson Immunocytometry systems, San Jose, 
USA) and a FACSCalibur® (Becton Dickinson Immunocytometry systems, San Jose, USA) 
using CellQuest™ software version 2.01 (Becton Dickinson Immunocytometry systems, San 
Jose, USA). A lymphocyte gate was set using forward scatter versus side scatter, in a linear 
mode, and only cells within the lymphocyte gate analysed. Fluorescent channel 1 (FL1) set in 
logarithmic mode was used to detect positive cells. CD4 (W3/25) positive cells as a percentage 
of positive CD2 (0X34) cells, within the lymphocytes gate, was found to be the most reliable 
method of monitoring the changes within the lymphocyte subsets. 0X8, the monoclonal used to 
identify the CD8 lymphocyte gave less separation between positive and negative peaks and 
therefore, produced less consistent results.
Immunofluorescence
This was used to establish the phenotypes of the lymphocytes infiltrating the grafts, following 
various immunosuppressive protocols, in snap frozen sections using the same monoclonal 
antibodies W3/35 (CD4), 0X8 (CD8), 0X34 (CD2) and 0X 39 (CD25) as used in the 
immunophenotyping of the peripheral blood lymphocytes. These antibodies were selected to 
establish the lymphocyte phenotype i.e. T-cells of either CD4 or CD8 lineage and state of 
activation by CD25 expression, present in the grafts.
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Immunofluorescence technique: (Methods after Herrington et al. 1992; Bancroft et al. 1990; 
Pharmingen Technical Protocols104’105,106).
Tissue was embedded and orientated in Tissue Tek® OCT™ embedding compound (Sakura 
Finetek, Torrance, USA), snap frozen with liquid nitrogen onto a piece of cork. Frozen sections 
of 5-10 fim were cut on an American Optical Cryo-cut® microtome, mounted onto lysinized 
slides and allowed to air dry for 30 minutes. Air dried sections were briefly fixed in absolute 
acetone for 5 minutes at room temperature and allowed to air dry for a further 30 minutes. Once 
dried, sections were washed in PBS pH 7.4, excess PBS blotted from the slides. The sections 
were then covered by the primary antibody supernatant of W3/35 (CD4), 0X8 (CD8), 0X34 
(CD2) and 0X39 (CD25) for 30 minutes, in a damp chamber to prevent drying of the antibody 
onto the sections. After incubation, primary antibody was drained from the section, the section 
jet washed with PBS and washed in 3 changes of PBS, by immersion and magnetic stirring for 5 
minutes each. The slides were then removed from the PBS; the excess buffer drained and blotted 
from the slides and fluorescein conjugated secondary rabbit anti-mouse IgG (Kirkegaard & Perry 
Laboratories Inc, cat no. 02-18-15, Gaitherburg, USA) diluted 1:10 with PBS applied to the 
sections. The sections were incubated in a moist chamber in the dark for 30 minutes. Following 
incubation the secondary antibody is the drained from the section, jet washed and washed in PBS 
as described earlier. Once excess buffer was removed the sections were mounted in PBS 
buffered glycerin. Sections were viewed with a Fluorescent Microscope (Carl Zeiss, Jena, 
Germany) fitted with a mercury vapour lamp and blue exciter filter (450 -  490 nm) using x25 
and x63 objectives.
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Light Microscopy: (Technique After Bancroft et al. 1992105).
This was used, histologically, to evaluate and score the harvested grafts in terms of survival and 
development. Rejection, both in terms of graft destruction and infiltration by inflammatory cells, 
was evaluated.
All tissues were fixed in 10% formaldehyde in phosphate buffered saline pH 7.4 for 6-12 hours 
and processed overnight in an automatic tissue processor (Shandon Eliott Duplex processor, 
Runcorn, England), through ascending concentrations of ethyl alcohol (70%, 2 x 96% and 3x 
100%) and xylene into molten paraffin wax. Tissue was then embedded in paraffin wax and 5-7 
|im sections cut on a rotary microtome (Jung, Heidelberg, Germany). Sections were floated out 
on a waterbath (±40 °C), placed onto a glass slide, baked in a 70 °C incubator for 30 minutes 
prior to staining.
Stained sections were evaluated on a Leitz Laborlux microscope (Ernst Leitz Wetzlar, Wetzlar, 
Germany) using x4, xlO, x20, x 40 and xlOO oil objectives.
Haematoxylin and Eosin (H&E) staining: (Technique After Bancroft et al. 1992105).
This was used to evaluate and differentiate between the different tissue elements including islets 
of Langerhans, exocrine acinar tissue and ducts. Changes in graft morphology i.e. fibrosis, fat 
deposition and infiltration by mononuclear cells can be scored using this stain.
Cut sections were baked for one hour in a 70 C incubator to facilitate effective adherence to the 
slide. Sections were then dewaxed in xylene and hydrated through descending concentrations of 
alcohol (2 x 100%, 96% and 70%), rinsed in running tap water. The sections were then stained 
in Harris haematoxylin for 5 minutes. Excess stain was removed by rinsing in running tap water
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for 5 minutes. The tap water, due to its relatively high pH, changes the haematoxylin stained 
elements into a deep blue colour (blueing). Sections were counterstained with-1% eosin for 3 
minutes, and briefly washed in tap water. The sections were then dehydrated though ascending 
concentrations of ethyl alcohol (70%, 96% and 2x 100%), cleared in xylol and coversliped with 
DPX mountant.
Stain results: Nuclei - dark blue, Cytoplasm - bright pink 
Histology of harvested foetal pancreata.
This was used to establish a light- and electron microscopic baseline for evaluating graft 
endocrine development against normal pancreatic development and growth.
Harvested WAG foetal pancreatic tissue of 16-18 days, 20-21 days gestation and adult WAG 
pancreas tissue was fixed in 10% buffered formaldehyde pH 7.2 and 2.5% phosphate buffered 
glutaraldehyde pH 7.4 for 18 hours, and processed for light and electron microscopy 
respectively.
Graft scoring.
All grafts were evaluated histologically and scored by the method described by Guymer and 
Mandel (1993) see Table 3 107. Pancreas development and survival was graded between 1 and 4. 
A score of 4 represented well-developed and intact grafts while a score of 1 represented severe 
destruction of the grafts with only secretory ducts remaining without any surviving islets. A 
score of 0 was awarded if no viable graft remained or had been replaced by fibrous tissue. A 
score of 2 was given if in addition to the secretory ducts some viable endocrine cells were
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recognizable. A score of 3 was awarded if viable islets were present along with secretory ducts. 
Exocrine acinar tissue survival was not scored by this system as the acinar component of the 
graft atrophies in all foetal pancreas transplants7,108,109. Graft infiltration by mononuclear cells 
(MNC) was scored between 1 and 4. A score of 0 represented no perigrafit or intragraft 
infiltration by mononuclear cells when viewed by high magnification (x40 objective). A score of 
1 indicated only a slight perigraft infiltrate of 1 < 2 mononuclear cell per high field magnification 
with no intragraft MNC infiltration. A marked perigraft infiltrate together with an intragraft 
infiltrate of < 5 MNC/high field magnification scored 2. A score of 3 was given if there was a 
diffuse lymphocytic infiltrate throughout the graft with perigraft infiltration. A score of 4 
represented an extensive intra- and perigraft infiltrate.
SCORE GRAFT SURVIVAL * GRAFT INFILTRATE
0 No survival of any tissue No peri- or intragraft MNC infiltrates
1 Graft destroyed except for secretory 
ducts
Perigraft infiltrate < 2 MNC’s -  no 
intragraft infiltration
2 Secretory ducts and viable endocrine 
cells (loose or in groups)
A marked perigraft infiltrate with a 
intragraft infiltrate of < 5 MNC’s
3 Secretory ducts and some viable islets 
of Langerhans
A diffuse infiltrate throughout the 
graft
4 Well developed islets of Langerhans 
and secretory ducts
A massive infiltrate obscuring all 
tissue structures
The exocrine acinar component o f the grafts was not scored
Table 3: Graft scoring after Guymer and Mandel 1993.
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Immunocytochemical staining of paraffin sections 93,105
This was used to demonstrate and classify the different endocrine cells in the islet of Langerhans 
by the hormones they secrete. Immunoglobulins raised against these specific peptides 
(hormones) allow for classification of these cells by light microscopy.
Formaldehyde fixed paraffin sections were dewaxed in xylene, hydrated through various 
concentrations of ethanol and washed in distilled water. Endogenous peroxidase was blocked 
with 3% hydrogen peroxide in methanol for 10 minutes. Sections were then washed in PBS 
(phosphate buffered saline) pH 7.6 at room temperature. Normal goat serum (DAKO, Glostrup, 
Denmark, cat no X0907) diluted 1:10 with PBS was applied to all sections to block non specific 
Fc binding. Excess normal serum was drained from the slides and the primary antibodies applied 
which included, insulin (DAKO, Denmark, Glostrup, cat. no A564) diluted 1:200, glucagon 
(DAKO, Glostrup, Denmark cat. no A619) diluted 1:100, somatostatin (DAKO, Glostrup, 
Denmark cat. no A566) diluted 1: 500 and pancreatic polypeptide (DAKO, Glostrup, Denmark 
cat. No A619) diluted 1:1000 in PBS pH 7.6. The sections were incubated with the relevant 
primary antibodies for 60 minutes. Following incubation the slides were jet washed and washed 
in three changes of PBS of 5 minutes each. The excess buffer was drained and the biotinylated 
goat anti-mouse and rabbit Immunogobulin LSAB2 kit link-antibody (DAKO, Glostrup, 
Denmark, cat.no. K0609) applied and incubated for 30 minutes. Thereafter the sections were 
washed as previously described and incubated with horse rabbit peroxidase conjugated 
streptavidin-biotin complex (ABC) LSAB2 kit (DAKO, Glostrup, Denmark cat.no. K0609), and 
allowed to incubate for 30 minutes. Sections were washed as before and positive labeling 
demonstrated, by 0.05% 3,3”-diaminobenzidine tetrachloride (DAB) in PBS, pH 7.6, to which
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hydrogen peroxide (160fil of 3%H2C>2 was added to 50ml of the DAB solution) was added, 
immediately prior to incubation in the substrate for 3-5 minutes. After washing in running tap 
water, sections were counterstained with Mayer's Haematoxylin, dehydrated, cleared and 
mounted in DPX.
Results:
Positive Ig staining 
Background 
Nuclei
Controls and cross reactivity
The primary antibodies selected all show a high level of inter-species cross-reactivity with rat 
antigens [+++ according to the DAKO inter-species cross reactivity chart (DAKO, Glostrup, 
Denmark)]. The DAKO LSAB2® biotinylated link antibody has been absorbed with rat, human 
and bovine immunoglobulins ensuring minimal cross-reactivity of the link antibody to rat tissue 
antigens.
Negative controls were included by substituting the primary antibody with normal mouse serum 
(DAKO, Glostrup, Denmark cat. no. X0910).
Electron microscopy: (method modified after Kay et al. 1967110).
This was used to evaluate the pancreatic grafts at an ultrastructural level. Different cell types i.e. 
p-cells, a-cells and 5-cells can be identified by their ultrastructural characteristics and can be
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correlated with normal light microscopy and immunocytochemistry. Cell ultrastructure i.e. 
presence of secretory granules and other organelles, including rough endoplasmic reticulum and 
golgi apparatus, can also give an insight into the viability and function of cells. Early signs of 
“cell stress” i.e. swelling of mitrochondia and peri-nuclear space, leading to necrosis and 
apoptosis can be observed.
Tissue was fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer pH 7.4 at 4 °C for 4 -  6 
hours and cut into small blocks of no more than 1-2 mm thickness. Following fixation the tissue 
was rinsed in phosphate buffer to remove unbound glutaraldehyde. The tissue was post-fixed 
with 1.5% osmium tetroxide in Palade's buffer pH 7.4. for one hour and then rinsed with two 
changes distilled water to remove excess unbound osmium. Tissue was further fixed and 
contrasted by 2% uranyl acetate in 70% ethyl alcohol and further dehydrated in ascending 
concentrations of ethyl alcohol (70% for 5 minutes, 2x 96% for 5 minutes each, 3x 100% for 10,
15 and 20 minutes respectively). Following dehydration the tissue was impregnated initially 
with a 50/50 mixture of Spurr's resin (NSA x 13 ml, ERL 4206 x5 ml, DER x3 ml and DMAE 
x0.2 ml all reagents from Agar Scientific, Stansted, UK) and 100% ethyl alcohol followed by 
two changes of clean Spurr's resin. Resin impregnated tissue was embedded into resin filled 
gelatin capsules and the blocks allowed to polymerise overnight at 60°C. The tips of the 
capsules were trimmed with a Reichert TM60® block trimmer (Reichert, Vienna, Austria) in 
order to expose the embedded tissue. Semi-thin sections (1 (am) were cut on a LKB Bromma 
ultratome III (LKB, Vienna, Austria) with a glass knife fitted with a water trough. Sections were 
removed from the trough and placed on a drop of water and the sections are allowed to dry on a 
hot plate. Once the drop of water had evaporated and the sections adhered to the slide, the resin
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was then removed from the sections with sodium methoxide. Sodium methoxide was prepared 
by reacting 1% metal sodium in absolute methanol. The slides were washed in tap water, to 
remove the sodium methoxide, and stained with warm 1% toluidine blue in 1% borax for 1 
minute. Slides were washed in distilled water, blotted on filter paper and dried on a hot plate. 
Dry sections were mounted with DPX and studied under the light microscope. The area of 
particular interest was identified light microscopically and matched with the corresponding area 
in the resin block. The resin block was retrimmed into a small (max 2x1 mm) trapezium shape 
containing the area of interest by a Reichert TM60® block (Reichert, Vienna, Austria) trimmer 
fitted with a diamond tip trimming blade. Gold sections, thickness 90 -120 nm were cut on the 
LKB Bromma Ultratome III (LKB, Vienna, Austria) using the heat feeding mechanism and a 
glass knife with a water trough. A ribbon of sections was then picked up, from the water bath, 
onto a G200 copper grid and allowed to dry on a filter paper. The sections were then stained for 5 
minutes with 2% acetyl acetate in 50% ethyl alcohol, rinsed in clean 50% ethyl alcohol and 
double stained with Reynold's lead citrate (Kay et al. 1967) for a further 5minutes. Reynold's 
lead citrate was prepared by mixing lead nitrate (1.33 g) with sodium citrate (1.76 g) in distilled 
water (30 ml). After thorough mixing the solution was allowed to react for at least one hour for 
the lead nitrate to convert to lead citrate. Lead citrate was dissolved with 1 N sodium hydroxide 
(8ml) and distilled water added to a final volume of 50 ml. After staining the grids were washed 
in two changes of distilled water and replaced onto a filter paper in a closed petri dish. Once the 
grids had dried the sections were viewed in a Hitachi H600 transmission electron microscope 
(Hitachi Corp, Tokyo, Japan) operated at 50 kV. Electron micrographs were taken at xl500, 
x3500 and x 10000 to record and to analyse structures or cells.
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Animals: selection, care and sample size.
Experimental design was based on close control over all variable factors influencing or skewing 
the outcomes of our allogeneic foetal pancreas transplant model. Breeding of donor and 
recipient animals was done at the Faculty of Health Sciences, University of Stellenbosch, animal 
breeding facility where close control was kept on atmospheric conditions and light/dark cycles. 
Particular attention has been paid to correlate age, sex and weight of the experimental animals. 
All procedures performed were standardized. Infection and spread of infection was prevented by 
the use of parenteral antibiotics post-transplantation and by daily cleaning and disinfection of 
animal cages. The animals had free access to clean drinking water and chow at all times. Taking 
the above into consideration together with the minimal genetic variances between the animals, 
thereby minimizing type I and especially type II errors, small sample groups of 5 animals were 
deemed sufficient per experimental group to test the hypothesis.
Controls
Both syngeneic control groups were included to assess any genetic variation within the donor 
groups. Provided that the strain has not become contaminated, inbred rat strains such as the 
WAG express a homogenous HLA halotype i.e. a major histocompatibilty complex class I 
(MHC class I), RT1U in the case of WAG’s6. MHC class I mismatches have been shown to play 
a vital role in allograft outcome116' 120. To test for genetic variation within our DA stock 
autologous transplants (DA => DA) were included. These animals served as histological controls 
for non-rejecting grafts at corresponding ages. The untreated control groups were used to assess 
unmodified rejection in the allogeneic model. These animals will give insight as to the rate of 
rejection (low - or high responders) as determined histologically i.e. loss of graft tissue by
136
Stellenbosch University http://scholar.sun.ac.za/
apoptosis or necrosis and infiltration of mononuclear cells into the graft. To eliminate individual 
lymphocytic phenotype variation, each recipient acted as its’ own control for flow cytometric 
analysis of peripheral blood lymphocyte subsets. A specimen was taken prior to transplantation 
in all cases. This specimen acted as the baseline for all subsequent phenotypic values.
Statistical Analysis, Motivation and Comparison of Results. 
Methods used:
Statistical analysis o f the flow cytometry data of the peripheral blood lymphocyte subtypes, using 
the control values before each treatment, were performed by the Wilcoxon signed rank test for 
parametric and Mann-Whitney-U rank test for non-parametric data116. The Mann-Whitney 
ranking test for unpaired, nonparametric data was used to analyse graft survival, scored 
according to the method by Guymer and Mandel 1993 as described earlier107, and to compare 
specific treatment groups and controls116. Analysis of Variation between the different treatment 
groups was done by the two-way ANOVA test116. Percentage endocrine tissue, expressed as a 
percentage of the total area, was used to draw up the final tables, and the data was statistically 
evaluated using the student's t-test for independent samples115. All statistical analysis was done 
with either Graphpad Introstat or Statistica software. A P-value of less than 0.05 (P<0.05) was 
considered as statistically significant116.
Image analysis macro.
A macro was specifically created (Author CJ.F. Muller) to determine total islet number, islet 
area, immunocytochemically positive insulin and glucagon areas, which included cell numbers 
and cell size.
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Calibration of the software
The objectives (xlO, x20, x40) of the Zeiss Axiophot linked to the Image Analyser were 
calibrated using a 1 mm slide graticule (Nikon, Tokyo, Japan). An image of the graticule was 
captured with the Zeiss KS 300 and the x and y values of the image adjusted in relation to the 
1mm scale on the graticule. Accuracy was confirmed by taking measurements at various lengths 
along the graticule scale. Once calibrated, a measurement file was saved for each objective. The 
appropriate measurement file was then written into the macro.
To determine islet area the macro was written to allow interactive tracing of the islet perimeter 
by the operator using the computer mouse. The demarcated area i.e. the total area within the 
traced islets was then directly calculated in jam2 by the software.
Insulin and glucagon positive staining within the islets was differentiated from negative staining 
by RGB thresholding. The RGB thresholding was adjusted until only the brown staining DAB 
positive cells were visualized. To separate positive cells for counting, the binary image was 
firstly eroded and then in order, to accurately determine cell size, the image was dilated to its 
original size.
Data acquisition and analysis.
Acquired data of the different parameters measured were stored in a KS 300 database and 
exported into Excel 97 (Microsoft Corp, USA). Statistical analysis o f the data was performed 
using either Statistica ’99 (StatSoft Inc, Tulsa, USA) or Instat vers 1.15 (Graphpad Corp, USA).
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Statistical Analysis of Data
Statistical analysis on data captured included total area measured, total area immunoreactive 
positivity for a particular hormone, percentage area of immunoreactivity in relation to total area 
studied124'130.
Further calculations determined the standard error of mean, standard deviation and the 
percentages of the various endocrine hormones studied in relation to the total islet area.
Statistical Analysis
The p-levels reported with the test used represents the probability of error involved in assuming 
that a significant difference exists between and two particular series of data. P-values reported 
are designated "p" indicating the comparison between an internationally accepted norm and 
experimental values and "pi" indicating a comparison between the values of control animals and 
experimental values. Differences between experimental results and an accepted norm or control 
is considered significant if P < 0.05. All values of P > 0.05 are not considered to be significantly 
different124.
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Chapter  7
RESULTS
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Summary.
This chapter deals with the results achieved following foetal pancreatic iso- and allogeneic rat 
pancreas transplantation. The pharmacokinetic effect of various immnosuppressants and 
immunosuppression protocols (cyclosporin, mycophenolate mofetil, anti-rat CD4 monoclonal 
antibody (clone W3/25) and donor specfic transfusion on the peripheral blood T-cell 
immunophenotypes and the efficacy of these immunosuppresion protocols in preventing 
pancreatic allograft rejection is reflected in this chapter.
Normal Controls:
In Section one, of this chapter reference values, histological and immunocytochemical 
parameters of the normal adult rat are established. Peripheral blood flow cytometry reference 
values for T-cell immunophenotypes (CD2, CD4, CD8 and CD25) of the normal SD and PVG 
rats were established. The concept of gating lymphocytes from whole blood, by forward scatter 
vs side scatter is, introduced and the results achieved by single- and two-colour flow cytometry 
are reflected for comparison.
The histology and immunocytochemistry of the 17-day gestation foetal pancreas pre­
transplantation and at 3-, 5-, 10-, 20- and 30-days post-transplantation are demonstrated.
Non-immunosuppressed Control Groups:
In section two, the flow cytometry and histology of the non-immunosuppressed controls used to 
validate the rejection potential of the DA=>SD and DA=>PVG allogeneic rat foetal pancreas 
tranplantation model, is reflected.
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Cyclosporine (CsA) and Mycophenolate Mofetil (MMF) Groups:
Section three demonstrates the efficacy of cyclosporine and mycophenolate mofetil, either as 
monotherapies or in combination, in preventing rejection in the allogeneic foetal rat models. The 
pharmacokinetic effect of these conventional immunosuppressants on the peripheral blood T-cell 
immunophenotype is documented. Graft survival, morphology and functionality are 
demonstrated by histology, immunocytochemistry and electron microscopy.
Anti-CD4 (W3/25) Monotherapy Groups:
In section four, the immunosuppressive potential of a rat anti-CD4 monoclonal antibody (clone 
W3/25) is reflected. The dramatic effect of W3/25 therapy on the CD4 molecule is demonstrated 
by flow cytometry. The immunosuppressive efficacy of W3/25 as a monotherapy in preventing 
foetal rat allograft rejection, in the models studied, is evaluated by histology.
Donor Specific Transfusion (DST) and Combination Therapy Groups:
In section five, results of immunosuppressive protocols, in which donor specific transfusion
(DST) were used either alone or in combination with CsA and W3/25 induction therapy, are 
presented. In this section the combination of DST with 5-days of CsA and W3/25 induction 
resulted in graft acceptance and development without the need for daily immunosuppression. 
Flow cytometry was used to establish the effect that the different and combined therapies had on 
the PBL T-cell immunophenotypes. Harvested grafts were histologically evaluated and graft 
survival determined. Immunocytochemistry and electronmicroscopy on the DST, CsA and 
W3/25 combination therapy groups demonstrated the efficacy of the protocol in preventing graft 
rejection and resulting in the development of morphologically normal and functional islets.
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Autologous and Allogeneic Diabetic Groups and Controls:
In section six, the efficacy of iso- and allogeneic foetal rat transplantation in the reversal of 
streptozotocin-induced diabetes is demonstrated. Metabolic profiles and glucose tolerance test 
results, comparing normal and non-transplanted diabetic controls, are compared to the 
transplanted diabetic animals. The harvested grafts were evaluated by histology, 
immunocytochemistry and electron microscopy. Morphometry of the islets of Langerhans was 
performed to establish islets size and cell composition.
Histological Graft Scoring -  All Foetal Rat Pancreas Transplantation (FRPT) Groups:
In the final section (seven) of this chapter, graft score for all the experimental groups are
tabulated. The scoring method, as described by Guymer and Mandel (1991), was used to 
enumerate graft survival and graft infiltration by mononuclear cells.
Results Achieved - Conclusions:
1. Isografts display near normal islet histology (endocrine/ICC).
2. No immunosuppression (across major histocompatibilty barrier -  DA => SD and DA => 
PVG) results in unmodified rejection within 4 -9  days.
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3. Summarised histological results (DA => SD and DA => PVG):
Groups Treatment Histology
CsA 5 mg/kg/d Good graft survival
MMF 50 mg/kg/d Heavy graft infiltration -  rejection
CsA+MMF 5 mg/kg/d+50 mg/kg/d Excellent graft survival
W3/25 200 jag/d Graft survival + heavy infiltrate
W3/25 500 p,g/d Good graft survival + light infiltrate
DST 3 ml Complete rejection
DST + CsA 3 ml + 5 mg/kg/d/5 
days
Rejection (some graft survival -  PVG)
DST + W3/25 3 ml + 500 (a.g/d/5 days Graft survival + heavy infiltrate
DST + CsA + 
W3/25
3 ml + 5 mg/kg/d/5 
days+ 500 |_ig/d/5 days
Excellent graft survival + light infiltrate
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4. Summarised flow cytometry results (DA => SD and DA =t> PVG):
Groups Treatment Pharmacokinetic effect on T-cells
CsA 5 mg/kg/d CD2+CD4+ slight decline; p=NS
MMF 50 mg/kg/d No effect
CsA+MMF 5 mg/kg/d+50 mg/kg/d CD2+CD4+ decline; p=0.001
W3/25 200 [ig/d Rapid CD2+CD4+ decline; p=0.008
W3/25 500 ng/d Rapid CD2+CD4+ decline; p=0.008
DST 3 ml No effect
DST + CsA 3 ml + 5 mg/kg/d/5 
days
CD2+CD4+ mariginal effect; p=NS
DST + W3/25 3 ml + 500 |a,g/d/5 days Rapid CD2+CD4+ decline; p=0.05
DST + CsA + 3 ml + 5 mg/kg/d/5 
days
SD rapid CD2+CD4+ decline; p=0.008
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Functional:
5. Isogeneic FRPT can render diabetic rats normoglycaemic
6. Allografts without immunesuppression are unable to induce normoglycaemia in diabetic 
rats due to rapid rejection of the grafts.
7. DST, CsA and W3/25 induction therapy results in allograft unresponsiveness that allows 
for graft growth and development, without daily immunosuppression, capable of inducing 
normoglycaemia in diabetic rats.
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SECTION 1.
NORMAL CONTROLS AND ISOGENEIC RAT FOETAL PANCREAS CONTROLS.
1.1. Results of flow cytometry used to establish normal reference ranges are reflected in 
Figures 19a, 19b and 20a - 20F and in tables 4 and 5.
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Fig. 19a.
Forward Scatter
Fig. 19b.
Forward Scatter
Figure 19a shows forward vs. side scatter dot plot which was used to distinguish the lymphocyte 
populations (L) other leukocytes (monocytes M and granulocytes G) and debris (D) by their 
relative positions on the dot plot. Figure 19b demonstrates a poor quality dot plot that makes 
accurate discrimination of populations impossible. Attempting to gate on indistinct lymphocyte 
populations, which inevitably includes unlysed red blood cells and debris in the gate, affects the 
accuracy of the researcher’s analysis.
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Figures 20a, 20b and 20c show the typical flow cytometric dot plots and histogram used to 
determine the peripheral blood lymphocyte (PBL) immunophenotypic profiles o f the mature 
male SD rat. Within a FSC vs SSC lymphocyte gate the mean PBL percentage for CD2+CD4+ 
lymphocytes was 51.5% ± 1.6 and 48.7% ± 1.8 for CD2+CD8+ lymphocytes. The CD4+CD25+ 
mean PBL percentage was 5.2 ± 0.5. The PBL immunophenotypic profile of the mature male 
PVG rat as represented by the dotplots (Figures 20d, 20e) and histogram 5.2 ± 0.5 (figure 20f) 
showed a mean percentage of CD2+CD4+ lymphocytes to be 72.0% ± 2.0, the CD2+CD8+ 
lymphocytes were 24.3% ±1.3 and CD4+CD25+ PBL’s were 7.2% ± 0.8.
Fig. 20b.
C D 2 /C D 8
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Strain CD2 CD4 CD2/CD4 CD8 CD2/CD8 CD4/CD8 CD4/CD25
SD 48.52 35.08 72.3 12.37 25.5 1.38 19.58
SD 48.79 33.18 68 18.16 37.22 0.89 3.87
SD 45.62 31.16 68.3 9.8 21.5 1.45 N/A
SD 40.7 26.66 65.5 13.46 33.07 0.81 28.22
SD 41.46 27.32 65.9 10.3 24.8 1.10 20.24
SD 45.62 33.49 73.4 8.97 19.7 1.70 N/A
SD 35.7 24.6 68.9 9.39 26.3 0.94 13.94
SD 42.94 26.45 61.6 10.4 24.2 1.09 4.76
SD 33.56 22.72 67.7 16.05 47.8 0.48 6.3
SD 43.52 30.25 69.5 7.97 18.3 1.65 7.64
SD 44.36 27.81 62.7 14.8 33.4 0.83 1.86
Mean 42.8 ± 1.4 28.9 ± 1.2 67.6 ±1.1 12.0 ± 1.0 28.3 ±2.7 1.1 ±0.1 11.8 ± 3.0
PVG 58.6 45.8 78.2 10.08 17.2 2.66 3.2
PVG 41.17 30.27 73.5 6.92 16.8 1.80 2.37
PVG 29.5 21.87 74.4 5.58 18.9 1.16 1.32
PVG 30.62 22.03 71.9 5.48 17.9 1.23 3.71
PVG 41.27 29.83 72.28 6.81 16.5 1.81 22.21
PVG 48.15 30.82 64 7.8 16.2 1.90 28.62
PVG 39.93 29.94 74.98 6.27 15.7 1.91 12.62
PVG 44.68 31.04 69.47 6.39 14.3 2.17 7.78
PVG 39.71 30.26 76.2 6 15.1 2.00 23.2
Mean 41.51 ±2.9 30.21 ±2.3 72.77 ± 1.4 6.81 ±0.5 16.51 ±0.5 1.85 ±0.2 11.67 ± 3.5
Table 4: Single colour flow cytometric PBL analysis o f untreated normal control rats 
(unmodified immunophenotypic profiles)
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Strain CD2 CD4 CD2/CD4 CDS CD2/CD8 CD4/CD8 CD4/CD25
SD 48.38 23.2 47.9 24.89 51.5 0.93 4.28
SD 32.9 17.22 52.1 15.35 46.9 1.11 5.62
SD 30.7 17.5 57.4 14.02 45.4 1.26 4.56
SD 21.63 10.34 46.6 12.33 58.5 0.80 3.46
SD 37.08 19.47 51.3 17.48 48.3 1.06 4.33
SD 39.71 24.07 59.4 16.26 41.8 1.42 6.04
SD 41.95 20.11 49.4 19.57 45.3 1.09 5.84
Mean 36.6 ±2.9 18.9 ± 1.5 51.5 ± 1.6 17.6 ± 1.4 48.7 ± 1.8 1.1 ±0.1 5.2 ±0.5
PVG 41.34 31.16 75.4 9.76 23.6 3.19 6.83
PVG 47.37 31.07 65.4 13.65 28.9 2.26 12.09
PVG 41.2 32.09 76.2 8.7 21.6 3.53 5.68
PVG 32.85 24.53 75.3 6.29 19 3.96 5.92
PVG 34.69 26.66 73.9 6.59 19.8 3.73 6.84
PVG 40.35 29.85 72.6 8.07 20.4 3.56 7.01
PVG 55.51 34.67 63.4 13.86 24.6 2.56 6.3
PVG 46.77 33.86 74.11 13.36 27.92 2.65 N/A
PVG 34.17 24.9 71.68 10.9 32.44 2.21 N/A
Mean 41.6 ±2.9 29.9 ± 1.3 72.0 ± 2.0 10.1 ± 1.2 24.3 ± 1.3 3.1 ±0.2 7.2 ±0.8
Table 5: Two colour flow cytometric PBL immunophenotype analysis of untreated normal 
control rats (unmodified immunophenotypic profiles).
1.2. Histology and immunocytochemistry of the normal mature SD pancreas and islet of 
Langerhans are reflected in Figures 21 to 25.
168
Stellenbosch University http://scholar.sun.ac.za/
Figure 21: Normal pancreas of the SD shows the presence of a large islet of Langerhans 
surrounded by numerous serous acini that make up the largest part of the exocrine portion of the 
pancreas (H&E x 400). Scale bar = 20 |am.
Figure 22: Immunocytochemistry demonstrating that the islet of Langerhans consists mainly of 
insulin positive (brown staining) p-cells, which make up approximately 60% of the islets area in 
the normal pancreas (insulin x400). Scale bar = 20 (j,m.
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Figure 23: Glucagon positive a-cells are less numerous than p-cells constituting up to 20% of the 
islet o f Langerhans area. They are mostly limited to the peripheral part of the islet (glucagon 
x400). Scale bar = 20 pm.
Figure 24: Immunocytochemistry demonstrating somatostatin shows the presence of a few single 
8-cells that are found in the periphery of the islet (somatostatin x400). Scale bar = 20 pm.
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Figure 25: Pancreatic polypeptide positive F-cells are also seen as single cells limited to the 
periphery of the islet (PP x400). Scale bar = 20 |am.
1.3. Histology, immunocytochemistry and electron microscopy of the 17-day gestation 
foetal DA pancreas are reflected in Figures 26 to 30.
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Figure 26: The typical histology of a 17 day gestation foetal pancreas. The pancreas consists of 
undifferentiated ductular structures and capillaries. Note the mitotic figure (arrow) (H&E x 400). 
Scale bar = 20 pm.
Figure 27: Insulin positive staining cells are seen as single cells or loosely arranged small clusters 
associated with ductules. No islets are recognised in the 17 day gestation control foetal pancreas 
(insulin x400). Scale bar = 20 pm.
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Figure 28: Glucagon positive staining cells are present as single cells associated with the ductules 
in the 17 day gestation control foetal pancreas (glucagon x 400). Scale bar = 20 pm.
Figure 29: Somatostatin positive staining cells were rarely seen in the 17 day gestation pancreas 
but when present they appeared as single cells associated with the ductules (anti-somatostatin x 
400). Scale bar = 20 pm.
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Figure 30: Electronmicrograph of a 17 day gestation foetal pancreas showing a ductule 
containing granulated endocrine cells with the ultrastructural features of a- and p-cells. The 
interstitium contains undifferentiated mesenchymal cells and capillaries (x4500). Scale bar = 2.2
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1.4. The immunocytochemistry of transplanted 17 day gestation DA foetal rat pancreas 
isografts harvested at days 3, 5,10,20 and 30 are reflected in Figures 31 to 42.
Figure 31: Insulin staining of a foetal rat pancreas isograft, 3 days post-transplantation, shows the 
development of small clusters of positive staining cells. In all cases the clusters are in close 
association with the ductules (insulin x 400). Scale bar = 20 pm.
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Figure 32: Insulin staining of the foetal pancreatic isografts, 5 days post-transplantation, showed 
clusters of positive cells either in association with ductules or loose in the surrounding stroma. 
These clusters appear to be more organised with the morphological appearance of small islets. 
Note mitotic cell in islet (insulin x 400). Scale bar = 20 |am.
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Figure 33: 10 days post-transplantation: small insulin positive islets appear in the stroma. These 
islets are mostly not associated with the remaining ductules (insulin x 400). Scale bar = 20 jam.
Figure 34: At 20 days post-transplantation: the islets consist of more mature and larger polygonal 
cells. The remaining ductules show signs of atrophy with excessive widening of the lumens 
(insulin x 400). Scale bar = 20 pm.
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Figure 35: 30 days post-transplantation: the isografts show the appearance of mature islets 
consisting almost entirely of insulin positive cells within fibrous tissue (insulin x 400). Scale bar 
= 20 jam.
Figure 36: A FRP isograft at 30 days post-transplantation shows the close association between 
the islets and adipose tissue. Ductules and other exocrine graft components have undergone 
extensive atrophy (insulin x 400). Scale bar = 20 jam.
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Figure 37: Glucagon positive cells are visible and appear as single lightly staining cells 10 days 
post-transplantation (glucagon x 400). Scale bar = 20 jam.
Figure 38: By 20 days post-transplantation single glucagon positive cells are seen associated with 
small islets (glucagon x 400). Scale bar = 20 pm.
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Figure 39: 30 days post-transplantation: glucagon positive cells appear as single cells in the 
mantle zone of the isogeneic islets (glucagon x 400). Scale bar = 20 ^m.
Figure 40: Somatostatin positive cells first appear around 10 days post-transplantation. 
Somatostatin positive cells are rare appearing as single cells (somatostatin x 400). Scale bar = 20
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Figure 41: At 20 days post-transplantation single somatostatin positive cells are seen in the 
peripheral part of the isogeneic islets (somatostatin x 400). Scale bar = 20 |am.
Figure 42: By 30 days post-transplantation the occasional somatostatin positive cells appear as 
single cells in the mantle zone of the islets (somatostatin x 400). Scale bar = 20 (j,m.
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SECTION 2.
RESULTS TRANSPLANTATION CONTROL GROUPS -  UNMODIFIED REJECTION.
The unmodified rejection groups were included to establish the rejection potential of the two 
transplantation models.
2.1. Results of flow cytometry used to establish whether the transplantation procedure, 
the introduction of allogeneic tissue, antibiotics had an effect on the T-cell 
immunophenotypes are shown tables 6 and 7.
Whole Blood Lymphocyte Flow Cytometry Non-immunosuppressed Controls
Post -Tx CD2 CD2/CD4 CD2/CD8 CD4/CD8 CD4/CD25
Day 0 43.2 ± 0.6 54.7 ±0.9 44.4 ± 0.4 1.1 ±0.02 6.0 ±0.2
Day 1
38.4 ± 1.1 
(p=0.2)
52.7 ± 1.1 
(p=0.1)
47.9 ±0.5 
(p=0.07)
1.1 ±0.03 
(P=0.1)
6.0 ±0.3 
(p=0.9)
Day 7
40.4 ± 1.5 
(p=0.4)
54.2 ±4.3 
(p=0.5)
45.2 ± 1.8 
(p=0.3)
1.2 ±0.1 
(p=0.1)
5.2 ±0.2 
(p=0.5)
Day 14
42.5 ± 0.6 
(p=0.5)
53.3 ± 1.8 
(p=0.4)
43.8 ±2.5 
(p=0.5)
1.3 ±0.1 
(p=0.1)
7.7 ±0.8 
(p=0.3)
Table 6: Group 3 - Two colour flow cytometric PBL analysis o f transplantation controls (DA 
=>SD) without immunosuppression (unmodified rejection profiles).
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Post -Tx CD2 CD2/CD4 CD2/CD8 CD4/CD8 CD4/CD25
Day 0 41.6 ± 0.8 73.1 ±0.5 21.6 ± 1.3 3.4 ±0.2 5.6 ±0.2
Day 1
37.6 ±1.3 
(p=0.2)
70.1 ± 1.0 
(p=0.3)
25.7 ±0.6 
(p=0.2)
2.7 ±0.1 
(P=0.1)
6.3 ±0.4 
(p=0.5)
Day 7
40.1 ±0.7 
(p=0.7)
72.6 ±0.7 
(p=0.5)
24.8 ± 0.7 
(p=0.3)
2.9 ±0.1 
(p=0.2)
7.0 ±0.7 
(p=0.09)
Day 14
41.6 ±0.7 
(p=0.8)
72.9 ±0.8 
(p=0.5)
24.4 ±0.7 
___ <1-0.2,
3.0 ±0.1 
(p=0.4)
6.7 ±0.3 
(P=0.1)
Table 7: Group 16: Two colour flow cytometric PBL analysis of transplantation controls (DA
=>PVG) without immunosuppression (unmodified rejection profiles).
2.2. Histological assessment of the grafts that had been completely rejected are reflected 
in Figures 43 to 44.
Figure 43: Group 3 - Histology showed severe rejection of FRPT in the DA to SD allogeneic 
model. By 14 days post-transplantation the grafts have disappeared and have been completely 
replaced by fibrous tissue. Note the presence of the overlying kidney capsule, the underlying
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kidney parenchyma, and the mononuclear infiltrate at the graft kidney interface (H&E x 100). 
Scale bar = 90 fim.
Figure 44: Group 16 - The untreated controls (transplantation across a strong histocompatibility 
barrier without immunesuppression) following FRPT in the DA to PVG allogeneic model also 
showed advanced and acute rejection 14 days post-transplantation. A band of mononuclear cells 
consisting mostly of lymphocytes can be seen at the graft kidney interface (H&E x 100). Scale 
bar = 90 (j,m.
184
Stellenbosch University http://scholar.sun.ac.za/
SECTION 3.
Results of the CsA, MMF and CsA/MMF combination immunesuppression 
Transplantation Groups.
CsA and MMF are well-established immunosuppressants used widely in transplantation. CsA is 
still regarded as the mainstay in most immunosuppression regimes and its mechanism of action is 
well known. MMF, a purine synthesis inhibitor, further enhances the efficacy of CsA in the 
clinical setting. This combination can be regarded as the gold standard in terms of the prevention 
of graft rejection in the rat pancreas transplantation model.
3.1. The pharmacokinetic effect of CsA, MMF and CsA/MMF combination therapies on 
the T-cell immunophenotypes, studied flow cytometrically, are reflected in Figure 45 and in 
Tables 8 and 13.
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Whole Blood Lymphocyte Flow Cytometry of the CsA, MMF and CsA/MMF combination
groups.
Fig. 45a.
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Figure 45: CsA monotherapy at the given dose of 5 mg/kg/d (group 17) had a small, but not 
significant (p=0.08) , suppressive effect on the CD2+CD4+ PBL profile of the adult PVG rat 
(Figures 45a, 45b and 45c). MMF monotherapy at the given dose of 50 mg/kg/d (group 18) had 
no measurable effect on the T-cell PBL’s (figs 45d, 45e and 45f). In combination however CsA 
and MMF had a general suppressive effect on the CD2+CD4+ T-cell PBL’s (p=0.001). Daily 
doses of CsA (5 mg/kg/d) and MMF (50mg/kg/d) resulted in a gradual but significant decline of 
CD2+CD4+ percentage in the adult male PVG rat from 71.3 ± 1.2 to 62.1 ± 2.0 and 52.4 ± 1.7 at 
14 and 30 days post-transplantation respectively (Figs 45g, 45h and 45i).
Day Tx CD2 CD2/CD4 CD2/CD8 CD4/CD8 CD4/CD25
Day 0 40.0 ±1.2 52 ± 0.8 47.7 ±0.8 1.1 ±0.1 6.1 ± 0.1
27.8 ±0.5 46.8 ±1.1 50.4 ±0.9 0.9 ±0.1 6.5 ± 0.2
Day 1 (p=0.008) (p=0.004) (p=0.05) (p=0.01) (p=0.3)
39.9 ±0.9 48.3 ±0.6 48.3 ± 1.0 1.0 ±0.1 6.5 ± 0.2
Day 7 (p=0.8) (p=0.08) (p=0.5) (p=0.08) (p=0.2)
40.2 ±0.6 48.7 ±0.8 47.9 ±0.4 1.0 ±0.1 6.3 ±0.3
Day 14 (p=0.8) (p=0.08) (p=0.8) (p=0.08) (p=0.8)
Table 8: Group 4 - Two colour flow cytometric PBL analysis following CsA 5mg/kg/d 
monotherapy (DA => SD).
Day Tx CD2 CD2/CD4 CD2/CD8 CD4/CD8 CD4/CD25
Day 0 41.5 ±0.9 70.5 ± 0.9 26.8 ± 1.1 2.5 ±0.07 6.5 ± 0.3
35.0 ±1.5 67.5 ±1.2 29.0 ±1.0 2.3 ±0.09 7.0 ± 0.2
Day 1 (P=0.1) (p=0.06) (p=0.2) (p=0.3) (p=0.2)
37.5 ± 1.1 48.3 ±0.6 28.2 ± 0.9 1.0 ±0.03 6.5 ± 0.2
Day 7 (p=0.2) (p=0.005) (p=0.4) (p=0.004) (p=0.2)
37.2 ±0.8 67.4 ± 1.4 28.3 ±0.2 2.4 ±0.05 7.1 ±0.2
Day 14 (P=0.1) (p=0.08) (p=0.5) (p=0.5) (p=0.08)
Table 9: Groupl7 -  Two-colour flow cytometric PBL analysis following CsA 5 mg/kg/d
monotherapy (DA => PVG).
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Post-Tx CD2 CD2/CD4 CD2/CD8 CD4/CD8 CD4/CD25
Day 0 39.8 ± 1.2 51.4 ± 0 .9 47.3 ± 1.2 1.1 ±0.02 6.3 ±0.2
37.5 ±1 .3 50.1 ± 1.4 48.9 ± 1.8 1.1 ±0.03 6.8 ±0.5
Day 1 (p=0.2) (p=0.3) (p=0.3) (p=0.8) (p=0.3)
36.8 ± 1.8 49.4 ± 2 .0 48.9 ±2 .3 1.0 ±0.02 6.2 ± 0.9
Day 7 (p=0.1) (P=0.1) (p=0.3) (P=0.1) (p=0.8)
34.2 ± 1.3 50.2 ± 2 .0 48.3 ± 1 .9 1.0 ±0.03 6.5 ±0.6
Day 14 (p=0.07) (p=0.4) (p=0.3) (P=0.1) (p=0.8)
Table 10: Group 5 - Two-colour flow cytometric PBL analysis following MMF monotherapy 50 
mg/kg (DA =>SD).
Post -T  x CD2 CD2/CD4 CD2/CD8 CD4/CD8 CD4/CD25
Day 0 43.8 ± 1 .0 70.7 ± 1.0 28.1 ± 1.3 2.5 ±0.08 7.2 ±0.5
Day 1
37.3 ± 3 .2  
(p=0.03)
68.2 ± 1.3 
(p=0.2)
27.9 ±1 .5  
(p=0.8)
2.4 ±0.1  
(P=0.1)
7.0 ±0.5  
(p=0.8)
Day 7
41.6 ± 1.6 
(p=0.8)
68.8 ±1.1 
(p=0.2) ?§
 
p 
i+
 
o 
O
 
^2
2.3 ±0.07  
(P=0.1)
6.8 ±0 .4  
(p=0.3)
Day 14
39.2 ± 0.9 
(p=0.08)
67.2 ± 1.3
. (p=o.i)
31.7 ± 1.4 
(p=0.08)
2.1 ± 0 .2  
(p=0.08)
6.7 ± 0.6 
(P=0.3)
Tablel 1: Group 18 - Two-colour flow cytometric PBL analysis following MMF monotherapy
(DA =>PVG).
Post-Tx CD2 CD2/CD4 CD2/CD8 CD4/CD8 CD4/CD25
Day 0 41.3 ± 1.7 53.1 ± 1.5 48.1 ± 1.1 1.1 ±0.1 6.0 ± 0 .7
39.8 ± 1.8 50.3 ±2.1 48.9 ± 1.5 1.0 ±0.1 5.7 ± 0 .6
Day 1 (p=0.4) (P=0.1) (p=0.4) (p=0.4) (p=0.4)
39.7 ± 2 .0 50.8 ± 1.8 50.1 ±1 .3 1.0 ±0.1 5.2 ± 1 .2
Day 7 (p=0.4) (P=0.1) (p=0.2) (p=0.3) (p=0.3)
38.2 ± 2 .6 44.9 ± 2.3 52.7 ± 2 .0 0.9 ±0.1 6.0 ± 1.6
Day 14 (p=0.4) (p=0.001) (p=0.001) (p=0.001) (p=0.8)
35.3 ±2.7 41.4 ± 2 .0 54.1 ± 1.7 0.8± 0.1 5.6 ± 0 .9
Day 30 (p=0.08) (p=0.001) (p=0.001) (p=0.001) (p=0.4)
Table 12: Groups 6 and 7 - Two-colour flow cytometric PBL analysis following CsA and MMF
combination therapy (DA =>SD).
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Day Tx CD2 CD2/CD4 CD2/CD8 CD4/CD8 CD4/CD25
Day 0 41.5 ±2.9 71.68 ± 1.4 32.44 ± 1.0 2.2 ±0.1 5.8 ±1.3
32.3 ±1.8 67.6 ± 1.2 33.8 ± 1.9 2.0 ±0.09 5.5 ±0.5
Day 1 I r l i l (P=0.1) (p=0.4) (p=0.4) (p=0.8)
38.9 ±2.3 65.7 ±1.3 31.2 ±1.3 2.1 ±0.1 6.1 ±0.9
Day 7 (p -n .h (p=0.1) (p=0.4) (p=0.4) (p=0.3)
41.7 ± 1.7 61.6 ±1.6 33.2 ±0.9 1.9 ± 0.1 5.8 ±0.4
Day 14 # 0 .1 ) (p=0.0003) (p=0.0001) (p=0.0001) (p=0.8)
38.0 ±1.1 57.0 ± 1.9 34.2 ± 1.5 1.7 ± 0.1 5.8 ±0.4
Day 30 (p=0.3) (p=0.001) (p=0.001) (p=0.001) (p=0.8)
Table 13: Groups 19 and 20 - Two-colour flow cytometric PBL analysis following CsA and
MMF combination therapy (DA =>PVG).
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3.2. Histological assessment of the grafts in CsA, MMF and CsA/MMF combination
groups are reflected in Figures 46 to 53.
Figure 46 - Group 4: Cyclosporine monotherapy 5 mg/kg/d prevented graft rejection. A well- 
preserved FRP allograft is clearly visible beneath the kidney capsule. Very little graft infiltrate is 
present (H&E x 100). Scale bar = 90 jam.
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Figure 47 - Group 5. MMF monotherapy (oral 50 mg/kg/d) failed to prevent a massive influx of 
mononuclear cells into the graft resulting in acute, irreversible rejection. Some remaining graft, 
mostly dilated ducts and islets still survive within the heavy infiltrate (H&E x50). Scale bar = 
170 (am.
Figure 48 - Group 6: MMF and CsA therapy (50 mg/kg/d and 2 mg/kg/d) not only prevented 
graft rejection but resulted in an infiltrate free graft at 14 days post-transplantation. (H&E xlOO). 
Scale bar = 90 fim.
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Figure 49 - Group 7: MMF and CsA therapy (50 mg/kg/d and 2 mg/kg/d) maintained an infiltrate 
free graft and allowed for excellent development of the islets of Langerhans 30 days post­
transplantation. Perigraft fat formation is visible. (H&E x 100). Scale bar = 90 (jrn.
Figure 50 - Group 17: In the PVG rat, daily cyclosporine injections of 5 mg/kg/d effectively 
suppressed graft rejection resulting in minimal graft infiltration by lymphocytes (H&E xlOO). 
Scale bar = 90 jam.
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Figure 51: Group 18 - MMF monotherapy (oral 50 mg/kg/d) shows a heavy inter- and intra-graft 
mononuclear cell infiltrate similar to that seen in the SD rats (group 5). A few dilated ducts and 
islets were still present (H&E xlOO). Scale bar = 90 pm.
Figure 52: Group 19 - MMF and CsA therapy (50 mg/kg/d and 2 mg/kg/d) effectively 
suppressed graft rejection allowing for excellent development of islets within an infiltrate free 
graft while the exocrine tissue shows the typical signs of atrophy at 14 days post-transplantation 
(H&ExlOO). Scale bar = 90 pm.
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Figure 53: Group 20 - MMF and CsA therapy (50 mg/kg/d and 2 mg/kg/d) effectively prevents 
rejection at 30 days post-transplantation and allows for the development of islets of Langerhans, 
which are present within a fibrous stroma. The presence of perigraft fat, possibly due to ectopic 
insulin secretion, into the surrounding interstitium was a constant finding in this group (H&E x 
100). Scale bar = 90 (j.m.
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3.3. Islet viability and function was demonstrated in the combination therapy group 
(group 20) by electron microscopy Figure 54.
Figure 54: Group 20 - Electron microscopy of the islets of Langerhans following MMF and CsA 
therapy (50 mg/kg/d and 2 mg/kg/d) showed viable and well granulated endocrine cells. The 
majority of the endocrine cells contained typical dense core insulin-like granules. A capillary 
and endothelial cell demonstrates a well vascularised structure (x4500). Scale bar = 2.2 |a.m.
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SECTION 4.
RESULTS OF THE ANTI-CD4 (W3/25) MONOCLONAL ANTIBODY 
IMMUNESUPPRESSION TRANSPLANTATION GROUPS.
W3/25 is a mouse anti -rat CD4 monoclonal antibobdy, which specifically binds to domain 1 of 
the CD4 molecule.
Flow cytometry of the peripheral blood lymphocytes demonstrated an 18% reduction of 
CD2+CD4+lymphocytes from the peripheral blood within 10 minutes (Figures 55d, 55e and 55f) 
of a single 500 jag intravenous injection with W3/25. Daily injection with W3/25 further reduced 
the CD2+CD4+lymphocytes from the peripheral blood (Figures 55c, 55f, 55i and 551).
4.1. The pharmacokinetic effect of W3/25, as demonstrated by flow cytometry, is reflected 
in tables 14,15 and 16.
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Whole Blood Lymphocyte Flow Cytometry W3/25 Monotherapy Groups
Fig. 55a.
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Fig. 55j. Fig. 55k. Fig. 551.
Figure 55: W3/25 has a dramatic effect on the CD4 expression of CD2+CD4+ PBL’s. The above 
dotplots and histograms (demonstrating the gated CD2+CD4+ PBL population) show the effect of 
500jj,g W3/25 injections on a 450 g adult male SD rat. Figures 55a, 55b and 55c show the 
CD2+CD4+ and CD2+CD8+ PBL expression prior to W3/25 administration, which is 54.2% and 
47.8% respectively. 10 minutes after a 500 |ug intravenous injection of W3/25 (Figs 55d, 55e 
and 55f) the CD2+CD4+ PBL’s have already declined to 36.2% while the CD2+CD8+ PBL’s 
percentage has increased to 66%. 1 day after the commencement of W3/25 therapy the 
CD2+CD4+ PBL’s continue to decline further to 28.7% and conversely the CD2+CD8+ PBL’s 
percentage continues to increase 70.1%. Daily injections for 30 days result in severe CD2+CD4+ 
lymphocytopenia as demonstrated in figures 55j and 551 (16.1% CD2+CD4+ PBL’s) and an 
marked increase of CD2+CD8+to 84.5%
The CD2+CD4+ decrease, and the CD2+CD8+ PBL percentage increase, correlated significantly 
SD (groups 6 and 7) - non-parametric Spearman Rank test (correlation r = -0.8655 and the two- 
tailed p value for r was < 0.0001) and (r = -0.9652 and a two-tailed p value for r was < 0.0001) in 
the PVG (groups 19 and 20).
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Post-Tx CD2 CD2CD4 CD2CD8 CD4/CD8 CD4/CD25
Day 0 35.311.7 53.811.0 46.11 1.0 1.210.01 6.41 0.9
32.512.2 41.814.1 58.413.8 0.710.1 7.211.0
Day 1 (p=0.3) (p=0.008) (p=0.008) (p=0.008) (p=0.2)
28.111.8 34.812.3 60.312.3 0.6 10.1 7.911.0
Day 3 (p=0.2) (p=0.008) (p=0.008) (p=0.008) (P=0.1)
29.2 13.2 33.112.3 67.812.2 0.510.1 7.011.3
Day 7 (P=0.3) (p=0.008) (p=0.008) (p=0.008) (P=0.1)
27.812.0 30.912.2 68.3 12.8 0.5+  0.1 7.611.0
Day 14 (p=0.1) (p=0.008) (p=0.008) (p=0.008) (p=0.1)
Table 14: Group 8 - Two colour flow cytometric PBL analysis of W3/25 monotherapy 200 
(ag/day (DA =>SD).
Post-Tx CD2 CD2CD4 CD2CD8 CD4/CD8 CD4/CD25
Day 0 34.712.5 50.412.0 50.812.3 1.010.1 5 .11  0.7
25.210.9 25.513.2 67.913.1 0.410.1 9.411.5
Day 1 (p=0.2) (p=0.008) (p=0.008) (p=0.008) (p=0.03)
25.611.6 19.810.9 75.611.3 0.3 10.1 8 .610 .6
Day 3 (p=0.2) (p=0.008) (p=0.008) (p=0.008) (p=0.02)
23.3 11.0 17.810.9 78.911.2 0.210.1 7 .810 .8
Day 7 (p=0.09) (p=0.008) (p=0.008) (p=0.008) (p=0.03)
24.413.3 17.311.9 87.7 13 .7 0.2 + 0.01 7.810 .8
Day 14 (p=0.2) (p=0.008) (p=0.008) (p=0.008) (p=0.03)
21.411.0 16.5 11 .7 81.911.0 0.210.01 8.2 10 .6
Day 21 (p=0.03) (p=0.008) (p=0.008) (p=0.008) (p=0.03)
20.9 11.3 16.811.2 82.5 1 0.7 0.2 10.001 9.0 + 1.0
Day 30 (p=0.03) (p=0.008) (p=0.008) (p=0.008) (p=0.02)
Table 15: Groups 9 and 10 - Two colour flow cytometric PBL analysis of W3/25 monotherapy 
500 fxg/day (DA =>SD).
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Post-Tx CD2 CD2CD4 CD2CD8 CD4/CD8 CD4/CD25
Day 0 40.9 ± 1.3 72.3 ±1.0 21.1 ± 1.0 3.5 ±0.2 6.4 ± 0.3
27.8 ± 1.1 60.8 ± 1.9 36.6 ±2.2 1.7 ±0.2 6.2 ± 0.4
Day 1 (p=0.008) (p=0.03) (p=0.008) (p=0.008) (p=0.9)
25.7 ± 1.2 56.9 ±1.6 36.1 ± 1.4 1.6 ±0.1 6.7 ± 0.3
Day 3 (p=0.008) (p=0.008) (p=0.008) (p=0.008) (p=0.4)
21.8 ±2.0 50.0 ± 1.9 38.8 ± 1.3 1.3 ±0.1 7.0 ±0.7
Day 7 (p=0.008) (p=0.008) (p=0.008) (p=0.008) (p=0.4)
18.3 ±1.1 42.9 ± 1.6 43.4 ±0.7 1.0 ±0.05 8.4 ± 1.0
Day 14 (p=0.008) (p=0.008) (p=0.008) (p=0.008) (p=0.2)
15.3 ± 1.7 34.5 ±4.3 57.8 ±4.5 0.6 ±0.1 7.9 ±0.8
Day 21 (p=0.008) (p=0.008) (p=0.008) (p=0.008) (p=0.2)
15.7 ±0.9 28.7 ±3.8 64.7 ±3.9 0.5 ±0.1 7.8 ±1.3
Day 30 (p=0.008) (p=0.008) (p-0.008) (p=0.008) (p=0.7)
Table 16: Groups 21 and 22 - Two colour flow cytometric PBL analysis of W3/25 monotherapy 
500 ^g/day (DA => PVG).
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4.2. The efficacy of W3/25 as an immunosuppressant in preventing graft rejection in both 
rat foetal rat pancreatic models is demonstrated by the histology of the harvested grafts in 
figures 56 to 60.
Figure 56: Group 8 - A photomicrograph demonstrating the presence of renal subcapsular grafts 
following daily W3/25 (200 fig/d) injections, at 14 days post-transplantation. Note the clear 
glandular appearance of the grafts under the kidney capsule. Scale 1:3.5
2 0 1
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Figure 57: Group 8: Following daily W3/25 (200 jag/d) injections,at 14 days post-transplantation, 
histology of the graft showed well preserved islets. The exocrine tissue showed ductal 
dilatation and some destruction. A light to moderate inter- and intragraft mononuclear cell 
infiltrate is present. This may be indicative of early rejection but may well reflect resolving 
inflammatory cells following transplantation (H&E x50). Scale bar = 170 jam.
2 0 2
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Figure 58: Group 8 - Higher magnification of the graft clearly illustrates the presence of the islets 
and the mononuclear cell infiltrate present within the graft. Exocrine tissue undergoing artophy 
is still present within the graft (H&E xl 00). Scale bar = 90 p.m.
Figure 59: Group 9 - Demonstrated excellent graft survival following daily 500 |ig/d W3/25 
injections. At 14 days post-transplantation, the grafts showed the presence of well developed 
islets and atrophying exocrine tissue. A light peri- and intragraft infiltrate is present (H&E 
xlOO). Scale bar = 90 p.m.
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Figure 60: Group 10 - Histology of the grafts at 30 days following daily 500 (ig/d W3/25 
injections showed that the grafts consisted mostly of well developed islets. The exocrine tissue 
has atrophied and is absent except for a few ducts still present. A moderate peri- and intragraft 
infiltrate is present (H&E x 100). Scale bar = 90 jam.
204
Stellenbosch University http://scholar.sun.ac.za/
Figure 61: Group 21 - Graft survival at 14 days post-transplantation, following daily 500 |ag 
W3/25 injections, showed similar graft survival as seen in group 6 (SD rats). A mild peri- and 
intragraft infiltrate is present (H&E xlOO). Scale bar = 90 jun.
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Figure 62: Group 22 - Good graft survival at 30 days post-transplantation, following daily 500 
|ig W3/25 injections, showed a moderate lymphocytic graft infiltrate [DA => PVG]. Perigraft 
WAT is present (H&E xlOO). Scale bar = 90 pm.
Figure 63: Group 22 - Higher magnification shows the presence of well developed islets of 
Langerhans within a fibrous stroma 30 days post-transplantation (H&E x200). Scale bar = 20
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SECTION 5.
RESULTS OF DONOR SPECIFIC TRANSFUSION (DST), CYCLOSPORINE (CSA)
AND ANTI-CD4 (W3/25) INDUCTION THERAPY GROUPS -  DONOR SPECIFIC 
ANTIGEN INDUCED UNRESPONSIVENESS.
In these groups, by combining CsA with its broader immunosuppressive effect, and anti-CD4, 
known to act synergistically with CsA with DST, donor specific tolerance was demonstrated. To 
test the efficacy of this treatment regime, a single 3ml DST transfusion was given 1 day pre­
transplantation. In the combination groups, DST was followed by 5 days of either CsA 
(5mg/kg/d) or W3/25 (500 pg/d) or a combination of the two. Thereafter no further 
immunesuppression was given until harvesting at either 14 or 30 days post-transplantation.
5.1. Flow cytometry:
DST had no measurable effect on the peripheral blood T-Cell immunophenotypes (pre-DST vs. 
DST 14-days post-DST; p=NS) as reflected in tables 17 and 18.
In comparison to the pre-treatment levels, DST and W3/25 induction therapy resulted in a 
significant decline of CD2+CD4+ PBL cell percentage at 14-days post-transplantation from 
53.0% ± 0.7 to 28.5% ± 1.7; p=0.03 (group 13 -  Table 21) and 72.3% ± 2.3 to 65.4% ± 1.4; 
p=0.05 (group 25 -  Table 22).
The pharmacokinetic effect of W3/25 therapy and DST on the peripheral blood CD2+CD4+ T- 
Cells (Tables 21 and 22) was significantly enhanced by the addition of CsA and DST in the SD 
groups (14 and 15 -  Table 23) declining from 52.7% ± 2.9 to 14.4% ± 2.5 (p=0.003) while in the
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*
PVG groups (26 and 27 -  Table 24) the PBL CD2 CD4 cells had recovered from 73.2 ± 2.0 to 
67.2 ±1.3 (p=0.1).
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Figure 64: The above flow cytometric dotplots and histograms demonstrate the effect of DST as 
a monotherapy or in combination with either CsA or W3/25 induction or as a triple combination 
induction therapy protocol on the SD rat (Groups 11, 12, 13, 14 and 15). A single donor specific 
transfusion (Fig 64a, 64b and 64c) had no significant effect on the PBL immunophenotype 
percentages. DST in combination with CsA resulted in a significant decline in CD2+CD4+ 
(52.0% ± 1.3 to 21.7 ± 1.4; p=0.05) and the CD4/CD8 ratio (1.1 ± 0.1 to 0.3 ± 0.1; p=0.05) 1 day 
post-transplantation, (group 12 - SD group) but had recovered by day 7 (Figures 64d, 64e and 
64f). In the PVG rats (group 25) no significant effect was demonstrated. A marked decline in 
the CD2+CD4+ PBL’s (53.0% ± 0.7 to 28.5% ± 1.7; p=0.03) is clearly noticeable (fig 64g: left 
upper quadrant) following DST and W3/25 induction therapy (group 13) 14 days post­
transplantation. Conversely the CD2+CD8+ lymphocytes had increased from 47.3% ±0.1 to 69.9 
±2.1; p=0.03. In the DST, CsA and W3/25 induction therapy group (groups 14 and 15) the loss 
of CD2+CD4+ cells from the PBL population was significant both at 14 and 30 days post-
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was significant both at 14 and 30 days post-transplantation (Figs 64j and 64m). This resulted in 
a significant increase of both the CD2+CD8+ lymphocytes (figs 64k and 64n). Of interest is the 
increase, although not significant, in the percentage of CD4+CD25+PBL’s (figure 64o) compared 
to the pre-transplantation values 30 days post-transplantation (from 5.8% ± 0.5 to 12.3% ± 1.8; 
p=0.2).
PBL CD2+CD4+% PBL CD4/CD8 Ratio
Days post-Tx Days post-Tx
Fig. 65a. Fig. 65b.
Figure 65: Graphs comparing the pharmacokinetic effect of DST (group 11), DST+ CsA (group 
12), DST+W3/25 (group 13) and DST+CsA+W3/25 (group 14) therapy on the PBL CD2+CD4+ 
percentage (figure 65a) and the CD4/CD8 ratio (figure 65b) of the SD rat groups.
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PBL CD2+CD4+% PBL CD4/CD8 Ratio
Days post-Tx Days post-Tx
Fig. 66a. Fig. 66b.
Figure 66: Graph comparing the pharmacokinetic effect of DST (group 23), DST+ CsA (group 
24), DST+W3/25 (group 25) and DST+CsA+W3/25 (group 26) therapy on the PBL CD2+CD4+ 
percentage (figure 66a) and CD4/CD8 ratio of the PVG rat groups (figure 66b).
Post -Tx CD2 CD2/CD4 CD2/CD8 CD4/CD8 CD4/CD25
Day 0 37.3 ± 0.6 52.7 ± 0.9 47.4 ± 0.4 1.1 ± 0.1 6.0 ±0.2
35.0 ±2.6 48.5 ±2.2 51.4 ± 1.8 1.0 ± 0.1 7.3 ±0.8
Day 1 (p=0.7) (p=0.3) (p=0.3) (p=0.3) (p=0.3)
38.3 ±3.7 49.3 ±0.7 49.6 ± 0.9 1.0 ± 0.1 7.1 ±0.5
Day 7 (p=0.9) (p=0.4) (p=0.5) (p=0.3) (p=0.4)
33.7 ± 1.8 49.6 ± 2.3 52.4 ±2.2 0.9 ±0.1 7.1 ±0.3
Day 14 (p=0.5) (p=0.4) (p=0.2) (p=0.2) (p=0.4)
Table 17: Group 11 - Two colour flow cytometric PBL analysis following DST (DA => SD) 
monotherapy. Values are mean ± SEM.
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Post -T x CD2 CD2/CD4 CD2/CD8 CD4/CD8 CD4/CD25
Day 0 39.5 ±2.6 73.3 ±2.0 22.6 ± 1.8 3.3 ±0.3 6.0 ±0.2
37.4 ±2.4 70.3 ±1.7 28.2 ±1.7 2.5 ±0.2 5.7 ±0.1
Day 1 (p=0.8) (p=0.3) (p=0.06) (p=0.06) (p=0.3)
39.0 ± 1.7 71.4 ±1.0 29.9 ± 1.9 2.4 ± 0.2 5.8 ±0.2
Day 7 (p=0.8) (p=0.2) (p=0.05) (p=0.06) (p=0.6)
39.4 ±2.6 72.3 ± 2.0 28.5 ± 1.7 2.6 ± 0.2 5.4 ±0.2
Day 14 (p=0.8) (p=0.9) (p=0.06) (p=0.08) (P=0.1)
Table 18: Group 23 - Two colour flow cytometric PBL analysis following DST (DA => PVG) 
monotherapy. Values are mean ± SEM.
Day Tx CD2 CD2/CD4 CD2/CD8 CD4/CD8 CD4/CD25
Day 0 38.3 ±0.7 52.0 ± 1.3 47.4 ±0.7 1.1 ± 0.1 5.7 ±0.3
27.5 ± 1.8 21.7 ±1.4 (p= 75.9 ±2.0 0.3 ±0.1 9.2 ±1.6
Day 1 (p=0.08) 0.05) (p=0.06) (p=0.05) (p=0.09)
43.0 ±2.1 47.6 ± 1.9 49.0 ±2.2 1.0 ± 0.1 6.9 ± 0.6
Day 7 (p=0.1) (p=0.6) (p=0.6) (p=0.5) -P 0.31
40.9 ±0.9 49.0 ±2.3 52.4 ±2.0 1.0 ± 0.1 6.0 ± 0.8
Day 14 (p=0.3) (p=0.2) (p=0.2) (p=0.1) (p=0.9)
Table 19: Group 12 - Two colour flow cytometric PBL analysis following DST + CsA induction 
therapy for 5 days (DA => SD). Values are mean ± SEM.
Day Tx CD2 CD2/CD4 CD2/CD8 CD4/CD8 CD4/CD25
Day 0 43.6 ± 3.6 70.9 ± 1.9 25.8 ± 2.1 2.8 ± 0.2 6.7 ± 0.2
28.7 ±3.4 67.3 ±3.1 26.9 ±3.0 2.5 ±0.3 7.3 ± 1.3
Day 1 (P=0.1) (P=0.1) (p=0.1) (p=0.2) (p=0.2)
32.1 ± 2.4 73.9 ±2.2 23.3 ±0.9 3.2 ±0.2 7.1 ±0.6
Day 7 (P=0.1) (p=0.4) (p=0.3) (p=0.3) (p=0.6)
37.6 ± 1.3 72.6 ±1 .9 23.9 ±2.1 3.1 ±0.3 8.3 ±1.1
Day 14 (p=0.2) (p=0.5) (p=0.4) (p=0.4) (p=0.6)
Table 20: Group 24 - Two colour flow cytometric PBL analysis following DST + CsA induction 
therapy for 5 days (DA => PVG). Values are mean ± SEM.
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Post-Tx CD2 CD2/CD4 CD2/CD8 CD4/CDS CD4/CD25
Day 0 37.3 ± 1.8 53.0 ± 0.7 47.3 ± 0.4 1.1 ± 0.1 6.6 ± 0.3
Day 1 26.8 ± 2.4 25.6 ±2.7 
(p=0.02)
74.7 ±2.7 
(p=0.02)
0.4 ± 0.1 
(p=0.02)
5.8 ± 0.1
(p=oi)
Day 7 48.6 ± 2.7
( M W
38.2 ± 1.7 
(p=0.06)
60.7 ± 0.6 
(p=0.06)
0.6 ± 0.1 
(p=0.03)
5.9 ± 0.5 
(p=0.2)
Day 14 26.6 ± 1.0 
(p=0.03)
28.5 ± 1.7 
(p=0.03)
69.6 ±1.4 
(p=0.03)
0.4 ± 0.1 
(p=0.03)
9.6 ± 0.9 
(p=0.06)
Table 21: Group 13 - Two colour flow cytometric PBL analysis following DST + W3/25 (ag/day 
combination therapy for 5 days (DA => SD). Values are mean ± SEM.
Post-Tx CD2 CD2/CD4 CD2/CD8 CD4/CD8 CD4/CD25
Day 0 40.9 ± 4.0 72.3 ± 2.3 21.1 ± 1.0 3.5 ± 0.2 6.4 ± 0.3
27.8 ± 1.0 59.8 ± 1.6 38.1 ± 1.7 1.6 ± 0.1 6.2 ± 0.4
Day 1 (p=0.05) (p=0.03) (p=0.03) (p=0.02) (p=0.7)
30.9 ± 0.7 61.1 ± 0.7 37.8 ± 1.2 1.6 ± 0.1 7.2 ± 0.4
Day 7 (p=0.07) (p=0.03) (p=0.02) (p=0.02) (p=0.2)
34.7 ± 1.3 65.4 ± 1.4 33.4 ± 1.5 2.0 ± 0.1 6.6 ± 0.6
Day 14 (p=0.1) (p=0.05) (p=0.05) (p=0.05) (p=0.9)
Table 22: Group 25 - Two colour flow cytometric PBL analysis following DST + W3/25 pg/day 
combination therapy for 5 days (DA => PVG). Values are mean ± SEM.
Post Tx CD2 CD2/CD4 CD2/CD8 CD4/CD8 CD4/CD25
Day 0 41.1 ±2.8 52.7 ±2.9 52.5 ± 1.3 1.0 ± 0.1 5.8 ±0.5
27.5 ± 1.8 21.7 ± 1.4 75.9 ±2.0 0.3 ± 0.03 9.2 ± 1.6
Day 1 (p=0.008) (p=0.003) (p=0.003) (p=0.003) (p=0.2)
17.8 ±1.1 29.0 ±2.8 66.7 ± 3.4 0.4 ±0.07 6.2 ± 0.8
Day 7 (p=0.03) (p=0.008) (p=0.004) (p=0.008) (p=0.4)
25.2 ±3.3 23.2 ± 1.9 78.0 ±1.9 0.3 ± 0.04 7.0 ±0.7
Day 14 (p=0.03) (p=0.008) (0.004) (p=0.008) (p=0.5)
22.9 ± 1.6 14.4 ±2.5 74.4 ±3.0 0.2 ± 0.02 12.3 ± 1.8
Day 30 (p=0.03) (p=0.003) (p=0.004) (p=0.003) (p=0.2)
Table 23: Groups 14 and 15 - Two-colour flow cytometric PBL analysis following DST + CsA + 
W3/25 induction therapy for 5 days (DA => SD). Values are mean ± SEM.
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Day Tx CD2 CD2/CD4 CD2/CD8 CD4/CD8 CD4/CD25
Day 0 39.5 ±2.6 73.2 ±2.0 22.6 ± 1.8 3.3 ±0.3 7.5 ±1.2
Day 1
22.3 ± 0.6 
(p=0.008)
51.4 ±0.9 
(p=0.008)
39.4 ±2.0 
(p=0.008)
1.3 ±0.1 
(p=0.008)
6.3 ±0.2 
(p=0.5)
Day 7
18.6 ±0.9 
(p=0.008)
50.6 ±2.3 
(p=0.008)
44.2 ± 1.5 
(p=0.008)
1.2 ± 0.1 
(p=0.008)
7.9 ±0.6 
(p=0.3)
Day 14
22.2 ± 1.0 
(p=0.008)
63.3 ±1.6 
(p=0.3)
35.0 ±2.1 
(p=0.02)
1.8 ± 0.2 
(p=0.02)
7.9 ±1.1 
(p=0.9)
Day 30
25.0 ±1.2 
(p=0.008)
67.2 ± 1.3 
(p=0.1)
28.9 ± 1.9 
(p=0.2)
2.3 ( 0.4 
(p=0.08) 6.7 (0.4 (p=0.9)
Table 24: Groups 26 and 27 - Two-colour flow cytometric PBL analysis following DST + CsA + 
W3/25 induction therapy for 5 days (DA ( PVG). Values are mean ( SEM.
5.2. Graft histology:
Grafts harvested at 14 days post-transplantation in the DST monotherapy groups showed 
complete rejection and were replaced by fibrous tissue in both groups (11 and 23). Lymphocytes 
were still present within the fibrous tissue and at the kidney graft interface (figures 68 and 79).
The grafts harvested from the DST, CsA and W3/25 induction therapy groups (groups 14,15, 26 
and 27) showed excellent graft survival and development, especially, of the islets of Langerhans 
at 14 and 30 days post-transplantation. Graft infiltrates were minimal (figures 72, 73, 75 and 76). 
Immunocytochemistry showed the islets mostly consisted of insulin positive cells with some 
peripheral glucagon positive cells and the occasional somatostatin positive cell (figures 77, 86, 
78 and 79).
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Figure 67: Group 11- A photomicrograph of FRPT 14 days post-transplantation (allografts) 
showing a white fibrous area at the transplantation site. No viable graft is macroscopically 
visible.
Figure 68: Group 11 -  DST monotherapy shows advanced acute rejection with complete 
destruction of the grafts that are replaced with fibrous scar tissue. A moderate lymphocytic 
infiltrate is present at the site of engraftment (H&E xlOO). Scale bar = 90 (m.
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Figure 69: Group 12 -  DST and CsA induction therapy resulted in accelerated rejection of the 
grafts at 14 days post-transplantation. A dense band of lymphocytes are present at the kidney 
graft interface. The grafts are completely destroyed. An eosinophilic fibrinoid exudate is seen at 
the graft site (H&E x50). Scale bar = 170 pm.
Figure 70: Group 13 -  DST and W3/25 combination therapy, 14 days post-transplantation shows
“surviving” identifiable graft with islets and exocrine tissue present within a heavy lymphocytic
graft infiltrate (H&E x50). Scale bar = 170 pm.
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Figure 71: Group 14 -  DST, CsA and W3/25 combination therapy, 14 days post-transplantation 
shows excellent graft survival with islets, and dilated exocrine ducts. Very little graft infiltrate by 
lymphocytes is present (H&E x50). Scale bar = 170 (am.
Figure 72: Group 14 -  Higher magnification shows an islets and surrounding exocrine tissue. 
The exocrine tissue shows signs of atrophy and dilatation of ducts. Almost no lymphocytic graft 
infiltrate is present (H&E xlOO). Scale bar = 20 |j.m.
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Figure 73: Group 15 -  A photomicrograph of FRPT 30 days post-transplantation shows the 
presence of large coalesced subcapsular mass representing proliferating FRP allografts.
Figure 74: Group 15 -  DST, CsA and W3/25 combination therapy, 30 days post-transplantation
shows viable graft with islets, and dilated exocrine ducts. Perigraft subcapsular fat (WAT) is
present (H&E x50). Scale bar = 170 (j.m.
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Figure 75: Group 15 -  Higher magnification shows well-developed islets with a moderate peri- 
grafit lymphocytic infiltrate and dilated atrophing exocrine ducts and acini (H&E xlOO). Scale 
bar = 90 pm.
Figure 76: Group 15 -  ICC to demonstrate insulin shows that the islets consist mainly of insulin 
positive cells (Insulin x 100). Scale bar = 90 pm.
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Figure 77: Group 15 -  ICC to demonstrate glucagon shows a few glucagon positive cells mainly 
limited to the periphery of the islets. The occasional glucagon positive ductular cells as is 
demonstrated in this photomicrograph were an interesting observation (Glucagon x 200). Scale 
bar = 40 (j.m.
Figure 78: Group 15 -  ICC to demonstrate somatostatin shows the occasional somatostatin 
positive cells in the periphery of the islets. Somatostatin positive cells, if present, were limited to 
1 -  2 cells per islet (Somatostatin x 200). Scale bar = 40 jam.
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Figure 79: Group 25 - DST only shows a presensitized hyperacute type of rejection. The grafts 
are completely destroyed. A heavy lymphocytic infiltrate is still present (H&E xlOO). Scale bar 
= 90 pm.
Figure 80: Group 26 - DST and CsA combination therapy showed some graft preservation albeit 
within a heavy lymphocytic infiltrate (H&E xlOO). Scale bar = 90 pm.
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Figure 81: Group 27 - DST and W3/25 combination therapy showed graft survival and the 
presence of a heavy lymphocytic infiltrate (H&E xlOO). Scale bar = 90 pm.
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Figure 82: Group 16- A macroscopic view of FRPT 30 days post-transplantation. The presence 
of the grafts and formation of fat pads, as a result of insulin secretion, is clearly visible beneath 
the kidney capsule.
Figure 83: Group 16- A cross section of the subcapsular grafts following FRPT 30 days post­
transplantation shows coalescence of the grafts under the kidney capsule.
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Figure 84: Group 26- DST, CsA and W3/25 combination therapy, 14 days post-transplantation, 
shows well-preserved grafts and islets. A mild lymphocytic infiltrate is present (H&E xlOO). 
Scale bar = 90 pm.
Figure 85: Group 27 -  DST, CsA and W3/25 combination therapy, 30 days post-transplantation
shows well-developed islets and atrophing exocrine tissue and fat formation. A moderate
lymphocytic infiltrate is present in the graft (H&E xlOO). Scale bar = 90 pm.
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Figure 86: Group 27 -  DST, CsA and W3/25 combination therapy, 30 days post-transplantation. 
ICC to demonstrate insulin shows insulin positive islets of various sizes scattered throughout the 
graft (Insulin x 50). Scale bar = 170 |a,m.
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Figure 87: Group 27 -  Immunofluorescence to demonstrate CD4+ lymphocyte infiltrates in the 
graft 30 days post-transplantation. The presence of a light to mild perigraft infiltrate, in which 
CD4+ cells predominate (CD4/CD8 ratio 1.5), was a consistent finding following DST, CsA and 
W3/25 combination therapy (CD4 x 300). Scale bar = 30 fim.
Figure 88: Group 27 -  Immunofluorescence to demonstrating CD8+ lymphocyte infiltrates in the 
graft 30 days post-transplantation. (CD8 x 300). Scale bar = 30 p.m.
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SECTION 6.
RESULTS DIABETIC GROUPS -  REVERSAL OF STREPTOZOTOCIN (STZ) 
INDUCED DIABETES BY AUTOLOGOUS AND ALLOGENEIC FOETAL RAT 
PANCREATIC TRANSPLANTATION (FRPT).
Results in this section confirms the efficacy of autologous FRPT in reversing STZ induced 
diabetes (group 32) but, in addition, demonstrates allogeneic reversal of STZ induced diabetes 
(group 33) using an immunemodulation strategy that includes DST, CsA and W3/25 induction 
therapy. This strategy results in donor specific graft unresponsiveness without the need for daily 
immunosuppression.
Autologous and allogeneic FRPT (groups 32 and 33) prevented the significant weight loss and 
reversed the polydipsia and polyuria and restored normoglycaemia that occurred in the non­
transplanted controls (Tables 25 and 29).
IVGTT showed that, following autologous and allogeneic FRPT (groups 32 and 33), animals 
were able to respond to a 0.5 g/kg glucose bolus while the non-transplanted diabetic controls 
showed no response (Tables 26, 28 and figures 91, 99).
At autopsy, the grafts present in both the autologous and allogeneic groups (groups 32 and 33) 
appeared as prominent white sub-capsular masses associated with fat (figures 92,100 and 101).
Histology o f  the harvested auto- and allografts (groups 32, 33), 30 days post-transplantation,
confirmed the presence o f  islets o f  Langerhans with a normal appearance (Figures 93, 102 and
103).
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Immunocytochemistry showed insulin positive islets scattered throughout the grafts (figures 94, 
104 and 105) and some glucagon, somatostatin and pancreatic polypeptide positive cells (figures 
95, 96, 97 and 106).
The ultrastructure of the islets following autologous and allogeneic FRPT (groups 32 and 33) 
confirmed the presence of viable and well granulated endocrine cells containing the characteristic 
insulin-like granules (figures 998 and 107).
Morphometry to quantify the islet size, the % 0- and a-cell area of the islets and the (3-cell / a- 
cell ratio of the grafts (tables 26 and 29) gives an objective comparison of the graft islet 
morphometry (groups 32 and 33) with the normal (groups 28, 29) and diabetic pancreatic islets 
(groups 30 and 31).
6.1. STREPTOZOTOCIN (STZ) INDUCED DIABETES:
The effect a single 50 mg/kg IV injection of STZ, a diabetogenic agent, on the insulin positive 
cells in the islets o f Langerhans is clearly demonstrated in Figures 89 and 90.
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Figure 89: Group 29 - Immunocytochemistry demonstrating insulin positive staining of the 
majority of cells within in the islet of Langerhans in a normal non-diabetic SD rat (insulin x400). 
Scale bar = 20 |j.m.
Figure 90: Group 31 - Immunocytochemistry demonstrating the severe reduction of insulin 
positive staining within the islet of Langerhans 30 days after the induction of diabetes by a single 
50 mg/kg STZ intravenous injection (insulin x400). Scale bar = 20 Jim.
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6.1. WAG Autologous Diabetic Transplantation Groups.
Group Body weight 
(g)
WBG mmol/1 Water intake 
ml/24hrs
Urine output 
ml/24hrs
Group 28 344 ± 12.0 6.42 ±0.1 21.3 ± 6.8 7.9 ± 1.3
Group 30 249 ± 8.0 
(p= 0.005)
20.84 ± 1.3 
(p=0.002)
55.8 ± 10.9 
(p = 0.002)
29.9 ± 6.4 
(p = 0.008)
Group 32 325 ± 12.1 (p= 
0.4)
6.37 ± 1.0 
(p=0.4)
19.0 ± 10.7 
(p = 0.6)
7.5 ± 3.4 (p = 
0.7)
Table 25: Autologous transplantation diabetic experimental animal weights and metabolic 
profiles in normal non-diabetic controls (group 28), the diabetic non-transplanted controls (group 
30) and the autologous transplantation diabetic experimental animals (group 32).
Time Group 28 Group 30 Group 32
Basal 6.29 ±0.17 20.84 ±1.3 7.9 ±0.13
1 min 18.91 ±1.16 27.7 ±3.1 19.63 ± 1.39
2 min 16.24 ±0.98 25.36 ±2.44 18.65 ±1.29
3 min 17.3 ± .7 23.42 ±4.38 17.35 ±0.964
5 min 15.3 ±0.58 27.56 ± 5.24 14.5 ±2.14
10 min 12.4 ±0.81 25.64 ±2.16 13.5 ±0.77
20 min 8.53 ±0.57 25.34 ±1.22 10.85 ±0.6
30 min 6.39 ± 0.47 25.62 ±2.81 8.58 ±0.21
40 min 6.2 ± 0.48 25.36 ± 1.2 7.47 ± 0.49
50 min 5.46 ±0.57 24.46 ± 1.51 6.15 ±0.25
60 min 6.9 ±0.77 23.88 ± 1.57 5.6 ±0.2
Table 26: Whole Blood Glucose values of the normal non diabetic controls (group 28), the 
diabetic non-transplanted controls (group 30) and the autologous transplantation diabetic 
experimental animals (group 32) at various time points during an IVGTT; values are in mmol/1 ± 
SEM.
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IVGTT
Time (minutes)
Figure 91: Groups 28, 30, 32 - IVGTT graph comparing the WBG response to an intravenous 
glucose bolus at different time points in the syngeneic transplantation groups. The IVGTT 
values showed no significant differences between the syngeneic group and the normal controls 
(group 28 vs. 32; p=0.6), while the diabetic controls differed very significantly from the normal 
controls (group 30 vs. group 28 p =< 0.0001).
AUC (nun2) % of normal AUC K-value
Normal controls 511.1 100 2.31
Diabetic controls 1515 296 <1
Group 32 578.8 113 1.955
Table 27: Area under the curve- (AUC) and K-values following IVGTT in the diabetic and 
syngeneic transplantation groups.
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Figure 92: Group 32 - FRPT grafts, 1 month post transplantation are clearly visible as discrete fat 
deposits on the surface of the kidney.
Figure 93: Group 32 - The development of inter- and intragraft adipose tissue (white fat) was a 
constant feature following successful syngeneic subcapsular foetal rat pancreas transplantation. 
30 days post-transplantation grafts consisted of well-developed islets within fibrous tissue or in 
surrounding adipose tissue. The aethiology of the fat deposition remains unknown. Exocrine
tissue is absent H&E xlOO. Scale bar = 90 jam.
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Figure 94: Group 32 (autografts) - Immunocytochemistry of an islet of Langerhans, 30 days post­
transplantation, shows the islets consisted mostly of insulin positive cells (x.400). Scale bar = 20
Figure 95: Group 32 (isografts) - Glucagon positive cells formed an incomplete band at the 
marginal zone of the islet (x400). Scale bar = 20 pm.
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Figure 96: Group 32 - A few somatostatin positive cells are present in the marginal zone of the 
islet (somatostatin x400). Scale bar = 20 |0.m.
Figure 97: Group 32 - Pancreatic polypeptide positive cells are also seen in the marginal zone of 
the islet (PP x400). Scale bar = 20 jam.
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Figure 98: Group 32 - Electron micrograph of the central part of an islet of Langerhans, 30 days 
post-transplantation shows well-granulated endocrine cells containing characteristic insulin 
granules (x4500). Scale bar = 2.2 |iim.
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Group 28 Group 30 Group 32
% P-cell area/islet area 
(p vs. control)
64.14 ±1.94 28.4 ± 
(p=0.01)
12.48 57.12 ± 6.2 (p=0.3)
P-cell size (group vs. 
control)
158.43 ±8.16 66.25 ± 
(p=0.01)
6.77 123.78 ± 20.01 
(p=0.2)
P-cell/a-cell (group vs. 
control)
2.24 ±0.16 0.44 ± 
(p=0.01)
0.26 17.4 ± 1.9 (p=0.01)
Table 28: Groups 28, 30 and 32 - Morphometric analysis of the islets of Langerhans in the STZ 
autologous transplantation groups.
6.2. Allogeneic Diabetic Transplantation Groups
Group Body Weight 
(8)
WBG mmol/1 Water
ml/24hrs
intake Urine output 
ml/24hrs
Group
29
390.2 ±24.1 6.36 ±0.5 28 ±2.16 10.2 ± 2.11
Group 31 324.8 ± 19.9 
(p=0.03)
14.08 ± 3.2 
(p=0.008)
50.6 ± 
(p=0.06)
11.89 38.4 ± 10.74 
(p=0.05)
Group 33 406 ± 12.8 
(p=0.2)
6.9 ± 1.9 (p=0.5) 34.8 ± 
(p=0.1)
3.23 18.6 ± 5.73 
(p=0.4)
Table 29: Body weight and metabolic profiles in normal non-diabetic SD controls (group 29), the 
diabetic non-transplanted SD controls (group 31) and the DA=>SD allogeneic transplantation 
diabetic experimental animals (group 33).
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Time(min) Group 29 G rou p 31 Group 33
0 6.36 ± 0.49 14.4 ± 3.54 7.57 ± 1.58
1 16.58 ±2.59 21.78 ± 4.13 16.84 ±3.34
3 16.12 ±0.54 24.5 ± 3.25 15.01 ± 1.56
5 14.6 ± 1.2 24.92 ±3.26 15.07 ± 1.39
10 13.22 ±0.65 23.08 ±3.52 15.17 ± 1.69
15 12.34 ±0.64 21.56 ±3.24 14.7 ±2.19
30 9.9 ±0.7 22.54 ±3.98 12.9 ±2.47
60 6.5 ± 0.63 19.06 ±3.57 10.14 ±2.64
Table 30: Groups 29, 31 and 33 - Intravenous glucose tolerance test values following injection of 
a single bolus of 0.5 g/kg dextrose solution in the allogeneic diabetic groups; results are mean 
mmol/1 values ± SEM.
IVGTT
Group 33 (Allografts)
Time (minutes)
Figure 99: Groups 29, 31, 33 - IVGTT graph of the allogeneic diabetic groups, illustrating the
WBG values at different time points during the glucose tolerance test, following injection of a
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difference between the normal controls (group 29) and the allogeneic diabetic transplantation 
group (group 33) p=0.4, while there was a significant difference between the normal controls and 
the diabetic controls (group 31) p=0.0002.
AUC (mm2) %  of normal AUC K-value
Normal controls 621.1 100 2.175
Diabetic controls 1559 251 <1
Group 33 777 125 1.495
Table 31: Area under the curve- (AUC) and K-values following IVGTT in the diabetic and 
allogeneic diabetic transplantation groups.
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Figure 100: Group 33 - Macroscopic photomicrograph of an exposed kidney 30 days post-FRPT 
(allotransplantation) following DST, CsA and W3/25 induction therapy, showing the grafts in 
situ. To reverse STZ induced diabetes, sufficient endocrine mass has to be present (6 - 8  grafts) 
as is seen in this animal. Scale 1:3.5.
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Figure 101: Group 33 - Macroscopic photomicrograph of renal subcapsular grafts in the DST, 
CsA and W3/25 induction therapy (Allograft) group, 30 days post-transplantation. Grafts are 
associated with white adipose tissue, which may be the result of ectopic insulin secretion. 
Enhanced blood supply to the grafts is particularly evident in this graft (Scale 1 :4).
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Figure 102: Group 33 - DST, CsA, W3/25 induction therapy resulted in excellent preservation 
and development of the grafts. Numerous well-developed islets are present. The exocrine 
component of the grafts consists of dilated ducts and atrophing acinar tissue. Perigraft adipose 
tissue is present (H&E x 100). Scale bar = 90 pm.
Figure 103: Group 33 (Allograft: post-transpalntation) - higher magnification showing a well- 
developed islet and some atrophing exocrine tissue components (H&E x 400). Scale bar = 20
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Figure 104: Group 33 - Insulin immunocytochemistry demonstrating the presence of insulin 
positive (brown staining) islets of Langerhans distributed throughout the allograft (insulin x50). 
Scale bar= 170 |im.
Figure 105: Group 33 - Insulin immunocytochemistry demonstrating insulin in an allografted 
pancreas demonstrating positively staining within the central portion of the islet (insulin x400). 
Scale bar = 20 |im.
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Figure 106: Group 33 - Glucagon immunocytochemistry showed staining of a-cells in the 
periphery of the islets. Morphometry showed that the % of a-cells was reduced following 
allogeneic FRPT (glucagon x400). Scale bar = 20 jam.
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Figure 107: Group 33 - Electron micrograph of a part of an islet of Langerhans 30 days post­
transplantation, following DST, W3/25 and CsA induction therapy, shows viable well-granulated 
endocrine cells containing typical insulin granules (x4500). Scale bar = 2.2 pm.
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Group 29: normal 
Pancreas (fim2)
Croup 31: STZ 
Pancreas (pm2)
Group 33: 
Allografts (pm2)
% P - cell 
area/islet area
54.7 ±3.10 20.4 ± 2.64 
(p=0.003)
39.7 ±5.65 
(p=0.03)
% a - cell 
area/islet area
21.5 ±4.54 31.6 ± 3.87 
' )]}
3.1 ±0.81 
(p=0.01)
P -  cell / a  -  
cell
2.55 ±0.66 0.72 ±0.11 
(p=0.003)
12.8 ± 2.68 
(p=0.02)
Large islet size 82 390 ± 15 478 46 658 ± 6006 
(p=0.01)
25 373 ±4154 
(p=0.001)
Table 32: Groups 29, 31, 33 - Morphometrical analysis of insulin and glucagon 
immunocytochemistry of islets in normal pancreas, STZ pancreas and grafts, following allogenic 
FRPT. Values are mean ± SEM. P values reflect the difference between the diabetic control 
pancreata (group 31) and the allogeneic FRP grafts (group 33) compared to the normal non­
diabetic control pancreata (group 29).
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SECTION 7.
GRAFT HISTOLOGICAL SCORING AFTER AUTOLOGOUS AND ALLOGENEIC
TRANSPLANTATION
Group Graft Scores Islets Infiltrate Score % grafts rejected
Syngeneic Controls (DA => DA)
Group 2 Syngeneic 4,3,3,3,3,4,4,3 
(3.4)
++ 0,1,1,1,1,0,0,1 
(0.6)
0 (0/8)
Allografts (DA => SD) - Histocompatibilty Barrier -  Outbred strain
Group 3: Control 
DA => SD
0,0,0,0,0,0,0,0 (0) - - (no grafts) 100% (8/8)
Group 4: CsA 5 
mg/kg
3,3,2,3,3,2,2,3,2,3 
(2.6)
++ 1,1,2,2,2,2,2,1,2,2 
(1.6)
0 (0/ 10)
Group 5: MMF 50 
mg/kg/d
1,0,1,1,1,2,1 (1.0) (+) 4,4,4,3,4,2,4 (3.6) 100% (7/7)
Group 6: CsA & 
MMF
3,3,4,3,4 (3.4) ++ 0,1,0,1,0(0.4) 0 (0/5)
Group 7: CsA & 
MMF
3,2,3,3,3,2,3 (2.7) ++ 1,3,1,1,1,2,1 (1.4) 0 (0/7)
Group 8: W3/25 200 
M-g/d
2,1,2,1,2,2,2,1 
(1.6)
+ (+) 2,3,3,3,2,3,3 (2.6) 38% (3/8)
Group 9: W3/25 
500pg/d
2,3,3,2,2,2 (2.3) ++ 2,2,1,2,2,2 (1.8) 0 (0/6)
Group 10: W3/25 
500 (ig/d -  30 days
3,2,2,3,2,1 (2.2) ++ 3,3,3,2,3,3 (2.8) 17% (1/6)
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Group 11: DST lx  3 
ml.
0,0,0,0,0 (0) - - (no grafts) 100% (5/5)
Group 12: DST & 
CsA
0,0,0,0,0 (0) - - (no grafts) 100% (5/5)
Group 13: DST & 
W3/25 500 (ag/d
2,2,1,1,2,1 (1.5) ++ 3,2,2,3,2,3 (2.5) 50% (3/6)
Group 14: DST & 
W3/25 & CsA
3,4,3,3,4,3,3 (3.3) ++ 1,1,1,1,1,1,1 (1.0) 0 (0/7)
Group 15: DST & 
W3/25 & CsA - 30 
days
3,3,4,3,3,4,3,3,3 
4,3,4 (3.3)
+++ 2,2,1,2,2,1,1,2,1,1, 
2,1 (1.5)
0 (0/ 12)
Allografts DA => PVG Histocompatibilty barrier -  Inbred strain
Group 16: Control 
DA PVG
0,0,0,1,0 (0.2) - - (no grafts) 100% (5/5)
Group 17: CsA 
5mg/kg/d
2,3,3,2,2,2 (2.3) ++ 1,2,1,1,2,2 (1.5) 0 (0/6)
Group 18: MMF 50 
mg/kg/d
1,2,1,1,1 (1.2) + 4,3,3,3,4 (3.4) 100% (5/5)
Group 19: CsA & 
MMF
3,3,2,3,3,3 (2.8) ++ 0,0,0,1,0,1 (0.3) 0 (0/6)
Group 20: CsA & 
MMF -  30 days
3,3,2,2,3,2 (2.5) ++ 1,1,2,2,1,2 (1.5) 0 (0/6)
Group 21: W3/25 
500 jig/d
2,1,2,1,2,1 (1.5) + 2,3,2,3,2,3 (2.5) 50% (3/6)
Group 22: W3/25 
500 jag/d - 30 days
1,1,2,1,2,1 (1.3) + 3,3,2,3,3,3 (2.8) 67% (4/6)
Group 23: DST lx  3 
ml
0,0,0,0,0 (0) - (no grafts) 100% (5/5)
Group 24: DST & 
CsA
1,2,2,1,2 (1.6) - 4,4,4,4,3 (3.8) 40% (2/5)
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Group 25: DST & 
W3/25
2,1,1,2,1 (1.4) + 3,3,3,4,4 (3.4) 60% (3/5)
Group 26: DST + 
W3/25 & CsA
2,3,3,3,3 (2.8) ++ 2,1,1,1,2 (1.4) 0 (0/5)
Group 27: DST + 
W3/25 & CsA -  30 
days
3,2,3,1,2,2,2,1 
(2.0)
+ 1,3,2,3,3,2,3,2 
(2.4)
25% (2/8)
Diabetic Groups - STZ Induced diabetes
Autologous diabetic control group (WAG =>WAG)
Group 32: 
Autologous control -  
30 days
4,3,4,4,4,3 (3.7) +++ 0,1,1,1,1,1 (0.8) 0 (0/6)
Allogeneic diabetic group (DA => SD)
Group 34: DST & 
W3/25 & CsA -  30 
days
3,3,3,3,3,2,3,3,2,3 
(2.8)
+++ 1,1,1,1,1,2,1,1,2,1 
(1.2)
0 (0/ 10)
Table 33: Histological scoring of foetal pancreatic grafts according to the method described by 
Guymer and Mandel 1991. Results shown are the graft scores. A score of 4 denotes intact 
unaltered grafts while a score of 1 represents severe destruction of the grafts. A score of 0 was 
awarded if no viable graft remained, the presence of islets (graded -  to +++). A graft infiltration 
score of 0 represents no graft infiltration, 1 indicates slight perigraft infiltrate, a marked graft 
infiltrate scores 2, score of 3 represents diffuse lymphocytic infiltrate throughout the graft and a 
score of 4 extensive infiltration) and the percentage of grafts rejected (graft scores of land 0).
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Chapter  8
DISCUSSION
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Normal Controls.
The establishment of reliable, accurate CD2, CD4, CD8 and CD25 normal values is an essential 
part of this study. The CD4 molecule and the effect of various immunosuppressants on the 
expression/function of this molecule on the T-Lymphocyte is a central focus in this study.
Two-colour FACS analysis showed that the Sprague-Dawley rat peripheral blood lymphocyte 
CD4 and CD8 profile differed substantially from that of the PVG rat. The normal SD and PVG 
reference values established by this study were a CD2+CD4+ percentage of 51.5% and 72.0% 
respectively and a CD2+CD8+ percentages of 48.7% and 24.3% for SD and PVG rats 
respectively. Values for CD4+CD25+, a marker for early T-cell activation, and a subset of CD4+ 
T-cells thought to be regulatory cells, were 5.2% and 7.2% for the SD and PVG rats respectively.
In a comparative study Groen et al. (1993) showed that a large variation excists in the 
CD2+CD4+ (range 51 to 95%) and CD2+CD8+ (range 5 to 45%) PBL immunophenotypic 
percentages between different inbred rat strains1. Our PVG results, shown in brackets, CD4% - 
80% (72%), CD8% - 20% (24.3%) and the CD4/CD8 ratio was 4 (3.1) compared well with the 
PBL results described by Groen.
Groen et al. (1993) showed that the CD4/CD8 ratio of the rat strains he studied ranged from 9.7 
to 1.1 but there appeared to be no correlation between the CD4/CD8 ratio, the inducibility of 
disease or Th-2/Th-l ratio ’.
Flow Cytometry - Establishing Normal T-Cell Reference Ranges.
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Normal Adult Pancreas Histology of the Rat
Light microscopy of the control DA adult rat pancreata showed the typical pancreas architecture 
with approximately 2% of the pancreas area consisting of islets of Langerhans (endocrine 
portion) and the remaining 98% of the pancreas consisting of exocrine tissue (ducts, secretory 
acini) and stroma containing blood vessels and nerves. In the mature DA rat, islets of 
Langerhans measured between 50 -100pm in diameter with some bigger coalesced islets of up to 
300 pm in diameter dispersed throughout the pancreas. These findings are in agreement with 
those published by Elayat et al. (1995)2.
The mean islet area of the DA was 82 390 pm of which 54.7% of the total islet area consists of 
insulin positive p-cells. Glucagon positive a-cells, accounting for 21.5% of the mean total islet 
area, formed a mantle at the periphery o f the islet around the central portion of the islet. 
Somatostatin and pancreatic polypeptide positive cells appear as single cells among the glucagon 
cells in the periphery of the islets.
The typical organization of endocrine cells into a p-cell core surrounded by the glucagon,
somatostatin and pancreatic polypeptide secreting cells has significant physiological importance
for carbohydrate metabolism3. The glomerular microcirculation further illustrates the complexity
of the islet. The central insulin-secreting portion of the islet receives blood from afferent
arterioles which form fine glomerular capillary networks radiating towards the periphery of the
islets and the surrounding exocrine tissue3,4. Blood, enriched with insulin secreted by the central
P-cell core, percolates through the capillaries towards the non-P cells periphery and then drains
into an acinar capillary network supplying the peri-islet exocrine tissue4,5. At a functional level
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the numerous nerve fibres, that terminate in the pericapillary space, further complicate the 
hormonal regulation in the islet of Langerhans4. At the cellular level, gap junctions between the 
endocrine cells also regulate secretion by permitting transfer of low molecular weight substances 
between adjacent cells3. It is therefore clear from the islet structure that hormonal control of 
insulin, in particular in the islet of Langerhans and the surrounding exocrine tissue, is both 
complex and multifactorial3.
Histological Evaluation of Control and Transplanted DA Foetal Pancreatic Tissue 16-18 
Days Gestation (Autografts).
Histology of the foetal rat pancreas at 17 days gestation showed undifferentiated tissue consisting 
of ductular structures and capillaries. Endocrine cells were mostly associated with the ducts and 
had not yet formed morphologically recognizable islets of Langerhans. Secretory acini were 
absent. Brown et al. (1982) proposed that, due to the absence of developed exocrine tissue, this 
was the preferred gestation age for FRPT, yielding the highest proportion of endocrine tissue 
following engraftment6.
Immunocytochemistry showed that very few differentiated endocrine cells were present at this 
stage and that the insulin and glucagon positive cells were present either as single cells or as 
small clusters associated with the ductules. Somatostatin positive cells were rare. These findings 
concur with the chronological appearance of endocrine cells in the developing rat, as described 
by McEvoy et al. in 1980. He showed the appearance of glucagon cells at 12 days gestation
• 7 8followed by insulin cells at 15 days and somatostatin on gestational days 1 7 - 1 8
Autologous engraftment of 16 -  18 day gestation FRP allows for the continued development of 
the endocrine component of the pancreas. By 3 days post-transplantation the insulin positive
252
Stellenbosch University http://scholar.sun.ac.za/
cells have formed small clusters of cells closely associated with the ductules. At this stage many 
mitotic figures of ductular cells are seen. At 5 days post-transplantation, the insulin positive 
clusters/cells have increased in size and, although still associated with the ductules, they start to 
take on the morphological appearance of islets of Langerhans. By 10 days post-transplantation, 
most of the islets are no longer associated with the ductules and appear loose in the stroma. At 
this stage the ductules start showing signs of atrophy with widening of their lumens. The islets 
continue to grow and, by days 20 and 30 post-transplantation, they take on the appearance of 
mature islets, which consist almost entirely of insulin positive cells. At this stage some remnant 
ductules, characterized by their wide lumens, are still present in the grafts. The appearance of 
peri-graft subcapsular fat during this period, possibly related to the ectopic secretion of insulin by 
the islets, is a common observation 9.
In contrast to insulin positive endocrine cell growth, the glucagon positive endocrine cells, which 
are the first to appear in the normal developing pancreas, appeared to be present in reduced 
amounts per islet 7’8’l0’n . By 10 days post-transplantation the occasional glucagon positive cell is 
seen at the periphery of the developing islet and, although there is a slight increase in the number 
of glucagon positive cells at days 20 and 30, it is still far less than seen in the normal adult 
pancreatic islet. The possible cause and effect of the decreased a-cell (glucagon) presence in the 
transplanted islets is not known. Factors such as denervation, ischaemia or exocrine growth 
factors may play a role but there is no literature to support these views.
Somatostatin positive cells are present in the transplanted islet, appearing as single cells in the 
periphery of the developing islet and detectable from 10 days post-transplantation by 
immunocytochemistry.
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NON-IMMUNOSUPPRESSED TRANSPLANT ALLOGRAFT CONTROLS.
Flow cytometry, performed pre- and post-transplantation, showed that the procedure did not have 
a significant effect on either the CD2+CD4+, CD2+CD8+ or CD4+CD25+ PBL 
immunophenotypes.
Histology of the harvested non-immunosuppressed transplantation control grafts showed fierce 
rejection of the DA (R TlavI) donor strain pancreata in both the outbred SD and the inbred PVG 
(RT1C) recipients. Although the DA (RTlavl) to PVG (RT1C) strain is described as a low 
responder the strain rejected the FRPT completely by 14 days post-transplantation12,13. In all 
cases, the transplanted renal subcapsular foetal pancreata were completely rejected and replaced 
by fibrous tissue within 14 days of transplantation. In most cases a mononuclear cell infiltrate 
was still present mainly at the kidney graft interface.
CSA, MMF AND CSA/MMF: COMBINATION IMMUNOSUPPRESSION IN 
TRANSPLANTATION ALLOGRAFT GROUPS.
Flow cytometric monitoring of the peripheral blood T-lymphocytes in the SD rat, following FRP 
transplantation and daily CsA monotherapy (5 mg/kg/d), showed a significant decline in PBL 
CD2+, CD2+CD4+, CD2+CD8+ and the CD4/CD8 ratio 1 day post-transplantation. Although the 
CD2+ and CD2+CD8+ and the CD4/CD8 ratio levels had recovered by days 7 and 14 post­
transplantation the mean CD2+CD4+ percentages were still marginally lower than the pre­
transplantation levels. CsA monotherapy had a similar effect, following FRP transplantation, in
the PVG rat. The PBL CD2+CD4+ immunophenotype showed a significant decline on day 7
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post-transplantation, resulting in a reduced CD4/CD8 ratio. The CD2+CD4+ and the CD4+CD8+ 
levels recovered to non-significant levels by day 14 post-transplantation. The short term 
transient CD2+CD4+ PBL lymphocytopenia, following FRPT and CsA treatment, has also been 
reported following surgical trauma in humans: the observations of our study and could therefore 
be due to the animals recovering from the operation and acclimatising to the CsA therapy l4.
Mycophenolate mofetil monotherapy at the given dose (50 mg/kg/d) resulted in a slight (5%) 
decline in CD2+CD4+and a marginal increase of 13% in the CD2+CD8+ percentage of the PVG 
rats (p=NS) but had almost no effect on PBL imunophenotype of the SD rats. It would appear as 
if MMF does not have an immediate measurable immunosuppressive effect on the PBL and that 
it is well tolerated by the rat.
Cyclosporine and MMF combination therapy, at the given dose, resulted in significant decline of 
PBL CD2+CD4+ percentage of both the SD and PVG experimental animals by days 14 and 30 
post-transplantation. The CD2+CD4+ PBL decline resulted in a significant increase of the 
CD2+CD8+ percentage and therefore a significant decline in the CD4/CD8 ratio.
Cyclosporine suppresses activation transcription factor genes that are necessary for cytokine 
production (including IL2, IFN-y, GM-CSF, TNF-a and IL-4). It therefore inhibits downstream 
lymphocyte proliferation, resulting in a general suppressive effect on activated PBL T-cells, B- 
cells and monocytes. MMF, known to be synergistic with CsA, prevents de novo purine 
synthesis and, because activated lymphocytes lack the purine salvage pathway, MMF effectively 
prevents clonal expansion15'18. Why CsA and MMF combination therapy affected CD2+CD4+ 
PBL’s, more than CD2+CD8+, is open to speculation but probably relates to the activation status 
and T-cell subset regeneration of the lymphocytes during the period. Persistent CD4+
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lymphocytopenia, disproportionate CD2+CD8+ regeneration and a consequent decline of the 
CD4/CD8 ratio have been described in MMF/CsA treated human renal recipients and in 
mice19,20,21. The CD4+CD25+ PBL percentages were unaffected by CsA and MMF either as 
monotherapy or in the combination therapy groups (p=NS).
The histology confirmed that, at the given dose (5 mg/kg/d), CSA consistently prevented acute 
rejection in both the SD and PVG transplanted animals, allowing for the development, 
predominantly, of the endocrine component (islets o f Langerhans) following FRPT. 
Graft/infiltrate scores, in these groups, reflected good graft survival with light to moderate 
mononuclear cell infiltrates at the time of harvest -  14 days post-transplantation. These results 
concur with the findings of Brown et al. (1988) who demonstrated the efficacy of CsA 
monotherapy, at 15 mg/kg/d, in preserving the graft and limiting the mononuclear infiltration 
into foetal pancreas allografts in the DA (RTla) to PVG (RTl0)22.
In contrast to CsA, MMF monotherapy, at the given dose (50 mg/kg/d), failed to prevent 
rejection at 14 days and showed only remnants of the rejected graft, amongst a massive 
mononuclear cell graft infiltrate, in both the SD and PVG groups. These findings are similar to 
those achieved by Schulak et al. (1996) who showed that MMF was ineffective as a 
monotherapy in preventing rat pancreas allograft rejection .
Combination of CSA and MMF (at the given dose of 5 mg/kg/d and 50 mg/kg/d respectively) 
resulted in excellent graft survival and development of the grafts in both the SD and PVG 
recipients which were essentially infiltrate free at the time of harvest 14 and 30 day post­
transplantation. Excellent graft scores, with low infiltrate scores, were achieved in the SD
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recipients at 14 and 30 days post-transplantation, and this was marginally better than what was 
achieved in the PVG recipients.
The low graft infiltrate scores, associated with CsA and MMF combination therapy, could be of 
clinical importance in the prevention of chronic rejection which, despite the introduction of new 
immunosuppressants, is still a major cause of graft loss24.
Electron microscopy of the islets, 30 days post-transplantation, confirmed the presence of viable 
and functional endocrine cells containing numerous secretory granules, most of which had the 
characteristic dense core insulin-like appearance. The presence of numerous capillaries, 
between the endocrine cells, indicated that the islets were well vascularised and therefore viable.
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Figure 108: An illustration demonstrating the highly effective two-stringed bow approach to 
immunosuppression when using CsA and MMF therapy. CsA, by inhibiting calcineurin 
(highlighted in green), acts early in the lymphocyte activation pathway, preventing the 
transcription of various cytokine genes (eg. IL-2), which are necessary for the activation signal 3 
in the illustration above. MMF acts late in the activation pathway by inhibiting the enzyme 
IMPDH. It effectively inhibits purine synthesis (highlighted in yellow) and therefore 
lymphocyte proliferation15'18 (Illustration by Halloran in Am. J. Med. Sciences 1997; 313(5): 
283-288).
ANTI-CD4 (W3/25) MONOCLONAL ANTIBODY IMMUNESUPPRESSION OF 
TRANSPLANTATION ALLOGRAFT GROUPS.
Flow cytometric analysis showed that a single intravenous dose of 500 jug W3/25 resulted in a 
rapid 33.2% decrease of the CD2+CD4+ PBL percentage in the adult 450 g SD rat, within 10 
minutes of the antibody infusion. Subsequently, the CD2+CD8+ PBL percentage increased by 
38% and the CD4/CD8 ratio declined from 1.5 to 0.7. In 1995, Pelegi et al. hypothesised that the 
reduction of CD4+ cells from the peripheral blood circulation, following W3/25 in vivo
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administration, was due to a decrease in CD4 antigen expression or a reduction of circulating 
CD4+ lymphocytes 25.
In this study daily administration of 200 pg W3/25, to the SD recipients, caused the CD2+CD4+ 
PBL percentage to decline significantly by 42.6% from pre-transplantation values to 14 days 
post-transplantation (p=0.008). The CD2+CD8+ PBL percentage increased significantly in this 
period, by 49.2%, resulting in a significant decline in the CD4/CD8 ratio to 0.4. Of interest is 
that the CD2+% of the gated lymphocytes declined by 20% in the 14-day period but this was not 
significant.
Increasing the daily dose of W3/25 from 200 to 500 (ig further reduced the CD2+CD4+ PBL 
percentage by 65.7% at 14 days and by 66.7% at day 30 post-transplantation. The CD2+CD8+ 
PBL percentage increased by 72.6% and 62.4% at 14 and 30 days post-transplantation. 
Subsequently the CD4/CD8 ratio was reduced to 0.2 by 30 days post-transplantation. The non- 
parametric Spearman Rank test, to test for a correlation between the CD2+CD4+ decrease and the 
CD2+CD8+ PBL percentage increase, gave a significant negative correlation. An important 
feature of the W3/25 treatment is the gradual decline of CD2+ percentage from the lymphocyte 
gate (FSC vs. SSC) reaching significance by day 30 (from 34.7% to 20.9%: p=0.03). Taking the 
above into account it becomes clear that following W3/25 administration, the CD2+CD4+ PBL’s 
are rapidly removed or migrate from the peripheral circulation. This is supported by the 
significant correlation between the declining CD2+CD4+ percentage and the increasing 
CD2+CD8+ PBL percentage, and the declining CD2+ percentage from the lymphocyte gate, 
rather than the down regulation of surface CD4 expression of the CD2+CD4+ PBL’s, as
suggested by Pelegi et al. 25. The significant decrease in circulating host CD4+ cells following
26W3/25 administration has been described by Sablinski et al. (1991) .
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An interesting observation was the significant increase of CD4+CD25+ PBL’s following W3/25 
administration at 14 and 30 days post-transplantation. CD25 is a marker both for early activation 
of CD4 T-cells and for a subset o f CD4 T-cells, which include regulatory T-cells. It is difficult 
to speculate if  the increase in the CD4+CD25+ PBL percentage is induced by the W3/25 therapy 
or whether, in fact, these are either established CD4+CD25+memory/suppressor cells, which are 
not migrating from the peripheral circulation, or more likely are newly released CD2+CD4+, or 
even CD4 CD8 , cells from the thymus which have become activated .
In the PVG, 500 jjg W3/25 had a similar effect on the CD2+CD4+ subset, resulting in the 
significant decline of CD2+CD4+ by 40.6% and 60.3% and a CD2+CD8+ percentage increase of 
105.7% and 206.6% at 14 and 30 days post-transplantation respectively. The non-parametric 
Spearman Rank test showed a negative correlation between the CD2+CD4+ and CD2+CD8+ 
percentage. In clinical transplantation the use of ATG results in long-term, (up to 5 years after 
transplantation) depletion of CD4+ cells and an increased regeneration of CD8+ cells, especially 
the CD8+CD57+ subpopulation21.
In the PVG the CD2+%, within the lymphocyte gate, declined significantly following W3/25 
treatment, by 55.3% and 61.6% from the pre-transplant levels at 14 and 30 days post­
transplantation, indicating that W3/25 treatment had the same effect on the SD and the PVG 
CD4+ and CD8+ T-lymphocyte subsets. Following W3/25 treatment, the CD4+CD25+ PBL 
subset in the PVG was slightly increased but, in contrast to the SD, failed to reach significance.
Following 200 (ig W3/25 per day, histology o f  the grafts showed slight graft survival but with a
marked mononuclear cell infiltrate consisting mostly o f  small lymphocytes. In an attempt to
improve mean graft/infiltrate score, the dose o f  W3/25 was increased from 200 (j.g/d to 500 |ag/d.
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The higher dose improved the graft score but failed to maintain a low infiltrate score at 30 days 
post-transplantation. The graft survival and development of islets of Langerhans in the SD rat 
was comparable to that achieved with CsA monotherapy but with a slightly higher graft infiltrate 
score. Grafts harvested from the PVG rats, at 14 - and 30 days post-transplantation, showed low 
graft survival but the graft/infiltrate scores were not markedly improved. Although the PVG 
scores following W3/25 treatment are disappointing, variation in the efficacy of anti-CD4
treatment in different strain combinations is a well-described phenomenon. In some strains the
• "1" 28 * i activation of the rejection response is totally dependent on CD4 cells . In these strains, the
hosts develop specific tolerance to the graft however, in strain combinations in which CD8+ cells
can be activated without CD4+ help, anti-CD4 therapy simply results in a delayed rejection of the
grafts 28. In in vitro MLC results, the DA (RTlavl) and PVG (RT1C) strain combination
confirmed the presence o f a population o f CD4+ T-cells, which were refractory to the inhibitory
action of W3/25 on T-cell activation29. Qi et al. (1997) identified the DA (R Tla) strain as a low
responder characterized by the inability of its pure CD8 population to proliferate or reconstitute
rejection following antigen presentation30. Tolerance was easily achieved, by a single dose of a
depleting anti-CD4 (OX-38), in the PVG (RT1°) to DA (R T la) low-responder strain
combination. By switching donor and recipient strains, tolerance could not be achieved in the
DA (RTla) to PVG (RT1C) constituting a high-responder strain combination30. This could
explain why W3/25 therapy was less effective in our studies in the PVG than in the SD rat.
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DONOR SPECIFIC TRANSFUSION (DST), CYCLOSPORINE (CSA) AND ANTI-CD4 
(W3/25) INDUCTION THERAPY GROUPS -  DONOR SPECIFIC ANTIGEN INDUCED 
UNRESPONSIVENESS.
Medawar first demonstrated the potential benefit of donor specific transfusion to the recipient,
prior to transplantation, in 1946. In clinical transplantation, the use of DST remains
controversial, but is still used, in combination with conventional immunosuppression, by some 
t i i
transplantation units .
Donor specific transfusion, in combination with CsA induction therapy had no significant effect 
on the T-cell immunophenotypes, apart from a drop in CD2+CD4+ PBL cell percentage 1-day 
post-transplantation. Combining DST with CsA induction therapy (x5 days) resulted in 
accelerated rejection of the grafts in the SD rat. However in the PVG, the response was less 
acute and, although there was a pronounced lymphocytic infiltrate present, some graft elements 
were still identifiable.
Woods, a renowned transplantation immunologist at Oxford, first demonstrated that specific 
donor tolerance could be achieved in the mouse and rat, if  DST was given in combination with 
anti-CD4 28 days prior to transplantation32,33’34.
In this study, the potential of DST was utilized as an adjunct to anti-CD4 and CsA, specifically to 
induce graft unresponsiveness in the strong responding DA to SD and PVG, FRPT model.
Flow cytometry analysis, following a single 3 ml DST, showed a slight, but not significant 
decline of 5.9% and 1.4% in the CD2+CD4+ population and a 10.5% and 26.1% disproportionate 
increase in CD2+CD8+ of the SD and PVG respectively, at 14 days post-transplantation. The 
CD4+CD25+ expression also increased slightly in the SD rats but had declined slightly in the
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PVG group 14 days post-transplantation. Although these changes were not significant and were 
within established normal ranges.
Professor Bert Myburg, an eminent transplantation biologist, at the Witwatersrand Medical 
School suggested (oral communication) that the inadvertent introduction of viruses into SPF rats, 
used as transplantation models, often plays a major role in the outcome of these experiments and 
this is seldom appreciated by researchers in the field. For example, an increase in CD8+CD57+ 
cells has been described in patients with CMV infection19. An increase in the CD4+CD8+ cells, 
which normally represent approximately 6% of the T-cells in the peripheral blood of the adult 
rat, could also account for a disproportionate increase in CD2+CD8+ 21.
Flow cytometry of the DST and CsA combination therapy groups showed no significant changes 
in the PBL immunophenotype combinations, at 14 days post transplantation, except for a slight, 
but not significant, increase in the CD4+CD25+ expression in the PVG group. On day 1 post­
transplantation in the SD group, the significant changes in the values o f all the T-cell subsets did 
not fit in with the general trend: this can only be due to technical problems either with the 
staining or the FACS analysis on the specific day. In comparison to the CsA monotherapy 
groups, the DST and CsA combination resulted in similar non-significant changes in the T-cell 
immunophenotypes.
Combining DST and W3/25 resulted in a significant (51.7%) decrease in the CD2+CD4+ 
percentage in the SD rat while, in PVG rats, a more moderate but still significant 17.3% 
reduction could be demonstrated one day after commencement of treatment. Although W3/35 
administration was intentionally stopped at 5 days, CD2+CD4+ percentages remained 
significantly lower in both SD and PVG rats 14 days post-transplantation. In response to the
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W3/25 induced CD2+CD4+ PBL lymphocytopenia, CD2+CD8+ percentages increased by 47.1% 
and 58.3%, 14 days post-transplantation in SD and the PVG rats respectively. DST and W3/25 
combination therapy resulted in a significant 28.7% decline of FSC vs. SSC gated CD2+ cells in 
the SD rats. In the PVG rats, the CD2 cells were still 15.2% lower at 14 days post­
transplantation but this was not significant. Apart from a non-significant increase in the SD rat 
on day 14, DST and W3/25 induction therapy had no significant effect on the CD4+CD25+ 
percentage. In comparison to the 500|j.g/d W3/25 monotherapy groups, the CD2+CD4+ 
suppression, induced by DST and W3/25, was less marked, and although still significantly lower 
at day 14 post-transplantation, showed some signs of recovery following the withdrawal of 
W3/25 therapy on day 5.
Using 3 mg W3/25 doses, administered on days 0, 2, 4, 7, 9, 11 and 14 to an adjuvant arthritis 
Wistar rat model, Pelegri et al. (1995) found that all CD4+ cells were removed from the 
circulation by day 8, after 4 doses. CD4+ cells were only detected on day 17, 3 days after the last 
dose of W3/25 was given, and only returned to normal levels on day 49. CD8+ cells were found 
to be significantly higher on days 24, 38 and 4925. The findings of Pelegri et al. (1995) 
corresponded with the CD4+ decline and the CD8+ increase, following 5 days of W3/25 
administration in our model. However Pelegri et al. (1995) hypothesizes that the decline of 
peripheral blood CD4+ cells was due to a W3/25 induced down-regulation of CD4. They based 
these findings on single-colour indirect immunofluorescence FACS analysis which showed the 
absence of a positive peak but a wider than normal negative peak. By using two-colour directly 
conjugated FACS analysis, I believe this study shows that the CD2+CD4+ cells are eliminated or 
migrate from the peripheral circulation. The decline of CD2+ cells from the lymphocyte gate 
would support this hypothesis. Two-colour FACS showed no sign of a CD4dim population, as
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this would correspond with the wider negative peak described by Pelegri et al?5. The secondary 
antibody used by Pelegri et al. in the indirect immunofluorescence method, was a FITC 
conjugated goat anti-mouse IgG which would detect any exogenous W3/25 and result in such a 
broader negative peak. Using in vitro blast cultures, Stumbles et al. (1995) found that W3/25 
uniformly bound to all CD4+CD5+ T-cells without modulating the cell surface expression of CD4 
antigen35.
The rapid reduction of circulating CD2+CD4+ cells from the peripheral blood, although 
recovering slightly after stopping therapy, evokes the issue of the relevance of depleting and non­
depleting antibodies. W3/25, a mouse anti-rat CD4 mAb of IgGi isotype, is described as a non­
depleting antibody35. This is due to its inability to elicit antibody-dependent cellular cytotoxicity 
and complement-dependent cytolysis 5. In vivo, our results suggest that W3/25, by removing the
• • 35 36CD4 T-cells subset, acts more like a depleting antibody in the rat strains we utilized ’ .
The effect on the T-cell immunophenotypes was greatly enhanced in the DST, CsA and W3/25 
combination group, with significant declines of CD2+, CD2+CD4+ and the CD4/CD8 ratio of the 
SD rat at 30 days post-transplantation i.e. 25 days after CsA and W3/25 therapy was stopped. 
The CD2+CD8+ PBL percentage was still greatly increased by 41.7% from pre -treatment levels 
and the CD2+CD25+ percentage was also higher at 30 days post-transplantation, (p= NS). In the 
PVG rat the combination therapy had a shorter lasting effect. At 7 days post-transplantation i.e. 
2 days after termination of treatment, the CD2+, CD2+CD4+ and CD4/CD8 ratio was 
significantly lower while the CD2+CD8+ was significantly higher that pre-treatment values. By 
30 days post-transplantation, apart from the CD2+ T-cells, all phenotype values had recovered to 
near normal but these values did not differ significantly from controls.
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Although the W3/25 effect of eliminating circulating CD2+CD4+ T-cells from the peripheral
circulation is similar in both the SD and PVG rat, it is clear from the flow cytometry results,
following W3/25 treatment, that the immunological effect in the SD is more severe and longer-
lasting following W3/25 monotherapy, DST and W3/25 therapy or DST, CsA and W3/25
combination therapy. In a review article by Sablinski et al. (1991) the divergent mAb effects in
• • • 26vivo, were alluded to and may be due to the diversity of low- and high-responder animal strains . 
Histology
A single 3 ml dose of DST did not prevent the acute rejection of the FRPT in either the DA to 
SD or DA to PVG rat model. This finding was not unexpected. By 14 days post-transplantation 
all the grafts in the DST monotherapy groups were completely rejected and replaced by fibrous 
tissue with some focal areas of mononuclear cell infiltrates. DST, as a monotherapy, is generally 
not effective in preventing allograft rejection and generally requires some adjunct 
immunosuppression to achieve graft acceptance. This has also been documented in clinical 
transplantation in man. However Kataoka et al. (2002)37 demonstrated indefinite survival of 
more than 100 days of Lewis (RT11) cardiac allografts into DA (RTla) - low responder model. 
This finding was confirmed by Hamano et al. (1989)38. If our DA to SD and PVG strain 
combinations, are compared to the non-immunosuppressed controls, DST monotherapy had no 
effect or FRP graft survival.
Grafts harvested 14 days after transplantation, following DST and CsA (5 days) induction 
therapy, displayed accelerated rejection in the SD rat strain. The grafts were completely rejected 
and consisted o f fibrinoid material and mononuclear infiltrates, typical of immunological 
destruction. Rejection was not as fierce in the PVG rats, with some ducts and islets of
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Langerhans still surviving within a pronounced mononuclear cell infiltrate. Tchervenkov et al. 
(1995) showed a synergistic effect between DST and CsA in the Lewis to DA model. This 
synergy was dose dependent, high CsA doses were detrimental while the length of CsA coverage 
contributed to graft survival39. In our groups, CsA administration for 5 days was probably 
insufficient to establish graft unresponsiveness in our high responder models. Frede et al. (1997) 
showed that combining DST with a 14 day course of CsA, significantly prolonged cardiac 
allograft survival in the ACI (R Tla) to Lewis (RT11) strong responding allograft model. These 
workers showed that DST and CsA therapy caused an early shift to a Th-2 phenotype but that 
additional immunosuppression was required to establish long-term unresponsiveness and to 
combat rejection episodes40.
Histology of the harvested grafts, following DST and W3/25 induction treatment, yielded 
disappointing results in both the SD and PVG groups, from a rejection point of view. In both 
cases, minimal viable graft elements, including islet components, could be identified amongst a 
pronounced mononuclear cell infiltrate. The use of DST and anti-CD4 mAb is a well-established 
protocol for inducing donor specific tolerance in certain rodent strains. In rodents it takes 28 
days to establish the immunological unresponsiveness by regulatory T-cells, which forms part of 
the CD4+CD25+ subset41,42. The heavy infiltrate into the graft, following DST and W3/25 
combination induction therapy, suggests that additional immunosuppression is needed to reduce 
graft rejection, while allowing the establishment of donor specific T-cell regulation. To achieve 
this, CsA was therefore included together with the DST and W3/25 induction therapy.
DST, CsA and W3/25 combination treatment in the SD rat yielded excellent well-preserved
grafts at 14 and 30 days post-transplantation, with almost no graft infiltration. Histology of the
grafts, 30 days post-transplantation, showed the presence of well developed and near normal
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islets of Langerhans within a loose fibrous stroma. The islets were histologically shown to 
consist chiefly of insulin and a few glucagon positive cells indicating that the islets were 
functioning from an insulin point of view. The reason for the reduced glucagon component 
remains speculative. Renal subcapsular adipose tissue associated with the grafts, possibly due to 
ectopic insulin secretion, was a common observation and has been reported, previously 9.
In the PVG rat the DST, CsA and W3/25 combination induction therapy resulted in excellent 
histological graft survival with a mild to moderate graft infiltrate at 14- and 30 days post­
transplantation. Immunofluorescence labelling showed that the graft infiltrate consisted of both 
CD4+ and CD8+ cells. The lack of rejection in the presence of the infiltrate could indicate active 
graft specific suppression by suppressor or anergic T-cells or might be due to chonic rejection of 
the graft.
Immunocytochemistry confirmed that the islets consisted mainly of insulin positive endocrine 
cells, which is a positive outcome in a strong responding allograft model.
Although the SD rats responded better to the DST, CsA and W3/25 induction therapy than the 
PVG rats, this protocol effectively prevented rejection of the FRPT in both rat strains without the 
need for continuous daily immunosuppression. This observation is of great immunological 
importance and has direct clinical application.
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DIABETIC GROUPS -  REVERSAL OF STREPTOZOTOCIN (STZ) INDUCED 
DIABETES BY AUTOLOGOUS AND ALLOGENEIC FOETAL RAT PANCREATIC 
TRANSPLANTATION (FRPT).
The diabetic model.
Streptozotocin, a glucosamine derivate with well know beta-cytotoxic properties, depletes 
insulin-producing P-cells in a dose dependent manner43,44. In the diabetic model a dose must be 
selected that does not result in uncontrollable ketotic diabetes, which is considered to be 
detrimental to the development of islets of Langerhans following FRPT43.
Injection of 50 mg/kg STZ, in age-matched and genetically identical rats, resulted in 
unpredictable levels of hyperglycaemia, necessitating selection of diabetic animals with non­
fasting WBG values of between 10 and 20 mmol/1 45. Although several groups used this model 
as a model for type I diabetes, the difficulty of using STZ to obtain a modest and reproducible 
elevation of glucose levels has been acknowledged previously46.
Isogeneic (autologous) Foetal Rat Transplantation of STZ induced Diabetic Rats.
Syngeneic renal subcapsular foetal pancreas transplantation has the potential to normalize the 
gross clinical and metabolic disorders of streptozocin-induced diabetes mellitus in a rat model 
and maintaining near normal blood glucose levels 47'51. Normoglycaemia was consistently 
restored 30 days post-transplantation, by autologous foetal pancreas transplantation, resulting in 
non-fasting whole blood glucose levels in the range of normal controls. Although the rats gained 
weight and appeared to grow normally after transplantation, they had not reached the weight of 
the normal age-matched controls, probably due to STZ toxicity and the metabolic deficiencies of
experimental diabetes. The metabolic profile showed that the clinical signs of insulin-dependent
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diabetes in the rat model i.e. polydipsia, polyuria, glucosuria and wasting had been consistently 
and permanently reversed. These findings are similar to those documented after isogeneic 
isolated renal subcapsular islet transplantation52,53.
Intravenous glucose tolerance tests showed that the transplanted animals were able to mount a 
response to the glucose bolus, returning to baseline glucose levels at 40 minutes. This compared 
well with controls which returned to basal values at 30 minutes. Comparison of the control 
glucose clearance rate, of the control and isograft animals showed that the K-values had been 
restored to 85% of normal at 30 days post-transplantation. Analysing the area under the IVGTT- 
curve showed that the glucose metabolism had been restored to 88% of normal. Although both 
the K-values and the area under the IVGTT-curve showed a subnormal response to the glucose 
bolus, one must acknowledge that the IVGTT is far beyond the normal dietary carbohydrate load 
and therefore probably reflects on the reserve capacity rather than the physiological 
requirement53. It is but one instrument to test glycaemic control. In humans the oral glucose 
tolerance test is preferred to IVGGT as the insulin response is more physiological.
Histologically, the grafts showed a classic development, with the exocrine tissue being replaced 
with fibrous tissue at 30 days post-transplantation. The islets were well developed within the 
fibrous stroma or in the perigraft white adipose tissue. Immunocytochemistry confirmed the near 
normal endocrine morphology of the islets, with the majority o f the cells within the islets staining 
positive for insulin. This has been reported previously and this work supports the findings of 
other researchers54,55.
Morphological analysis of the different islet cell populations showed that (3-cell volume did not 
differ significantly from controls, but that a significant decrease of a-cells as measured by % a-
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cell area/islet area and a-cell size was present. The suppression of a-cell development in the 
grafted islets could be due to some form of negative feedback from functional a-cells present in 
the pancreas. The outcome of poorer distribution of glucagon positive staining a-cells and other 
components within the transplanted islets is however not fully understood. However, isografts 
have a near normal complement of insulin producing cells that are capable of restoring 
normoglycaemia in diabetic rats. These studies show that this outcome can be consistently 
achieved and that the results are durable as no animals reverted back to the diabetic state for the 
duration of the study. Revascularisation and reinnervation of the grafts are crucial for the 
function and survival of the islets56. Although we were unable to demonstrate reinnervation of 
the islet using neurofilament protein, neuron-specific enolase and S100 protein, Adeghate (2002) 
demonstrated that early reinnervation of islets transplanted into the anterior rat chamber of the 
eye had occurred within 5 days of transplantation36,57. Adeghate demonstrated the presence of 
extrinsic nerves containing calcitonin gene-related peptide, galanin, neuropeptide Y and choline- 
acetyl-transferase within the 5-day transplanted islets56.
Allogeneic Foetal Rat Transplantation of STZ induced Diabetic Rats.
Streptozotocin induced diabetes, as shown in this study and by others, can be successfully
reversed by isogeneic FRPT. It should therefore theoretically be possible to reverse STZ 
induced diabetes in the rat by allogeneic transplantation provided rejection could be combated. 
In practice, however, rejection and the significant diabetogenic side effects and obstacles 
associated with steroid and calcineurin inhibiting immunosuppressants have proved difficult to 
overcome. By combining DST with a short course of anti-CD4 (W3/25) and CsA, graft 
unresponsiveness was achieved without the need for daily immunosuppression. The
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immunemodulation induced by this treatment protocol resulted in sufficient graft growth and 
maturation to reverse the clinical signs of the streptozocin induced diabetes mellitus in the DA 
to SD rat model and to sustain normoglycaemia. Following allogeneic FRPT, non-fasting 
euglycaemic blood glucose levels were constantly achieved and maintained for 30 days post­
transplantation. Following FRPT, metabolic aberrations including weigh-loss, polydipsia, 
polyuria, glucosuria were functionally reversed.
Intravenous glucose tolerance tests showed that in contrast to the diabetic controls, the allogeneic 
transplanted recipients where able to respond to the glucose bolus although, as with some normal 
controls, terminal blood glucose levels were still slightly elevated at 60 minutes. The area under 
the IVGTT-curve showed that the AUC glucose metabolism had been restored to 80% of normal 
and the control glucose clearance rate showed the K-values were restored to 85% of normal 
values at 30 days post-transplantation.
Macroscopically, the grafts appeared well vascularised and associated with subcapsular white 
adipose tissue as seen in the isogeneic model. Histologically, the grafts consisted of well- 
developed islets of Langerhans and atrophying exocrine tissue, mostly dilated ducts. Very few 
graft infiltrates were present within the grafts. Immunocytochemistry showed that the islets 
consisted mostly of insulin positive endocrine cells. Electron microscopy confirmed the 
ultrastructural viability of the endocrine cells.
Morphological analysis showed that, despite the ability of allogeneic foetal islets to reverse the 
STZ-induced diabetes, these islets were significantly smaller and contained fewer P-cells per islet 
area than pancreatic islets of the normal controls. The P-cell/a-cell ratio of the transplanted area
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was however 5 times higher than that of the normal pancreatic islets. These findings are similar 
to those described by McEvoy et al. (1978)58.
The extent to which diabetes was reversed, following allogeneic transplantation, was comparable 
to that achieved by isogeneic transplantation. The genetic variation between the two rat strains 
used, and the biological variation of the STZ diabetes model, makes it impossible to make a 
meaningful quantitative comparison between the diabetic isogeneic transplantation and the 
allogeneic transplantation groups. From the results of the isogeneic and the allogeneic 
transplantations groups and controls, it is clear that allogeneic foetal rat pancreatic 
transplantation is a treatment modality capable of restoring normoglycaemia in the diabetic rat 
laboratory model and therefore has great potential for clinical relevance and application.
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Chapter  9
CONCLUSIONS
AND
FUTURE AREAS OF RESEARCH
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CONCLUSIONS.
1. Isogeneic foetal rat pancreatic transplantation under the kidney capsule allows for the 
development and differentiation of endocrine tissue (islets of Langerhans) which is 
capable of reversing and stabilizing the clinical and gross metabolic derangements of 
experimentally induced diabetes in a laboratory rat model. Normoglycaemia is thereby 
ensured following isogeneic FRPT in this model, provided sufficient foetal tissue is 
engrafted.
2. Following engraftment of isogeneic foetal rat pancreatic tissue under the kidney capsule, 
the endocrine tissue develops while the exocrine tissue component atrophies. 
Morphologically, the engrafted islets of Langerhans appear normal, although 
immunocytochemistry shows a decrease in the non-P cell islet component which could be 
due to a lack of growth factors in the renal subcapsular environment or some form of 
negative feedback from the existing host pancreatic cells. Functionally, these grafts do 
secrete insulin and are able to maintain normoglycaemia in STZ induced diabetic rats.
3. Allogeneic foetal rat pancreatic grafts, across weak or strong histocompatibility barriers, 
are rapidly rejected and destroyed unless immunosuppressive therapy is instituted that not 
only prevents rejection but also allows for growth and development of the foetal grafts 
into mature endocrine tissue. Non-immunesuppressed pancreatic allografts are 
consistently rejected within a period of 14 days.
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4. Flow cytometry shows that immunosuppressive agents that effectively target CD4+ T- 
cells and result in a significant decline in CD4+ peripheral blood percentage can 
predictably prevent or delay allograft rejection. By combining specific 
immunosuppressive agents that target different T-cell activation cascade molecules i.e. 
anti-CD4 monoclonal antibodies, cyclosporine and mycophenolate mofetil, the 
suppressive effect on the CD4+ T-cells is enhanced
5. CD4+ T-cells are rapidly removed or migrate from the peripheral blood circulation 
following the administration of a mouse anti-rat CD4 monoclonal antibody (W3/25). 
Although W3/25 is a non-depleting antibody, we have demonstrated that, by removing 
circulating CD4+ lymphocytes from the peripheral blood circulation, it acts in a similar 
manner to a depleting antibody. Withdrawal of the antibody leads to the reappearance of 
the circulating CD4+ lymphocytes.
6. Rejection of allogeneic foetal rat pancreatic transplantation can be consistently prevented, 
or delayed, by targeting the CD4 molecule with a mouse anti-rat CD4 monoclonal 
antibody (W3/25). A light to moderate graft infiltrate, which includes CD4+ and CD8+ 
lymphocytes, suggests a measure of peripheral immunological 
unresponsiveness/suppression which results in graft acceptance.
7. Cyclosporine (CsA), given daily as monotherapy or in combination with mycophenolate 
mofetil prevents rejection of allogeneic FRPT and allows for the development and 
maturation of endocrine tissue (islets of Langerhans).
8. Mycophenolate mofetil, as a monotherapy, failed to prevent rejection of allogeneic FRPT 
in these allogeneic models.
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9. W3/25 administered as daily doses of 500 fig per day, prevented graft rejection for 14 
days in the SD rat. However, by 30 days post-transplantation, one rejection (1/6) had 
occurred. In the PVG rat, W3/25 monotherapy was less effective with rejections 
occurring 14 and 30 days post-transplantation. These findings illustrate the importance 
of rat models used in transplantation, especially when using antibody therapy. The 
differences in the results between these two rat strains could be due to various strain 
specific factors such as the ability of CD8+ lymphocytes to initiate rejection without the 
help of CD4+ lymphocytes or direct alloantigen recognition.
10. By combining W3/25 and cyclosporine a synergistic effect results, which effectively 
prevents rejection of FRPT across strong responding rat strain histocompatibility barriers.
11. A single donor specific transfusion (DST), combined with 5 consecutive daily doses of 
W3/25 plus CsA induction prior to transplantation, resulted in graft unresponsiveness for 
a 30 day period without the need for any further daily immunosuppression. This 
induction protocol not only effectively prevents rejection, but also results in excellent 
growth and development of endocrine tissue from allogeneic foetal rat pancreata. This 
finding is of great importance to transplantation immunologists as similar 
immunosuppressive protocols are applicable in the clinical situation. This was one of the 
cardinal aims of this dissertation.
12. The clinical signs of streptozotocin-induced diabetes were successfully reversed by 
allogeneic FRPT immunesuppressed with DST, CsA and W3/25 induction therapy. To 
my knowledge, this is the first study in which streptozotocin induced diabetes could be 
effectively reversed in a fully MHC mismatched allogeneic rat model.
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13. The end-points and desired outcomes of the research have been consistently achieved. 
Hyperglycaemia has been consistly reversed and normoglycaemia restored in an 
isogeneic and an allogeneic diabetes rat model by foetal rat pancreatic transplantation. 
Utilization of combination therapy including DST, W3/25 and CsA proved to be highly 
effective in suppressing rejection-effector mechanisms.
FUTURE AREAS OF RESEARCH.
This foetal rat pancreatic transplantation model offers several exciting and challenging areas for 
further research. The small alloantigen load associated with FRPT and the growth potential 
makes this model ideal for evaluating the toxic side effects of the new generation of 
immunosuppressants including tacrolimus, sirolimus, everlimus and MNA.
The metabolic effect of immunosuppressants, and other pharmaceutical agents, on developing 
foetal pancreas transplant, can be established and monitored by insulin and blood glucose 
determinations in this experimental diabetic model.
Intragraft immunology is another field of transplantation biology worth pursuing. The cell 
immunophenotypes, function and cytokine profiles, both during rejection and in the unresponsive 
allograft, need to be elucidated as these data could hold the key for unlocking the mechanisms of 
the ultimate goal in transplantation, namely the establishment o f predictable tolerance.
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The model offers the embryologist an opportunity to study the endocrine development of the 
islets of Langerhans in an ectopic environment, which will contribute greatly to our knowledge 
of islet transplantation. Issues such as revascularization, reinnervation and the exocrine 
endocrine relationship are also important areas for future research.
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RESEARCH PROTOCOL: PROPOSAL FOR A Ph.D. DEGREE: REGISTRATION 
DURING 2000.
RESEARCHER: MR.C.J.F.Muller (Curriculum vitae attached).
DEPARTMENT: Anatomy and Histology, Tygerberg Campus.
PLACE OF RESEARCH: Department of Anatomy and Histology Research
Laboratory and the Department of Medical Biochemistry, Faculty of Medicine, University of 
Stellenbosch.
PROPOSED PROMOTOR AND
SUPERVISOR OF RESEARCH: Professor Don du Toit. Department of Anatomy and
Histology, Faculty of Health Sciences, Tygerberg Campus, University of Stellenbosch.
CO-PROMOTOR: Professor P.J.D. Bouic. Department of Microbiology
and Immunology, Faculty of Health Sciences, Tygerberg Campus, University of Stellenbosch.
CLASSIFICATION OF RESEARCH: Experimental animal bioresearch
THEME OF RESEARCH: Diabetes mellitus / transplantation / histology /
immunology / endocrinology / rejection.
TITLE OF RESEARCH PROJECT: Preclincal assessment of the novel immunosuppressive 
properties of anti-CD4 Monoclonal antibodies (mAb) in an allogeneic foetal rat pancreatic 
transplantation, diabetic, laboratory animal model.
290
Stellenbosch University http://scholar.sun.ac.za/
CURRENT PROTOCOL REGISTRATION WITH SUB-COMMITTTEE-C/ETHICAL
COMMITTEE.
1.1 Title: “In-vivo and in-vitro studies with human foetal pancreas: preclinical studies”. The 
study has been in progress since early 1995 and reregistered during 1995 -  2000.
1.2 Registration No: 87/072
1.3 The researcher wishes to concentrate on the animal experimentation portion of the protocol 
and possibly use the human slant at a later stage for which permission will be sought.
STATISTICAL PLANNING: Some of the tissue processing work has been performed in 
collaboration with the Medical Research Council for the past 4 months where computerized 
parametric and non-parametric analyses are currently being applied. Careful planning has been 
made to address the specific interpretation of the histological, glucose and insulin tolerance 
parameters. PC-Shareware statistical package/Statman(for means, medians, variance, standard 
deviation, range, descriptive statistics). Statistica for the determination of significant differences. 
In addition EC-Stat, multivariate statistical assessment is to be applied together with the 
multivariate statistical package (MVSP), Epistat and Statgraphics, which is available on the 
network. Specific attention has been payed to correct sample size, controls and avoidance of 
type-II errors.
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RESEARCH FUNDING: Grant awarded from the Harry Crossley Fund: November 1999 for 
protocol number 87/072.
INFRASTRUCTURE: The histology laboratory and theatre facilities in the Department allow 
the following techniques and procedures:
1.1 All microsurgical procedures/transplants/dissection.
1.2 Histological tissue processing at light and EM levels.
1.3 Staining capacity for routine H&E, EM, specialized light microscopy stains and 
immunocytohistochemistry (i.e. Immunoperoxidase).
1.4 Metabolic facilities to assess parameters of diabetes.
1.5 The infrastructure is of a high standard and sufficient to enable the completion of the 
experimental work. Excellent infrastructure is present in the Central Animal Research Unit 
and the Department of Medical Physiology and Biochemistry to raise the monoclonal 
antibodies in mice and perform the refining process.
RESEARCH STATEMENT: The current research is an advanced, original theme/approach 
based on laboratory-directed, animal research/methodology and is aimed at contributing to the 
fundamental and theoretical knowledge (endocrine, histological and immunological) and 
understanding of diabetes mellitus specifically by attempting to surgically ameliorate the
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hyperglycemia of chemically-induced diabetes mellitus (by Streptozotocin), by the sophisticated 
microtransplantation of foetal pancreatic tissue in diabetic inbred and allogeneic rats. The study 
of the use of novel monoclonal antibodies (mAb) such as clone W3/25 (Biological agent) alone 
or in combination with corticosteroid induction therapy, to suppress the rejection effector 
mechanisms responsible for graft destruction (as foetal pancreatica) has not been reported. The 
use of this new biological immunesuppressant will be a very valuable contribution to the current 
literature on anti-rejection therapy and immune-biology. This form of unique, sophisticated 
research with very strong clinical application/slant is only performed in a very few select 
laboratories in the world and in no unit in RSA. The potential of eventually being able to 
combine a biological immunosuppressant such as W3/25 or other with chemical 
immunosuppression such as corticosteroids or cyclosporine (CsA) may have far reaching 
positive benefits for transplant recipients with the added possibility of inducing specific immune 
tolerance. Thus, the problem in medicine being addressed in this study is the amelioration of 
chemically-induced diabetes mellitus in a diabetic rat model with the objectives of the 
transplantation of viable, foetal pancreatic tissue with potential to grow and differentiate across a 
strong histocompatibility barrier (i.e. allogeneic barrier), thus allowing partial or complete 
restoration of normoglycaemia apart from the other possible advantages, forthcoming to the 
disturbed metabolism.
STATEMENT OF ORIGINALITY: The following aspects o f the research endeavours make 
the project original and unique.
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1.1 Definition of the role of the CD4 lymphocyte in the rejection of MHC mismatched foetal 
rat pancreatic allografts in diabetic rats, assessment of the pharmacokinetics and 
modulation of the CD4 surface receptor molecule following the use of mAbs and 
characterization of the mononuclear cellular infiltrate in the foetal grafts by the use of 
immunofluorescent labeling (CD2, CD4 and CD8).
1.2 Combination of anti-CD4 mAb with high dose corticosteriod induction therapy to enhance 
a Th2 response to allogeneic antigen is an unique research slant not described in the 
literature.
1.3 Comparison and correlation of histological morphometric parameters of foetal pancreatic 
tissue organogenesis at immunocytohistochemical (i.e. maturation and development of the 
islets of Langerhans) level with specific reference to A, B, D and PP-cells in allogeneic 
diabetic recipients.
ETHICAL ASPECTS: Rigid ethical code conduct has been adhered to according to the 
“Ethical Considerations in Medical Research Revised Edition MRC” -  pages 34 -  39 pertaining 
to animal research since registration of protocol 87/072. In particular the proper use of 
painkillers, care and the administration of anaesthesia according to recognized veterinary practice 
has enjoyed high priority. As far as anaesthesia is concerned in rats, this laboratory has found the 
use of ether, thiopentone, Ketalar®, local anaesthesia and chloral hydrate (either singly or in 
combination) completely adequate for the type of specific procedure needed in this project. 
Postoperative warmth is provided by short-term overhead lighting, which also reduces immediate
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postoperative pain. A register of experimentation reflecting animal number, procedure and
outcome is kept and available for inspection.
NEED FOR THIS SPECIFIC STUDY: The motivation for undertaking this study and the
following circumstances prompted the research in this field.
1.1 Diabetes, apart from cardiovascular disorders, trauma and cancer is one of the leading 
causes of premature death in man, Thousands of papers on the disorder continue to appear 
yearly in medical journals as cited in the Index Medix and Scientific Index. The papers 
report on the controversial aspects of aetiopathogenesis, metabolic and endocrine 
abnormalities and treatment of diabetes.
1.2 The possibilities of treating diabetics, once rejection is controlled, by foetal implantation of 
endocrine tissue such as foetal islets is very exciting.
1.3 The prevalence of diabetes mellitus is increasing rapidly worldwide and in South Africa 
afflicts many underprivileged population groups.
1.4 Biological immunesuppressants such as mAbs, very importantly, do not show the 
diabetogenic potential induced by cyclosporine (CsA), steriods and FK506 (Tacrolimus) 
and are specific in their mechanism of action thus making it important to pursue this line of 
research.
1.5 The adverse side effects seen after conventional immunosuppression, necessitates a 
modified approach to immunosuppression. This study, by using monoclonal antibodies
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against epitopes of cell surface receptor molecules, associated with alloantigen recognition, 
will hopefully improve our understanding of the graft rejection process and 
immunosuppression. This would not only benefit diabetic patients receiving transplants 
but organ transplantation in general.
PROBLEM ADDRESSED: The following key research aspects are being addressed:
1.1 Inhibition or suppression of specific rejection effector mechanisms (T-cell generated) by 
the use of anti-CD4 mAb (in this case W3/25, a mAb obtained from the University of 
Oxford, UK), alone or in combination with high dose steriod induction therapy, in a 
allogeneic foetal rat pancreatic transplantation laboratory model.
1.2 Restoration of normoglycaemia in diabetic rats (induced chemically by streptozotocin. A 
known long-term B-cell specific toxin in adult rats) by allogeneic transplantation of foetal 
rat pancreata across a MHC barrier and inhibition of rejection by the use of mAb.
1.3 Correction and study of the clinical and some of the metabolic abnormalities (i.e. ketosis) 
induced by chemical diabetes in rats by allogeneic foetal rat pancreatic endocrine islet-cell 
replacement.
END-POINTS OF RESEARCH IN THIS MODEL: The following end-points of the research
have been defined:
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1.1 Reversal of hyperglycaemia by syngeneic and allogeneic FRPT in diabetic rats. Induction 
of random WBG <10 mmol/1.
1.2 Reversal of the clinical signs of diabetic rats by syngeneic and allogeneic FRPT (ketosis, 
polyria, polydipsia, glycosuria).
1.3 Medium to long-term (30 -  90 days) suppression of rejection by mAbs (as evaluated by 
graft histology at light and EM level) with the preservation and maturation of islets of 
Langerhans in allogeneic recipients.
PREAMBLE: The ultimate purpose, goals and clinical application of pancreatic transplantation
in diabetic patients are two-fold:
1.1 To establish a continuous normoglycaemic, insulin-independent state in a diabetic recipient 
and to induce a permanent state of euglycaemia in insulin dependant diabetics.
1.2 To prevent, halt or reverse progression of the secondary complications of diabetes in the 
long-term, thus improving the quality of life in the diabetic recipient. Early studies in man 
have shown that some of these objectives are achievable if the complications are not 
irreversible.
BRIEF LITERATURE REVIEW: Diabetes -  the problem, place of foetal pacreatic
transplantation, and use of monoclonal antibodies as immunesuppressants.
Briefly, the clinician knows and treats two types of “Diabetes” i.e. Type I (IDDM) and Type II
(NIDDM). Both conditions run in families, are associated with accelerated atherosclerosis,
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microangiopathy resulting in retinopathy, nephropathy and neuropathy. The risk of stroke is 
doubled: the risk for heart attacks are increased 2-3-fold, there is a 50-fold prevalence in the 
incidence of peripheral vascular disease. Finally, life expectancy is significantly shortened in 
both males and females (Joslin), and in the USA the disease kills several hundred thousands due 
to its effects on small blood vessels. Treatment is directed at correcting dietary deficiencies, 
weight reduction, prevention of infections, application of newer methods of insulin delivery and 
accurate blood glucose monitoring by portable glucometers. Despite this, secondary 
complications still occur and are particularly common in underprivileged third-world nations and 
races. Diabetics remain uninsurable by insurance companies or pay enormous premiums. The 
cost of insulin is staggering and most medical-aids refuse cover for diabetics, even if excellently 
controlled.
Apart from the conventional medical research in the field o f diabetes, the Pancreas Transplant 
Registry of June 1995 shows that 5546 pancreas transplants have been engrafted into diabetics 
worldwide over the last 7- years. Precise indications for transplantation now exist, but are 
mainly preformed on IDDM subjects with complications. USA statistics (of June 1995) show 
posttransplantation survival of 80% at 60 months and graft survival of 60% at 60 months. One- 
year graft survival of whole grafts is about 74%. In all cases the patient is committed to life-long 
cyclosporine based immunosuppressive treatment. Recurrence of the diabetes due to 
autoimmune destruction of the graft has been shown in extensive studies not to be a big clinical 
problem as the patients are committed to long-term immunesuppression. Islet and foetal 
transplantation have also become popular modes of transplantation and are gaining momentum. 
Human clinical islet transplantation results has despite early optimism been disappointing. 305 
adult islets allografts were preformed at 38 institutions by December 1995 of these patients only
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39 were insulin dependant at 1 month of which only 24 were still insulin dependant at 12 months 
and only 1 patient is still insulin dependant at 4 years (International transplant registry, 1996, 6). 
Analysis c-peptide negative patients receiving islet transplants, in the period 1990 -  94, showed 
that of 96 patients know to be c-peptide negative prior to transplantation, 27% had basal c- 
peptide levels in excess of lng/ml at 1 year and of these only 7% were insulin dependant 
(International transplant registry, 1996, 6). These patients with persisting c-peptide levels, 
although not sufficient to be insulin independent, benefit with lower doses of insulin and 
improved glycemic control and thus less complications (Weir Diabetes vol 46 1247 -56). More 
specific to this study, foetal tissue has been transplanted to the subrenal capsule site (favored site) 
in man and rodent models by a few other researchers abroad.
Successful engraftment of foetal tissue into the liver, spleen and muscle has been less successful 
for a variety of reasons. The main motivation for foetal transplantation is that foetal tissue has 
the capacity to grow, differentiate and function and to control diabetes when transplanted into 
athymic mice. Lafferty has shown growth and function in man following subrenal capsule 
transplantation in diabetic patients by demonstrating a sustained reduction in insulin requirement 
and elevation of basal C-peptide levels in IDDM recipients. Once the foetal pancreas is removed 
from the donor and transplanted, the exocrine component degenerates allowing the endocrine 
aspect to differentiate into islets with their own blood supply and capsule. In rodents only two 
foetal pancreases per adult rat are needed to consistently reverse streptozotocin-induced diabetes. 
Reversal takes about 2-3 weeks. The exuberant proliferation potential and ease and safety of 
engraftment in safe, accessible sites in diabetic rodents, with the ultimate potential of human 
application, promoted the study, the only of its kind in South Africa.
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Although the discovery of insulin by Banting and Best has lead to a great improvement of both 
life expectancy and quality of life in the diabetic, it soon became clear that the diabetic is faced 
with many disease related complications. Although there is a good correlation between tight 
diabetic treatment control as measured by a glycaemic index, complications like retinopathy, 
nephropathy and neuropathy still progress although at a slower rate. Sudden changes in diabetic 
control even for the better may accelerate the progression of the disease. Prediction of patients 
predisposed to developing these often life-treating complications is normally not possible 
although patients expressing the HLA-DR3 and -DR4 genotypes show an increased risk (Tam).
Successful pancreas transplantation, as a treatment option, has been shown to slow or even 
reverse the onset of diabetes related complications. This is especially true for nephropathy 
reoccurring in a transplanted kidney. Reversal of chemically induced diabetes in mice and rats 
by foetal pancreas transplantation is possible and euglycemia can be maintained for long periods 
provided that adequate immunosuppression is maintained (Brown). Conventional 
immunosuppressants, like cyclosporine (CsA) are effective in preventing both graft rejection and 
suppressing the autoimmune process provided that the treatment is maintained. The nephrotoxic 
effect of drugs like CsA combined with the high incidence of nephropathy in diabetic patients 
contraindicates against prolonged use of these drugs have a direct adverse effect on islet function 
(Weir). Depletion of CD4+ lymphocytes using a complement fixing monoclonal antibody 
directed at the CD4 cell surface receptors could induce indefinite survival of MHC incompatible 
pancreas allografts in mice (llano). Depletion of CD4 lymphocytes renders the animal highly 
immune compromised. Recent reports have shown that complete depletion of the CD4 
lymphocytes is not necessary and that non-depleting anti CD4 monoclonal antibodies like YTS 
177.9 in mice and RIB 5/2 in rats can induce allograft unresponsiveness while preserving the
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immune system (Lehmann). The use of monoclonals to prevent graft rejection could be very 
appropriate in pancreas allografts since it does not produce the unwanted side effects associated 
with chemical immunosuppressive drugs. W3/25 a non-depleting rat anti-CD4 mAb recognizing 
a different epitope to RIB 5/2 has been used to prevent the induction and progression of various 
autoimmune diseases but its efficacy in preventing allograft rejection has not been established 
(Mannie). W3/25, a rat anti-CD4 clone, has a strong inhibitory effect on mixed lymphocyte 
reactions and has been shown to shift the immune response from a T-helper 1 to a T-helper 2 like 
response by suppressing IFNy (a cytokine associated with rejection) production and enhancing 
IL-4 and IL-13 (cytokines associated with graft survival) secretion, provided W3/25 was 
administered during the primary exposure of the allograft antigen (Webb and Masson). A short 
high dose course of corticosteroids at the time of transplant (introduction of antigen) has a similar 
TH-2 promoting effect. The combination of anti-CD4 mAb with corticosteroid pulse therapy, to 
preferentially induce an tolerogenic TH-2 response, has not been described in the literature and 
provides an original area of research. Clonal development tolerogenic, TH-2 promoting CD4 
cells can be distinguished flow cytometrically from TH-1 promoting CD4 cells by their 
expression of CD45RC (0X22). Following antigen exposure these tolerogenic CD4 cells 
express low levels of CD45RC molecules while Thl effector cells have high levels of CD45RC. 
It is therefore possible to monitor the establishment and clonal expansion of 
tolerogenic/suppressor cells following different treatment protocols. This approach has direct 
clinical implications as the same regulatory CD4 subtype has been described in man (Mason. 
Immunlogy 1990).
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HYPOTHESES:
1. Transplanted foetal islet-containing pancreatic tissue undergoes selective histological 
differentiation and islet maturation in-vivo after engraftment thus allowing amelioration 
of hyperglycaemia of chemically induced diabetes (Streptozotocin) in allogeneic 
recipients across a strong histocompatibility barrier.
2. Foetal rat pancreatic transplantation (FRPT) is capable of partially or completely 
reversing the clinical and metabolic aberrations in diabetic rats.
3. Anti-CD4 monoclonal antibodies (such as W3/25) administered to allogeneic recipients 
of foetal rat pancreatic grafts in a strong responding model are capable of preventing or 
suppressing acute rejection of the transplanted tissue.
4. The action of anti-CD4 can be further enhanced by high dose corticosteroid induction 
therapy.
FEASIBILITY AND PILOT STUDY 1996/7: A feasibility and pilot study has been completed
with success during 1996/7 and confirms that the proposed research project is viable, the diabetic
rat model is established, surgical techniques are possible and that the laboratory infrastructure for
the sophisticated staining of tissues, production and refining o f W3/25 is in existance and
functioning. The study shows that successful engraftment of foetal pancreas beneath the renal
capsule is possible allowing proliferation and growth of the transplanted foetal tissue. Reversal
of chemical induced diabetes by streptozotocin is also capable in syngeneic recipients (WAG =>
WAG; substrain of Wistar and is inbred or isogeneic). The pilot study was further expanded to
establish the viability of the immunological arm of the project. WAG (a substrain of Wistar rats)
foetal pancreases of between 18 and 20 days gestation were transplanted under the kidney
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capsule of adult Spraque- Dawley rats. The recipients were then randomized into the following 
groups:
Group 1. Control group (n = 4) received no immunosuppression (unmodified rejection).
Group 2. CsA group (n = 5) received cyclosporine (CsA) 2 mg/kg/d (imi)
Group 3. W3/25 group (n = 5) received W3/25 200 (ig/d (ipi)
Group 4. W3/25 group (n = 5) received W3/25 500 fig/d (ipi)
All animals in groups 1,2 and 3 were sacrificed at 10 days. The animals in group 4 were treated 
for 50days and then sacrificed. Results showed fierce uncontrolled rejection of foetal pancreas 
allografts in the control group. This confirms the strength o f the histocompatibility mismatch 
and suitability of the model. Immunosuppression for 10 days using W3/25 or CsA 2mg/kg prove 
effective in preventing graft rejection and allowing development of islets from the foetal 
pancreas allografts. Two of the animals in group 4 showed substantial graft preservation while 
the other had rejected their grafts. These encouraging results show that W3/25 is capable of 
preventing graft rejection in the short and longer term. Results were presented as an publication 
in an international peer-reviewed journal and in the form of oral presentations which were well 
received at the following international and national congresses:
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Publication
1. Prolongation of Rat Fetal Pancreas Allograft Survival Using a Nondepleting Anti-CD4 
Monoclonal Antibody W3/25. CJF Muller, DF du Toit, AD Beyers BJ Page and N Muller. 
Transplant Proceedings 1998, 30 (8): 4180-4183.
Congress presentations
1. Does the Endocrine component of the Foetal Rat Islet Change Following Syngeneic and 
Allogeneic Transplantation and Suppression with Combinations of Anti-CD4 mAb, CsA 
and DST? Du Toit DF, Muller CJF, Mouton YM, Lyners RFC, Muller N, Wessels J, 
Fourie P, Beyers AD and Woodroof C (In association with the Medical Research Council). 
XVII Congress Of The Southern African Transplantation Society, Stellenbosch March 
1997.
2. Characterization Of The Intragraft Mononuclear Cell Infiltrate After Sub-Capsular 
Allogeneic Foetal Pancreas Transplants In Rats. Muller CJF, Du Toit DF, Mouton YM, 
Muller N and Beyers AD. 27th Congress of the Anatomical Society of Southern Africa 
Cape Town 15-18 April 1997.
3. A Comparison of Foetal Pancreas Allograft Immunemodulation in Rats, using a Non­
depleting Anti-CD4 Monoclonal Antibody (W3/25) to Cyclosporin. Muller CJF, Du Toit 
DF, Mouton YM and Beyers AD. 37th annual congress o f the federation of Southern 
African Society of Pathology, Cape Town 2 July 1997.
4. Prolongation of Rat Foetal Allograft Survival using a Novel non-depleting Rat Anti-CD4
Monoclonal antibody W3/25. Muller CJF. Du Toit DF, Beyers AD, Mouton YM, Muller
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N, Lyners RPC and Mattysen J. Surgical Research Society of Southern Africa Congress, 
17-19 July 1997, Stellenbosch.
5. Prolongation of Foetal Rat Pancreas Allograft Survival using a Novel non-depleting Rat 
Anti-CD4 Monoclonal Antibody Clone W3/25. Muller CJF, Du Toit DF, Page BJ, Beyers 
AD, Muller N, Mattysen J and Lyners RFC. 3rd International Conference On new Trends 
In Clinical And Experimental Immunosuppression, 1 2 - 1 5  Februarie 1998, Geneva, 
Switzerland.
6. Prolongation Of Foetal Rat Pancreas Allograft Survival Using A Nondepleting Anti CD4 
Monoclonal Antibody W3/25. CJF Muller. DF duToit, AD Beyers, BJ Page, N Muller, J 
Mattysen, and R Lyners. XVIII Congress Of The Southern African Transplantation 
Society. 18-21 April 1999. Mount Amanzi Lodge, Hartebeesport Dam.
PROPOSED RESEARCH PROGRAM - Research Aims and Objectives: 
A: Immunological and Endocrine Studies:
1.1 To define the role of the CD4+ lymphocyte in the rejection of MHC mismatched allografts 
with particular reference to foetal pancreas transplantation in the rat.
1.2 To modulate the CD4 surface receptor molecule using monoclonal antibodies directed 
against different epitopes of the CD4 molecule, and to study the pharmacokinetics 
following the administration of the antibodies.
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1.3 To combine anti-CD4 mAb therapy with short high dose corticosteriod induction therapy 
at the time of antigen exposure.
1.4 To study the immunological response following engraftment and mAb treatment using 
both in vivo (skin grafts) and in vitro (lymphocyte activation markers CD25).
1.5 To study the antagonistic or synergistic effect of combining CD4 mAb treatment with 
other co-signal producing membrane surface receptors like TCR, CD2, CD5 and CD28 in 
the modulation of graft rejection.
1.6 Assessment of the efficacy of anti-CD4 mAbs to suppress or prevent rejection of foetal 
allografts in the MHC mismatched DA (Dark Arguti) => PVG transplant model.
1.7 Assessment of the capability of allogeneic foetal rat pancreatic allografts to reverse the 
hyperglycaemia and other clinical features of chemically induced diabetes.
1.8 Evaluation of the endocrine response post-transplantation (IVGGT).
B: Histological Studies:
Assessment of the morphology of the developing foetal rat pancreas (18-21)  day, post-coitum,
time-bred pregnant foetal pancreases.
Histological assessment of the islet-cell morphology after allogeneic transplantation.
2.1 Light microscopy (H&E).
2.2 Special stains i.e. Gomori-Aldehyde fuchsin.
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2.3 Immunocytohistochemistry (insulin, glucagon, PP, somatostatin).
2.4 Transmission electron microscopy (ultrastructure).
2.5 Immunofluorescence.
2.6 Flow cytometry.
2.7 Confocal microscope (MRC).
3. Assessment of islet maturation and organogenesis (growth and development) following 
allogeneic foetal transplantation and immunosuppression with anti-CD4 mAb.
4. Correlation of posttransplantation graft morpholgy and endocrine response or dysfunction. 
MATERIALS AND METHODS OF THE PROPOSED STUDY.
Diabetic Model: A standardized laboratory model is utilized. Diabetes is induced by a single 
tail-vein intravenous injection of Streptozotocin (STZ) at a dose of 45 - 75 mg/kg. Diabetes is 
present usually within 48 hours and fasting PBG are usually > 15 - 20 mmol/1.
Donor Organs: 19-21 day time bred, post-coitum, DA foetal rat pancreata (standardized model). 
Between 2 - 8  foetal pancreata are transplanted at one sitting into the diabetic recipient after 
removal from the pregnant female rat. The harvesting of the foetal pancreata occurs via a 
laparotomy and hysterectomy under general anaesthesia. Thereafter the donor rat is euthanazed
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and the procedure becomes a terminal experiment. The tiny grafts are temporarily stored in 4°C 
RPMI medium (Gibco) before transplantation.
1.3 Transplantation: Under general anaesthesia, between 2 and 8, free, non-cultured, pancreata 
are transplanted microsurgically under the kidney capsule o f the diabetic recipients (renal 
subcapsular site) and control animals (see groups).
1.4 Method of Anaesthesia in the Rat: General anaesthesia is employed for all procedures 
performed in the rat and includes anaesthesia for:
(i) Laparotomy and transplantation of pancreatic foetal grafts.
(ii) Harvesting of pancreases.
(iii) Daily venesection for bloodsamples (0.01 ml/d)
(iv) Performance of glucose tolerance tests (IVGTT) (0.01 ml in total for all specimens).
Excellent and adequate levels and depth of anaesthesia are achieved by the use of intraperitoneal 
administered sodium pentobarbitone or thiopentone (Intraval) - doses (1 - 3 ml ip) for induction 
together with ether by inhalation for maintenance without the need for a tracheotomy. Special 
attention must, however, be given to the patency of the airway. The above provides an adequate 
depth of anaesthesia and suitable anaesthesia, together with a rapid recovery phase. Maintenance 
of general anaesthesia is enhanced by the addition of Ketalar®(Parke Davis®) given in 
intramuscular doses of 0.1 - 0.2 ml (of a 5 mg/ml solution) one or two minutes before a 
procedure is preformed. Ketalar® also has very potent analgesic properties, which is highly
suitable for reducing the pain during and after tissue engraftment.
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1.5 Immunesuppression: Central to this study is the use of anti-CD4 mAbs (W3/25) which is 
injected into transplanted allogeneic diabetic control rats via the intraperitoneal route (ipi) 
on a daily basis (0.1 ml) given under general anaesthesia W3/25 mAb will be prepared 
personally by the applicant from mouse ascitis, precipitated by (NH^SCU and then 
purified by ion exchange chromatography. Concentration of Ab will be determined by 
optical density. Appropriate dilutions will be made using sterile PBS. Doses of between 
200 - 500 (j.g/d indefinitely will be studied. Combination of anti-CD4mAb and 
corticosteriod (methylprednisolone) high dose pulse therapy (10 mg/d IV x 3 days) will 
further enhance anti-CD4 phamacological action. Control animals receive either no 
immunesuppression or conventional cyclosporine (CsA) at a determined dose of 2 mg/kg/d 
indefinitely (0.2 ml) and given intramuscularly (imi).
1.6 Post operative assessment of rejection: The following parameters are used to define 
rejection:
a. In diabetic transplanted recipients and immunosuppressed with W3/25 or CsA: A re­
occurrence of hyperglycaemia after transplantation (i.e. an elevated PLG > 1 0  mmol/1 on 
two consecutive days).
b. Histological assessment of harvested grafts at various intervals after transplantation at 
periods of 10, 30, 60, 90 days to show immunological infiltration with lymphocytes and 
graft destruction. Graft rejection to be scored by the method of Guymer and Mandel 
(1993).
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a. Fasting PLG (measured by an Ames Glucometer (blood obtained from a tail prick - 0.001 
ml) Blood glucose determinations are performed daily or every second day until rejection 
occurs. Rejection is defined as an elevated PLG or WBG . 10mmol/l on two consecutive 
days.
b. Intravenous glucose tolerance tests (IVGTT) via a standard laboratory technique using
0.5g 50% dextrose and measurement of bloodglucose at 5 minute intervals, after the bolus 
injection of glucose, for periods of up to 60 - 90 minutes. Insulin will be determined in 
select animals (Coat-a-count®)
c. Metabolic studies: Performed in specific metabolic cages. Studies include 24-hour 
determination of weight, water intake, urine output, urine glucose, and urine pH and ketone 
levels.
d. Pharmacokinetic studies of W3/25 in selected controls using standard methods. Has 
already been studied in the pilot study.
e. Peripheral blood monitoring (0.01 -  0.02 ml) using a panel of mAb consisting of 
CD2(OX34), CD4(W3/25), CD8(OX8), CD45RC(OX22), CD38, TCR (R73) and IL2R 
(0X39) will be analyzed on a FACScan flow cytometer (Becton Dickinson®). In-vivo 
binding of W3/25 will be monitored using FITC conjugated rabbit anti-mouse IgG.
1.7 Post transplantation Measurements/Parameters Studied:
310
Stellenbosch University http://scholar.sun.ac.za/
f. Histological assessment of harvested foetal pancreatic grafts at designated intervals after 
transplantation to study rejection, graft infiltration, maturation and development of islets of 
Langerhans especially in immunesuppressed diabetic recipients returned to 
normoglycaemia. The following methods will be utilized to attain those goals.
• Light microscopy
• Electron microscopy (EM)
• Immunofluorescent labeling
• Immunocytohistochemistry at light and confocal microscopic level -  this allows 
specific identification of A, B, D and PP cells.
g. Posttransplantation goals and end points of research:
• Reversal of hyperglycaemia in diabetic immunesuppressed recipients (measured by 
daily PBG and urine assessment).
• Lymphocyte reponse to treatment: Measured by flow cytometry of peripheral blood 
lymphocytes (blood specimen volume needed = 0.02 ml).
• Clinical monitoring of diabetes: Assessment of water intake, urine output, ketones and 
glucose content.
• Graft rejection: Measured by histology and specific immunocytochemistry and
immunophenotyping of CD4 and CD8. Histological scoring by the method of
Guymer and Mandel 1993. Characterization of the MNC infiltrate will be
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immunologically performed on frozen sections using a panel of antibodies consisting 
of CD2 (0X34 ), CD4 (W3/25), CD8 (0X8), CD45RC (0X22), TCR (R73) and IL2R 
(0X39).
• Graft and animal survival assessed in terms of postgraft days in the three 
immunesuppressed groups (i.e. W3/25, W3/25 / steriod combination and CsA) by 
Kaplan-Meier statistics and non-parametric analysis (Spearman-Rank, Mann-Whitney 
U test).
Experimental Groups. According to computer statistical randomization. A minimum of 10
animals per group will be used.
• Normal foetal pancreata (histological controls).
• Normal adult rats (DA and PVG): Immunological and endocrine controls.
• Diabetic, non-treated or transplanted controls (for metabolic studies).
• DA => DA transplantation (inbred, absence of rejection) in diabetic and non-diabetic 
recipients (to assess organogenesis and growth in the absence of rejection).
• DA => DA sham controls
• DA => PVG; no immunesuppression (untreated allograft controls -  i.e. unmodified 
rejection). Diabetic and non-diabetic controls.
• DA => PVG immunesuppressed with W3/25 (200 -500 (j.g/d ipi given indefinitely and
commencing on dayl o f transplantation). Diabetic and non-diabetic controls.
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• DA => PVG immunesuppressed with W3/25 (200 -500 pg/d ipi x28days) combined 
with methylprednisolone lOmg/d both therapies commencing on dayl of 
transplantation. Diabetic and non-diabetic controls.
• DA => PVG immunesuppressed with CsA 2 mg/kg/d imi indefinitely in diabetic and 
non-diabetic recipients. This group represents the control immunosuppression arm 
against which the other therapies is evaluated and is acknowledged to be the correct 
chemical immunosuppressive control for such studies i.e. CsA is considered to be the 
gold standard against which other immunosuppressants are tested.
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Guidelines on Ethics for M edical Research
Revised edition, 1993. Based with permission extensively on Reports from the Royal College of 
Physicians of London
USE OF ANIMALS IN BIOMEDICAL RESEARCH 
1. Introduction
The optimal care of animals used in biomedical experimentation is vital in the interests of both 
the animals and the research itself. There are two main reasons for this statement. Firstly, it is 
fitting for a civilised community to consider the humane aspects. Secondly, it must be 
remembered that trials involving animals are generally very expensive, and consequently the use 
of animals which are housed in poor facilities, which suffer from diseases or are infested with 
parasites, and which are badly cared for, will lead to results which are unreliable and/or 
unrepeatable. Good care improves the welfare of the animals and makes a large contribution to 
the attainment of high ethical and humane standards.
The MRC therefore wishes to:
• emphasise that the use of animals has made a large contribution to the welfare of both 
humans and animals in the past, and that future use of animals is necessary for further 
progress;
• acknowledge that humans have an ethical duty to treat all animals with great care and to 
be aware of their susceptibility to pain and suffering; emphasise that experimentation 
with a wide variety of animal species is necessary for the advancement of knowledge in 
biology, as well as the development of methods for prevention, diagnosis and treatment
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of diseases of humans and animals and the advancement of their welfare and 
productivity; support the responsible use of animals for experimentation and other 
scientific purposes, but encourage the use of valid alternative methods, where possible;
• insist that complete care be taken to protect animals from pain, suffering, discomfort and 
permanent injury, and will ensure that in cases where it is unavoidable, it will be kept to a 
minimum;
• ensure compliance with all relevant South African legislation, the National Code for the 
use of animals in research and international regulations. These include the following:
• the Animal Protection Act (Act No. 71 of 1962);
• the Animal Diseases Act (Act No. 35 of 1984);
• the National Parks Act (Act No. 57 of 1976);
• the Nature Conservation Ordinances of the four provinces (Cape Province - Ordinance 
No. 19 of 1974; Orange Free State - Ordinance No. 8 of 1969; Natal - Ordinance No. 15 
of 1974; Transvaal - Ordinance No. 12 of 1983); the National Code for the Handling and 
Use of Animals in Research, Education, Diagnosis and Testing of Drugs and Related 
Substances in South Africa; and Convention on International Trade in Endangered 
Species (CITES).
2. Definitions
• 'Experimental animal1 means any living non-human vertebrate, non-human vertebrate 
fetus, or any other animal species which in the opinion of the Ethics Committee for 
Research on Animals (ECRA), has a nervous system which is so sophisticated that it 
might be capable of experiencing pain in much the same way that any vertebrate might 
experience it.
• An 'animal experiment' is any procedure involving the use of live animals in which the 
aim is to test a hypothesis, collect information and advance, impart or demonstrate 
knowledge, test or collect a product, or register the effect of a certain procedure on an 
animal.
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Prerequisites for the use of animals in research
• The main purpose of any animal experimentation must be to gain usable results and 
scientific information o f high quality to the benefit of humans and animals. The 
experimentation must therefore not be purposeless or unnecessary.
• The experiment must be carefully and scientifically planned, based on the available 
knowledge of the disease or problem being studied and designed so that the expected 
results, wherever possible, will justify the experiment. A written protocol should 
therefore be prepared before each experiment which clearly indicates the purpose of the 
experiment as well as all procedures to be carried out. No experiments on animals must 
be allowed to start before the research protocol has been passed by the Research 
Committee of an institution and the ECRA has separately evaluated and passed the 
experiments.
• All attempts should be made to keep the use of animals to a minimum. Care should be 
taken to ensure that the correct species is chosen and that animals with all the necessary 
genetic attributes and microbiological qualities are chosen to ensure reliable results.
• The application of in vitro biological systems, statistical analyses and mathematical 
models should be considered as alternatives to supplement or replace animal 
experimentation. These alternatives must not only be considered on the grounds of 
humane principles but also because they generally demand less time, space, equipment 
and funding. Where the experiment inflicts inescapable pain or more pain than the use of 
anaesthetics would cause, the proper use of analgesics or the administration of 
anaesthesia according to recognised veterinary practice is obligatory until the procedure 
is completed. The only exception to this principle is in cases where the administration of 
anaesthesia would nullify the aims of the experiment and the results could not be 
obtained by any other more humane method. If approved, the Committee must then 
appoint a veterinarian to take responsibility for the welfare of the animals subjected to 
those procedures. As a general guide, researchers should accept that any procedure which 
will cause pain to humans will also cause pain to other vertebrates.
• The scientist in charge of any animal experiment must be prepared to terminate it if it 
becomes clear that the continuation thereof will cause unwarranted pain and suffering. If 
the procedure causes serious injury, the animal should be killed before recovery from
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anaesthesia. If it becomes clear that an animal will suffer unwarranted pain or discomfort 
after an experimental procedure, it should be killed in a humane manner. The veterinarian 
must have an overriding discretion as to when animals shall be killed or withdrawn from 
an experiment for humane reasons.
• The clinical care of experimental animals before, after and during the application of the 
experimental procedure must be of high standard and according to accepted veterinary 
practice so that pain, discomfort and any detrimental effects, caused by the procedure, 
can be eliminated. If it becomes necessary to kill an experimental animal it must be 
done in a humane manner and according to accepted principles which ensure immediate 
death. It is preferable that only personnel with experience in the application of euthanasia 
are responsible for this task.
• No animal may be disposed of before there is absolute certainty that it is dead.
• Animals already used in an experimental procedure should not be subjected to it for a 
second time, unless the first procedure was harmless or non-invasive and left the animal 
in good health.
• No animal should be subjected to more than one procedure that causes significant pain.
Care
• The care of experimental animals should be under the direct control and supervision of a 
veterinarian, preferably one with experience in animal experimentation, and a qualified 
laboratory animal technologist. The supervisory personnel should also include the 
services of technical staff and workers with experience and/or training in laboratory 
animal science.
• High standards should be maintained in the daily care of experimental animals. Special 
consideration should be given to regular feeding, adequate and clean water, hygienic 
surroundings, adequate ventilation and the elimination of excessive heat, cold or noise in 
the animals' environment.
• Care should be taken to eliminate disease, injury, overpopulation and stress factors and to 
safeguard the animals from endo- and ectoparasites. Careful and thorough supervision of 
the welfare o f all animals is absolutely essential.
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• Experimental animals should be kept under optimal conditions at all times. This includes 
good housing, correct environmental conditions with acceptable space for movement and 
opportunity for social interaction except where non-compatibility or the requirements of 
the experiment prevent it. The animal holding cages as well as the premises in which the 
cages are housed should therefore meet with accepted minimum standards.
• Wild animals which are captured in their natural habitat, for research purposes, should be 
trapped in cages that meet with the standards of the nature conservation authorities. The 
traps should be visited regularly, preferably daily, to prevent animals being left without 
food and water for long periods.
• It is the duty of the head of the research institute to ensure that all researchers who use 
experimental animals have the necessary training and experience to do so correctly. In- 
service training programmes should be established at research institutes to ensure that this 
requirement can be met.
Transport
• Experimental animals must be transported according to the recognised minimum 
standards and regulations for the transportation of animals.
• During transportation special care should be taken for the provision of good ventilation, 
the elimination of discomfort, excessive cold or heat and the spread of diseases.
• Provision must be made during long journeys for regular provision of food and water.
• Animals must be unloaded as quickly as possible on arrival at an airport, harbour or 
railway station. At their ultimate destination they must be removed from their transport 
cages immediately and placed in suitable permanent accommodation.
• Appropriate veterinary care must be given to animals found to be diseased, injured or in a 
poor state during travel or on arrival.
Ethics Committee for Research on Animals (ECRA)
• All institutions using animals in experimentation must establish an ECRA. No animal 
experiment may be permitted to start before the research protocol has been passed by 
both the ECRA and the Research Committee of the institution.
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• The objective of an ECRA is to control the use and care of experimental animals. The 
ECRA must be properly constituted, ensure that these guidelines are followed and 
applied, keep records of the type and number of animals used in each experiment and 
ensure that quantifiable norms and standards are adhered to.
• An ECRA must be constituted by and shall report to the management of the research 
institution.
• The ECRA shall preferably include persons from each of the following categories as 
members:
• Etablished researchers who have experience of the use of animals in experiments.
• A registered veterinarian.
• Persons not engaged in research representing recognised animal welfare organisations 
and appointed by mutual agreement between the institution and the organisation.
• Persons not engaged in research and not associated with the institution or a recognised 
animal welfare organisation.
The responsibilities of an ECRA are:
• to establish an institutional code of practice for the use and care of experimental animals 
and to ensure that all proposed procedures comply with this code and meet accepted 
ethical, legal and scientific requirements;
• to maintain a register with particulars of the species, number and origin of the animals
used as well as the type of experiments done;
• to inspect the animal facilities regularly and without warning;
• to only approve an animal experiment if convinced that it is justified and feasible, if not, 
the ECRA must refer the matter back to the Research Committee or to subject-matter 
experts who are not members of the ECRA;
• to preview and review all animal experiments in the institution;
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• to ensure that the species chosen is the best model and that no valid alternative method 
can be applied;
• to ensure that pain, discomfort, stress or distress is minimised or eliminated;
• to ensure that experiments do not exceed preset time limits, and that avoidable delays do 
not occur;
• to ensure that all experimental procedures and related activities done on animals are 
performed by persons with the necessary experience and skills; and
• to ensure that its decisions are carried out, because the final responsibility for the welfare
of experimental animals lies with the Committee.
The duties of the ECRA shall be to create mechanisms that provide for:
• regular meetings;
• the stringent review of experiments;
• acceptable standards of clinical care of animals;
• acceptable standards of husbandry care of animals;
• the immediate termination of experiments in which the animal is suffering unacceptable 
or uncontrollable pain, in the view of the veterinarian; and
• to report regularly to the management of the institution.
Special provisions in respect of standards and norms
Organisations using experimental animals should accept and apply quantifiable norms and 
standards. For this purpose, the proposals of recognised national and international authorities, 
advisory bodies and other authorised organisations should be accepted, in order to make 
provision for:
• the appointment o f ECRAs;
• the procurement o f experimental animals;
• correct transportation of animals;
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• adequate accommodation and animal care;
• optimal environmental conditions;
• correct feeding;
• thorough veterinary care and treatment;
• the keeping of thorough records; and
• euthanasia.
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